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Abstract 
The St Andrews group has recently developed a range of novel fluorinated motifs, 
which include all-cis fluorocyclohexanes, difluoro oxy- and thio- ethers and ,,-
trifluorocyclopropanes. Fluorinated motifs are often sought after in medicinal 
chemistry, and it became one of the aims of this thesis to explore these new motifs in 
order to assess their validity for drug discovery programmes. 
The metabolic stability of each motif was probed in incubations with Cunninghamella 
elegans. This fungus is well known for its ability to biotransform xenobiotics 
mimicking the mammalian P450 profile, and thus, providing a useful model for 
metabolic vulnerability. This showed that the all-cis cyclohexyl derivatives were 
increasingly stable to the action of P450’s with increasing fluorine substitution. The    
 , -difluoro thioethers showed oxidation to sulfoxides and sulfones, and the 
difluorooxy analogue showed a rapid biodegradation into the corresponding acetate 
ester. The studied ,,-trifluorocyclopropanes proved challenging to isolate and 
identify, but it could be established that the fluorinated motif remained intact after the 
incubations. The enantioselectivity with which C. elegans transforms the products was 
explored by chiral HPLC, which allowed an estimation of the enantiomeric resolution 
of racemates, and also the enantioselectivity of sulfoxide formation. In both cases 
selectivities were relatively low. Additionally, the lipophilicity of the fluorinated 
motifs was calculated by reverse-phase HPLC. A general trend was that increasing 
fluorination led to increased polarity. 
A second aim was to explore the fluorometabolite biosynthesis in Streptomyces sp. 
MA37, isolated in Ghana (2014), which contains an active fluorinase. The metabolic 
pathway in Streptomyces sp. MA37 branches at 5-fluorodeoxyribose phosphate (5-
FDRP), allowing the formation of 5-fluoro-2,3,4-trihydroxypentanoic acid (5-FHPA) 
and other unknown metabolites. Each of the steps leading to 5-FHPA was studied, and 
the biotransformation was reconstituted in vitro.  
The production of fluorometabolites by Streptomyces sp. MA37 was investigated by 
carrying out cell-free and whole cell feeding experiments with [5’,5’-2H2]-5’-FDA. 
Incorporation into the fluorometabolites from [5’,5’-2H2]-5’-FDA was successful. 
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Chapter 1. Introduction  
1.1 A brief history of fluorine 
1.1.1 Discovery, early uses and applications 
Fluorine was first isolated in 1886 by the French chemist Henri Moissan.1, 2 His 
achievement had been unsuccessfully attempted by many chemists before – including 
his mentor Frémy –,3 and that granted Moissan a Nobel Prize in 1906.4 However, an 
awareness of fluorine preceeded these events. 
The name ‘fluorine’ was first used in 1812 (almost a century before Moissan’s 
achievement) by another French scientist, André Ampère.5 Ampère based his choice 
on the description of the use of fluorspar given by Georgius Agricola, in 1529. 
Agricola, a German scientist known in history as ‘the father of mineralogy’, noted that 
fluorspar could be used as a flux for molten metals in his most famous work, ‘De re 
metallica’.6 Agricola described how the fluorinated mineral melted and flowed when 
heated in a fire, and when added to metals, their melt would become more fluid. 
Therefore, Ampère took the Latin word ‘fluere’, meaning ‘to flow’, to name this new 
element in its molecular form, F2. It is said that he later regretted his choice, in favour 
of another characteristic of fluorine: destruction. He found the name ‘phthorine’, from 
the Greek word for destructive ‘phthoros’, much more appropriate.7 However, the 
name fluorine had been popularised already and other chemists, like Humphry Davy, 
were using it,8 so it secured its place in history. 
The element is found in its mineral forms, fluorite (or fluorspar), apatite and cryolite, 
as fluoride. Hence, Agricola might have been the first person to record the properties 
of fluorspar, but this fluorine-containing mineral had been used long before the Middle 
Ages.  
Egyptians were probably the first civilisation to use calcium fluoride. Its uses were 
mainly ornamental, being shaped into beads and vessels.9 Werner and Bimson (1963)10 
described fluorite as an ‘opacifying material’ used as an imitation for jade during the 
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times of the Tang dynasty (AD 618-907). In this context it was very specific to some 
regions of South-East Asia.11 
The use of fluorspar increased considerably, and according to McLaughlin, fluorite 
coming from the desserts of Iran became the most popular crystal for Roman society.12 
Apparently, during the early period of the Empire, the finest Iranian fluorspar goblets 
could command a price higher than a city mansion.12 One of the most famous 
examples of these goblets might be ‘The Barber Cup’, currently displayed in the 
British Museum in London. This one-handled fluorspar cup features vine leaves and 
grapes carved in low relief (Fig. 1, image courtesy of The British Museum). 
 
Fig. 1 The Barber Cup, located in the British Museum in London 
Fluorspar’s beautiful colours and shine granted its permanence in decorative objects 
from Ancient History throughout the Middle Ages and up until the modern era.  
Although fascinating, until the 16th century fluorinated minerals were only used for 
decoration or embellishment, with the exception of Agricola’s use of fluorspar as a 
flux. History changed for fluorine in the early 1700s, with the efforts of several now 
well-known scientists, who chased this element despite the practical difficulties of 
working with it. Glass equipment was excluded and there was danger of severe 
poisoning.  
An interesting use of a fluorine mineral surfaced in 1835, when cryolite glass was used 
to produce ocular prosthesis.13  
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Dr Lee McDowell reviews these early events in his book ‘Mineral Nutrition History: 
The Early Years’ (2017).14 It was the German chemist Andreas Marggraf who took the 
first step towards fluorine isolation in 1764 by managing to successfully heat fluorite 
with sulfuric acid to prepare hydrofluoric acid.15 However, he could not identify the 
product. Swedish chemist Carl Scheele repeated the procedure in 1771, and he was 
able to recognise its acidic nature.16,17  
The dangerous properties of this acid and other fluorinated compounds were later 
articulated and suffered by Gay-Lussac and Thénard (1809),18 Rabuteau (1867), Davy 
and the brothers Knox.14 Sadly, even more severe consequences befell Paulin Louyet19 
and Jerome Nicklès, who both died from hydrogen fluoride poisoning.14, 20  
These failed and sometimes dramatic attempts were rewarded in 1813, when Humphry 
Davy proved that although the substance was analogous to hydrochloric acid, the 
composing element must be different from chlorine. 21 
Electrolytic processes using hydrogen fluoride were then attempted by Frémy3 and 
Gore (1869).22 Moissan later used those ideas to build his own experiment, for the 
electrolysis of dry hydrogen fluoride with potassium bifluoride as an electrolyte. This, 
combined within a Dewar flask, led to the low temperature production of fluorine gas.1 
The combined efforts of these scientists, sometimes unsuccessful, have significantly 
changed the world we know today. We now enjoy multiple advantages of adding 
fluorine to our molecules. The following sections will describe how fluorine has 
influenced several fields, such as agrochemicals, materials chemistry and the 
pharmaceutical industry.23 
1.1.2 Fluorine in agrochemicals 
‘By morning, the wind had brought the locusts; they invaded all Egypt and settled 
down in every area of the country in great numbers. Never before had there been such 
a plague of locusts, nor will there ever be again. They covered all the ground until it 
was black. They devoured all that was left after the hail – everything growing in the 
fields and the fruit on the trees. Nothing green remained on tree or plant in all the land 
of Egypt.’ (Exodus 10: 13-15)24  
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Plagues and pests have been a problem for humanity since biblical times, and people 
had to look for solutions, apart from divine intervention. The first recorded use of 
insecticides dates back 4500 years, when the Sumerians used sulfur to control the 
spread of different insects.25 This and other inorganic elements, like arsenic or lead, 
have been used continuously throughout history until the 20th century. Nowadays, and 
due to its very high toxicity, sulfur has been generally banned in most countries for 
this purpose.25 
With the rapid development of modern science, more complex molecules were 
synthesised, including those to deter pestilence. Halogenated pesticides were widely 
used between the 1940s and the 1970s, but they have been banned due to their toxicity 
and environmental persistence.26 
Among these halogenated substances, dichlorodiphenyltrichloroethane (DDT) has the 
highest profile. DDT was used with no official control for decades, but it has 
extremely damaging effects on wildlife, as well as in human health, due to its capacity 
to accumulate in adipose tissues.27 DDT and some other examples of organochlorine 
pesticides are shown in Fig. 2.28 
 
Fig. 2 Organochlorine pesticides from the 20th century 
The introduction of halogens for pest control continued, even though it still required 
some effort to reduce their toxicity. The addition of halogens into well-known 
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structures by substitution of hydrogen atoms modulates the properties of these 
products. 
Halogen substitution generates a different steric and electronic profile when compared 
with hydrogen, and such substitutions can change the physicochemical properties of 
the original product. Thus, pKa, lipophilicity, stability and biological activity are all 
affected when a halogen atom is incorporated into a structure.29  
Of all the halogens, fluorine has been the most influential in more recent years for 
agrochemical and medical programmes. Its size – similar to hydrogen’s – reduces the 
steric impact, and being the most electronegative element of the Periodic Table, the 
effect on the molecule’s physicochemical properties can be substantial. 
As stated by Theodoridis in ‘Fluorine-containing agrochemicals: an overview of recent 
developments’, fluorine can not only dramatically improve the efficacy of the 
agrochemicals containing it – therefore allowing a lower application dose – but also 
reduces significantly the environmental impact of these chemicals.30 
A survey run on modern agrochemicals, provisionally approved by ISO between 1998 
and 2008, showed that around 79% contain at least one halogen atom, fluorine being 
the most common.29 A pattern has emerged regarding the level of fluorination. 
Fungicides usually have two fluorine atoms, herbicides at least three, and insecticides 
often contain a minimum of four fluorine atoms in their structure.29 A selection of the 
most successful fluorine-containing pesticides is displayed in Fig. 3. 
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Fig 3. Examples of licensed available fluorine-containing pesticides 
1.1.3 Fluorine in materials chemistry 
Like many of the most important discoveries, the introduction of fluorine into 
materials chemistry was rather serendipitous. In 1938, Plunkett discovered a white 
powdery residue inside one of his tetrafluoroethylene (TFE) canisters.31 While he did 
not know it at the time, he had just found what was to become one of the most 
enduring non-stick fluorinated materials of all time: Teflon®. 
Teflon® (DuPont) is a perfluorinated polymer, prepared from tetrafluoroethylene 
(PTFE) monomer. It is mainly used in cookery to apply a non-stick cover to pans and 
pots, and other kitchen utensils. It is extremely resistant to heat variations, and 
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completely waterproof, properties which make it attractive for a wide range of 
applications. 
PTFE is also used in Goretex® (WL Gore), a protective and waterproof fabric, with 
properties resembling those of nylon, but with the added advantage of being 
breathable. Goretex® is formed by a layer of PTFE, surrounded by layers of nylon and 
polyurethane rendering it gas porous.32 
Fluorinated polymers have proven to be extremely important in a range of everyday 
products, but they are also necessary in less mundane fields. An excellent example of 
this would be Fomblin®, which according to the Solvay website are ‘fluorinated 
lubricants representing the best choice when aggressive chemical environments, high 
temperatures or wide-working temperature ranges are involved’. 33  This high 
performance lubricant is used for machines operating in extreme environments of 
temperature, such as spacecraft engines or for military purposes.23 
Fluorine is also a valuable component of liquid crystals, and currently, fluorinated 
motifs have replaced earlier components such as the cyano group. The advantages they 
bestow in these materials are many; from improving their reliability to stabilising 
conformations and rigidify flexible alkyl chains.34 The location of the fluorine within 
the liquid crystal enables the tailoring of properties.35 The field of fluorinated liquid 
crystals is an expanding one, as personal devices have seen an exponential growth.36 
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Fig. 4 Successful liquid crystals published in recent years 
1.1.4 Fluorine in PET 
Positron-emission tomography (PET) is a non-invasive technique for clinical imaging 
of functional metabolic processes in real time.37 A crucial aspect for a successful PET 
experiment is the choice of the radioactive isotope, and an important factor is the 
isotope half-life (t1/2). 
The most popular positron-emitting isotopes are 15O, 13N, 11C and 18F. Although 15O is 
desirable for PET imaging, its half-life of only 2 min is extremely limiting. Slightly 
longer is the half-life of 13N (10 min) and 11C (20 min), but still these can only be used 
in on-site facilities, since their rapid decay does not allow shipping.38 
18F has a much more optimal half-life (109 min). This isotope is most commonly 
incorporated into fluorodeoxyglucose (FDG), which is taken up by metabolising cells. 
Furthermore, the sufficiently long half-life of 18F makes it much more practical for 
patient preparations, as well as for transport and delivery to a satellite laboratories. 
[18F]-FDG is used for a wide variety of health areas, including neurology, cardiology 
and oncology.39,40 
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Other 18F tracers are being developed as biomarkers. A local example has shown that 
both enzymatically and chemically prepared 18F-FDR (fluorodeoxyribose) could be 
used as an alternative to 18F-FDG for imaging tumours in mouse models (Fig. 5).40 
 
Fig. 5 [18F]-FDR and [18F]-FDG imaging of tumours in mice models40 
1.1.5 Fluorine in the pharmaceuticals and medicinal chemistry  
The substitution of hydrogen by fluorine has proven popular for tuning the properties 
of bioactive compounds, and in this context, fluorine applications continue to increase 
in importance in the pharmaceutical industry.41  
In 1955, the U.S. Food and Drug Administration (FDA) approved the first ever 
fluorine-containing drug. 42 This was the steroid fludrocortisone; which is used to treat 
low glucocorticoid levels caused by diseases of the adrenal gland, such as Addison’s 
disease. Fludrocortisone (Fig. 6) was developed from a glucocorticoid, a natural 
steroid generated in the human body.43,44  
 
Fig. 6 Structure of first fluorinated drug approved, fludrocortisone 
Between 2008 and 2010, it was suggested that fluorine was present in at least 20% of 
commercial drugs.45 However by 2016 this had grown to about a 30%.42 
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The current top-selling drug is a combination of ledipasvir-sofosbuvir (trade name 
Harvoni), used for the treatment of hepatitis C. In 2015, the sales from this drug 
totalled $14.3 billion!46 
 
Fig. 7 Structure of Ledipasvir and Sofosbuvir, for treatment of hepatitis C 
Sofosbuvir took over from atorvastatin (trade name Lipitor) – a fluorine-containing 
cholesterol biosynthesis inhibitor – as the top selling drug. This was ranked the 
number one best-selling drug for the previous decade. It was closely followed by the 
fluorine-containing drug fluticasone propionate (Advair Diskus, an anti-asthma drug) 
at number four in 2010, and lansoprazole (or Prevacid, an antacid remedy) at number 
five. Escitalopram (Lexapro), located at number eleven has effectively replaced the 
CF3-containing fluoxetine (Prozac) as the leading antidepressant. Fig. 8 displays these 
structures.47 
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Fig. 8 Fluorinated blockbusters in medicinal chemistry 
It is evident that fluorine provides some refined properties to these molecules. Among 
those improvements are metabolic stability and bioavailability or enhanced protein-
ligand interactions. Other properties affected include lipophilicity and pKa.48 
Metabolic stability constitutes a crucial factor when designing a drug, since it 
determines the drug’s efficacy. If a molecule is too labile and prone to be readily 
decomposed, metabolic oxidation processes will be fast and abundant, facilitating the 
drug’s excretion prior to its effect. This fast elimination of such a xenobiotic from the 
body will reduce its efficacy. Strategic fluorination has become one of the most 
effective solutions for this problem, leading to a generation of drugs who are up to 400 
times more potent at lower doses due to their increased in vivo metabolic stability.49 
For example, ezetimibe (a cholesterol reducing drug) has been optimised to its current 
structure through several improvements, as shown in Scheme 1.50, 51, 52, 53 
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Scheme 1. Optimisation process of ezetimibe53  
In ezetimibe’s case study, Scheme 1a displays the major metabolic issues with the 
drug’s precursor, while Scheme 1b shows how they were solved, leading to the active 
entity that is sold today.53 
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A second factor that affects efficacy is lipophilicity. Lipophilicity determines the 
permeability of the drug through the cell membrane and its interactions with proteins 
such as albumin, and it is a property that requires careful tuning in medicinal chemistry 
development. A lipophilicity that is too high will result in the molecule being trapped 
within the lipid bilayer or bound to protein; if it is too low the product will remain 
outside of the cell and be excreted by the urinary system. 
It has often been assumed that fluorine incorporation increases lipophilicity, however, 
this statement needs to be refined, according to the degree or type of fluorination. 
Mono- to trifluorination of saturated alkyl groups tend to decrease lipophilicity, 
whereas fluorination of aromatic or heterocycle rings tends to increase 
lipophilicity.54,55 
The influence of monofluorination on Log P values is reflected in Table 1, an example 
presented by Smart in 2001.56 In this case, the effect of fluorine substitution is 
described for small aliphatic molecules, where the Log P values immediately show a 
substantial decrease. 
Table 1. Effect of monofluorination on Log P in small aliphatic molecules 
Molecule Log P 
CH3CH3 1.81 
CH3CH2F 0.75 
CH3(CH2)3CH3 3.11 
CH3(CH2)3CH2F 2.33 
 
Table 2 shows the influence of trifluoromethylation in different substituents for 
leukotriene antagonists, as reported by Jacobs et al. in 1994.57, 58 For this more 
complex molecule, trifluoromethylation causes the lipophilicity values to increase, in 
comparison with the non-fluorinated analogues. 
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Table 2. Effect of trifluoromethylation on leukotriene antagonists57,58 
Structure R X Measured Log P 
 
 o-SO2Tol 5.85 
 o-SO2Tol 6.18 
 OH 4.86 
 OH 5.12 
 o-SO2Tol 6.29 
 o-SO2Tol 6.45 
 OH 5.42 
 OH 5.53 
 
Müller and co-workers have carried out multiple studies on how fluorine modifies the 
partition coefficient. Fig. 9 shows how the logarithm of the capacity factor (Log k), 
directly related to the Log P, behaves under the different degrees of fluorination for 
two series of diastereomeric indoles, with varying substituents. The image also depicts 
the changes in three sets of solvent conditions: 40% acetonitrile in water (log k40), 50% 
of acetonitrile (log k50) in water and 60% of acetonitrile in water (log k60). 59 
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Fig. 9 Fluorination effect on the log of the capacity factor (k) (lipophilicity) for two series of indoles 
The discussion on lipophilicity is a continuous one in medicinal chemistry. 
Historically, Lipinski defined the desired properties for a drug candidate in the 
commonly known ‘Rule of Five’. This popular rule explained that the perfect 
candidate would possess less than five hydrogen bond donors and ten hydrogen bond 
acceptors, a molecular mass of less than 500 Da, and finally, a partition coefficient 
factor (Log P) lower than five.60 Generally, pharmaceutical companies look for Log Ps 
lower than three.61 
Drugs targeting the Central Nervous System should have lipophilicities not higher than 
2.5 (but ideally on the 1.5 – 2.5 range);62,63,64 while for drugs orally or intestinally 
absorbed, ideal values are between 1.35 – 1.8. 65 Sublingual drugs can be used with a 
Log P closer to 5. 66,67 
Acidity and basicity can also be modulated by the introduction of fluorine atoms. This 
is usually measured by pKa.68 The addition of fluorine into non-fluorinated structures 
usually decreases the pKa values, thus making the structures more acidic. Table 3 
displays pKa values for a series of carboxylic acids, alcohols and amines.68  
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Table 3. Fluorination effect on pKa  
Carboxylic acid pKa Alcohol pKa Amine pKa 
CH3CO2H 4.8 CH3CH2OH 15.9 CH3CH2NH2 10.7 
CH2FCO2H 2.6 CF3CH2OH 12.4 CH2FCH2NH2 9.0 
CHF2CO2H 1.3 (CH3)2CHOH 17.1 CHF2CH2NH2 7.3 
CF3CO2H 0.5 (CF3)2CHOH 9.3 CF3CH2NH2 5.7 
CH3CH2CO2H 4.9 (CH3)3COH 19.0   
CF3CH2CO2H 3.1 (CF3)3COH 5.4   
C6H5CO2H 4.2 C6H5OH 10.0   
C6F5CO2H 1.7 C6F5OH 5.5   
 
1.2 Metabolism of Drugs 
Drug metabolism is closely associated with the pharmacokinetic properties displayed 
by a molecule. Absorption, distribution, metabolism and excretion (ADME) processes 
are extremely important aspects in drug discovery, since they determine the behaviour 
of a certain candidate within the human body. The development of a new drug and the 
optimisation of the ADME properties takes, on average, over $2.6 billion and more 
than a decade to be completed.69,70  
The cost and time spent usually include multiple failed attempts, detours, and fresh 
starts. In the whole, the design of new commercial drugs is a complex procedure, and 
special care must be taken when the outcome affects living organisms. 
In humans, most of the enzymatic drug metabolism is carried out by the liver, which is 
the most active tissue for processing xenobiotics. However, some drugs that are not 
metabolised by the liver can be degraded in the kidneys, intestines – including gut 
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flora – or lungs. In rare occasions, drugs can be metabolised in other tissues like the 
brain, heart, muscle, spleen or even the skin.71 
The metabolism of a drug can be viewed to progress through three stages: Phase I, 
Phase II and Phase III. Drugs are xenobiotics so an organism will operate to eliminate 
any traces or them from its system. 
Phase I involves modification of the molecule through oxidation, reduction or 
hydrolysis. Groups such as alcohols, carboxylic acids, amines or thiols are added to the 
original molecule.71 In particular, oxidation is usually carried out by the cytochrome 
P450 (CYP) enzymes, which hydroxylate and make the xenobiotic more soluble, a 
process that will be described in more detail in Section 1.3.2. 
Phase II or the conjugation phase – requires further modification, usually by the 
attachment (conjugation) of an ionised (eg. sulfate) or polar (eg. glucose) group that 
will enhance the water solubility of the metabolite for its excretion by the kidneys.  
The aim of the reactions occurring during Phase II is to inactivate the remaining drugs, 
or any of their active phase I metabolites.71 The transformations are also meant to 
produce a much more water-soluble derivative of the xenobiotic, and include the 
generation of glucuronides, sulfates, or the introduction of glycine, glutamine or 
cysteine.71 All of these changes then lead to Phase III, which involves excretion in the 
urine, bile or sweat. 
Pharmaceutical companies and research groups generally avoid experimentation with 
higher organisms until necessary. Cost increases considerably, and there are ethical 
and moral challenges with animal experimentation. Therefore, the use of more simple 
and readily available microbial models is attractive, certainly at early stage 
investigations. One of these microbial models is the fungus Cunninghamella elegans. 
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1.3 Cunninghamella elegans as a model for mammalian drug metabolism 
1.3.1 The fungus Cunninghamella elegans 
The genus Cunninghamella was described by Matruchot in 1903.72 Cunninghamella is 
a filamentous fungus that is found mainly in soil and plants, in Mediterranean and 
subtropical zones.73 This genus is currently formed by 14 species, some of which have 
been reported as human mucormycosis.72 Particularly, C. bertholletiae has been 
classified as a human and animal pathogen.73,74  
Initially, up to three different studies (Samson in 1969,75 Baijal and Mehrotra in 198076 
and Lunn and Shipton in 198377) described C. bertholletiae and C. elegans as the same 
species, given that there were no significant differences in their morphological 
characteristics.72 However, Weitzman and Crist (1979) 78  managed to make a 
distinction between both species according to their growth capacity under different 
temperatures. The maximum temperature of growth for C. elegans occurs at 37 ºC, 
while C. bertholletiae can grow at temperatures between 40 – 45 ºC.72 In addition to 
that debate, Weitzman made a case in 1984 as to why C. elegans, C. bertholletiae and 
C. echinulata should be maintained as three different species. The argument is based 
on the fact that those three fungi display different mating behaviour, morphology, and 
temperature tolerance, amongst other factors.79 
C. elegans has very mild culture conditions and fast growth; it matures after a 72 h 
incubation at 28 ºC. The appearance of the mature fungus in agar plates is cotton-like, 
of a very pale grey or yellowy tint, where the filaments are easily observed by the 
naked eye. When shaken in the liquid medium, the filamentous C. elegans tends to 
form spherical pellets. However, whenever bacterial contamination is present, the 
culture fluid quickly becomes turbid, and the hyphal pellets are not formed as usual.80 
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Fig. 10 Agar plates of Cunninghamella elegans 
C. elegans, like most of the Cunninghamella sp., possesses cytochrome P450 enzymes, 
which are analogous to those in mammals. This fungus is able to metabolise a wide 
range of xenobiotics using phase I oxidative and phase II conjugative 
biotransformations,73 and therefore, C. elegans has found use as an animal model. 
1.3.2 Cytochrome P450 and metabolism 
Drugs tend to be metabolised in such a way that excretion from the organism becomes 
possible. Cytochrome P450 enzymes play a role in phase I metabolism.  
In humans, P450 enzymes reside principally in the liver, but can also be found in the 
lungs and intestines, amongst other organs.71 In particular, they predominantly exist in 
the endoplasmic reticulum of the hepatocytes.73 Cytochrome P450 (CYP) is a carbon 
monoxide binding haemoprotein71 mainly involved in oxidative reactions, including 
carbon hydroxylation, heteroatom and/or double bond oxidation. However, in certain 
cases, reports of reductive biotransformations by these enzymes have also been 
described.73  
The way cytochrome P450 enzymes work usually requires an initial binding of the drug 
to the active site of the enzyme, before it can take part in the ‘P450 catalytic cycle’.73 It 
is largely accepted that they possess an open active site, and usually prefer lipophilic 
substrates.73 The quality of binding, as well as the specific orientation of a molecule 
binding CYP, largely depends on hydrophobic and steric interactions between the 
substrate and the enzyme; and these interactions are highly dependant on 
lipophilicity.73  
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The enzymes from this complex do not work independently, and they require the 
electron-donating activity of a second enzymatic system, in order to remain 
catalytically active. In mitochondria or prokaryotes this is a system of two proteins, 
while for the endoplasmic reticulum enzymes, the electrons are donated by just one 
other enzyme: cytochrome P450 reductase (or CPR).73 Additionally, CYP enzymes need 
NADPH as a coenzyme, and oxygen as a substrate, in order to function.73  
Oxidation by cytochrome P450 starts with hydride reduction (2 electron transfer) by 
NADPH and protons from the medium. The reduced and protonated CYP (‘CYP-H2’) 
then binds molecular oxygen, and the active complex formed (‘CYP-O2’) is now able 
to oxidise the drug (RH), releasing water and regenerating the original CYP.71 NADPH+ CYP+ H! → ′CYP− H!′+ NADP! CYPH! +  O!  → !CYP− O!′  ′CYP− O!! + RH → CYP+ ROH+  H!O 
However, a recent study has shown that the ‘CYP-O2’ complex, in which the iron (IV) 
is linked to the molecular oxygen, had a basic pH.81 This result indicated that that the 
‘CYP- O2’ species was not the previously presumed iron-oxo Cys-S-Fe(IV)=O, but it 
was the hydroxy form Cys-S-Fe(IV)-OH instead (Scheme 2).81,82  
 
 
 
 
Scheme 2. Pull-push mechanism in cytochrome P45082 
The basicity of that oxygen has been explained by the electron ‘push’ generated by the 
axial cysteine-thiolate ligand.81,82 This ‘electron push’ from the sulphurilated ligand 
creates a ‘pull’ from the ferryl oxygen that allows the C-H bond rupture (Scheme 2).82 
This balanced force from the ligands’ bonds to iron recreates a pull-push scenario that 
has been known as the ‘pull-push’ mechanism in cytochrome P450. 
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1.3.3 Biotransformation of xenobiotics  
In 1952, Peterson and Murray pioneered in the use of microbial biotechnology for 
steroid metabolism with the biotransformations of progesterone by a Rhizopus 
organism (Scheme 3).83 They demonstrated the use of microbiological tools for the 
synthesis – and scale-up – of otherwise chemically challenging transformations, by 
exploiting the natural metabolic pathways of different microorganisms.  
 
Scheme 3. Experiments by Peterson and Murray, using biotransformations to facilitate further 
reactions83  
Nevertheless, the use of microbes as simplified models for mammalian drug 
metabolism did not appear for almost two decades after these seminal studies. Beukers 
et al. published a book in 1972 entitled ‘Microbial conversion as a tool in preparation 
of drugs’ where they studied the application of microorganisms to assist in the 
discovery of new drugs.84  
Cunninghamella began to be used as a metabolic model in 1974.85 One of the early 
examples include the stereoselective metabolism of warfarin by C. elegans.86 
Cerniglia in particular has made a significant contribution to metabolism studies with 
Cunninghamella elegans, over 40 years. Some of his latter contributions with this 
organism include the biotransformation of the antidepressant amoxapine (2000)87 and 
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malachite green (2001)88. The hydroxylation and formylation of amoxapine by C. 
elegans is illustrated in Scheme 4.87  
 
Scheme 4. Biotransformation of amoxapine in C. elegans87 
C. elegans has also been used to explore the metabolism of fluorinated drugs. Within 
this topic, Murphy compared different strains of Cunninghamella and bacterial strains. 
For example, the biotransformation of the anti-cancer drug flutamide in C. elegans, C. 
echinulata and C. blakesleeana has been evaluated. In that case, C. elegans DSM 1908 
produced the best profile, affording phase I metabolites, and was chosen for more 
detailed analysis.89 
During the biodegradation of the anti-inflamatory flurbiprofen with C. elegans and C. 
blakesleeana, some phase II conjugated metabolites were observed, showing that the 
fungus can progress beyond phase I metabolites in some cases.90  
Another example focused on the biotransformation of 4-fluorobiphenyl in C. elegans 
which demonstrated phase I mono- and di-hydroxylation products, the major being 4-
fluoro-4’-hydroxybiphenyl (Scheme 5). The fact that there are multiple 
hydroxylations, suggests that C. elegans is a useful model for mammalian drug 
metabolism and as a means to prepare candidate metabolites.91 
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Scheme 5. Biotransformation of 4-fluorobiphenyl by Cunninghamella elegans91 
In 2013, Murphy and co-workers explored biotransformations in C. elegans biofilms, 
in place of the traditional suspension cultures. Fungal biofilms present the advantage 
of being easily recyclable, and have an increased facility of handling.92 Several studies 
have been published since then with biofilms as an improved approach for metabolism 
investigations. Both synthetic pharmaceuticals93 and relatively new motifs – such as 
sulfanylpentafluorides94 – were explored. 
These fungal biofilms studies allowed screening, as well as an ease in the scale-up of 
fluorodrug metabolites for characterisation. 95  Many compounds were not easily 
accessible by chemical methods. The mixture of both a chemical and a biological 
approach is extremely fruitful, and is being used increasingly to access fluorinated 
intermediates or for the easier production of fluorometabolites.96, 97 
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1.4 Natural Products. Relevance and biosynthesis 
1.4.1 Relevant natural products. Discovery, roles and applications 
Nature has played a crucial role in providing structurally complex chemical 
compounds. And many natural products are found to be bioactive. However, the 
isolation of these products can be difficult and chemists have placed a great effort into 
their total synthesis. 
In 1763, Stone described how the bark of willow trees had powerful astringent 
properties, and related them to the presence of salicylates (a general term used for the 
derivatives of salicylic acid).98,99 Although Stone was the first person to relate the 
medicinal properties of the willow bark to the salicylates, he was not the first to report 
its properties. Mention to the curative and pain-relieving effects of willow tree’s bark 
were already catalogued 2500 years previous, by Greek physician Hippocrates, and 
continued throughout the years of the Roman Empire.99 Acetylsalicylic acid is the 
active principle of aspirin, as we know it today. 
 
Fig. 11 Structures for salicin (a salicylate derivative) and acetylsalicylic acid 
In 1928, Alexander Fleming noticed that one of his agar plates – initially prepared to 
grow staphylococcus – had grown a mould impurity. After realising that the mould had 
effectively killed the surrounding bacteria, he decided to cultivate the new 
microorganism separately.99,100 This new organism was later found to be Penicillium 
notatum, and Fleming named the powerful antibacterial agent isolated from it as 
‘penicillin’ (Fig. 12).99,100 The isolation and medicinal properties of penicillin were 
subsequently demonstrated by a team led by Florey and Chain and in 1945, Fleming, 
Florey and Chain were awarded the Nobel Prize in Physiology or Medicine for ‘the 
discovery of penicillin and its curative effect in various infectious diseases’.101 
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Fig. 12 Structure of penicillin, as isolated by Fleming from Penicillium notatum 
Cobalamin, also known as vitamin B12, is a water-soluble vitamin – and a source of the 
primary function of cobalt in humans. This vitamin acts as a cofactor of two crucial 
enzymes for human’s health (methionine synthase and methylmalonyl-CoA mutase), 
and it also has a role as a transporting system.102 The structure of vitamin B12 (Fig. 13) 
was solved by Dorothy Crowfoot-Hodgkin,103 in 1956 by X-ray crystallography, in 
what has been described as ‘one of the finest contributions of British science’.99,104 
Crowfoot-Hodgkin was awarded the Nobel Prize in Chemistry in 1964 for ‘her 
determinations by X-ray techniques of the structures of important biochemical 
substances’, including penicillin.105 
 
Fig. 13 Structure of Cobalamin, by Dorothy Crowfoot-Hodgkin 
1.4.2 Halogenated natural products and enzymatic halogenation  
The first halogenated natural product was isolated and identified at the end of the 19th 
century by Drechsel. Investigations with the coral Gorgonia cavolii led to the 
discovery of diiodotyrosine (Fig. 14).106  
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Fig. 14 Diiodotyrosine, the first halogenated natural product to be discovered 
Since then, the number of halogenated natural products has grown considerably. In 
1973, a review stated that more than 200 halogenated products had been isolated from 
natural sources; while in 1991 that number had grown to 1500.107 By the end of 2010, 
more than 4700 halogen-containing structures from nature had been reported.108 More 
than 5000, were identified by 2015, the majority occurring in marine sources.109 
Chlorinated products are the most abundant, followed by their brominated analogues. 
However, only around a hundred feature iodine, and fluorinated natural structures are 
extremely rare.108 
The presence of the halogen atoms in the structure of a natural product has a marked 
effect on its properties, and actively influences biological activity.110 The bioactivities 
displayed are varied. Some halogenated antibacterial, antifungal and antiviral drugs 
include the well-known vancomycin, chloramphenicol or lanosol. One of the most 
sought-after drugs are antitumor and anticancer agents, such as rebeccamycin or 
phorbaketal N. 5,6-Dibromo-L-hipaphorine is an antioxidant and anti-inflammatory 
product isolated from the sponge Hyrtios sp., indigenous to Fiji. Compounds 
displaying enzymatic and molecular activity are also on the halogenated spectrum; the 
brominated callyspongic acid is a bromotyrosine that mediates cholesterol metabolism 
and is of use in the treatment of Alzheimer’s disease.110,108 These structures are shown 
in Fig. 15. 
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Fig. 15 Halogenated natural products and their biological activity 
The biosynthetic pathways to some of these metabolites has been studied as they hold 
the key to facilitate the discovery of new halogenated natural products.109  
The first halogenating enzyme (halogenase) was ß-ketoadipate chlorinase, reported by 
Hager and co-workers in 1959.111 This enzyme was found while investigating the 
biosynthesis of caldariomycin (Fig. 16) – a di-iodinated cyclopentane isolated from 
Caldariomyces fumago. This chlorinase is a type of haloperoxidase, able to catalyse 
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the C-Cl bond formation of the metabolites from the caldariomycin metabolic 
pathway, whenever hydrogen peroxide and chloride ions are present in the biosynthetic 
medium.111 
 
Fig. 16 Structure of caldariomycin 
Halogenases are classified according to several parameters – type of halogen, origin or 
functionality, among others or according to their mechanism, which span nucleophilic, 
electrophilic or radical.112 
ß-Ketoadipate chlorinase is a haloperoxidase.111 Haloperoxidases are the first of the 
two major classes of enzymes involved in electrophilic halogenation, the other being 
flavin-dependent halogenases.112 
 The exact mechanistic pathway of haloperoxidases is not yet known, but it is widely 
accepted that the electrophilic species involved is the corresponding hypohalous acid 
(OH–X). Scheme 6 presents the general mechanism for these enzymes; the halogen 
ion is oxidised by hydrogen peroxide, generating the highly reactive hypohalous acid 
intermediate, which is attacked by the organic nucleophile to produce the halogenated 
metabolite.110,112 
 
Scheme 6. General mechanism of haloperoxidases 
The highly reactive hypohalous intermediate is most probably the cause of the low 
regiospecificity exhibited by haloperoxidases, which often generate a mixture of 
mono-, di- and trihalogenated metabolites.112 
These peroxide-dependent enzymes are further divided in two categories: haem-iron 
and vanadium peroxidases. The mechanism for the formation of the electrophilic 
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hypohalous acid in these sub-categories is not precisely known, but the hypothetical 
routes are shown in Scheme 7 and Scheme 8. 
In haem-iron haloperoxidases, the mechanistic route starts with the addition of 
hydrogen peroxide to FeIII; this complex is subsequently oxidised to the FeIV species, 
prior to the addition of the corresponding halide, re-establishing FeIII and liberating 
hypohalous acid (Scheme 7). 
 
Scheme 7. Hypohalous acid formation by haem-iron haloperoxidases112 
The route is similar for vanadium haloperoxidases. In that case, hydrogen peroxide 
binds to the metallic complex, before halide addition and final release of the 
hypohalous acid (Scheme 8). 
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Scheme 8. Hypohalous acid formation in vanadium-dependent haloperoxidases112 
The exact mechanism by which flavin-dependent halogenases generate hypohalous 
acid may vary among the different members of the family. However, it is expected that 
the electrophilic agent is formed by the reaction of reduced flavin and molecular 
oxygen (Scheme 9).113, 112 
 
Scheme 9. Formation of the hypohalous acid intermediate in flavin-dependent halogenases 
In 2005, Naismith and co-workers reported the existence of a 10 Å tunnel which 
separates the flavin from the substrate binding site, and through which the electrophilic 
hypohalous acid needs to migrate. This separates the generation of the electrophilic 
agent lysine residue from the actual site of the halogenation.114,115,110 At the end of this 
tunnel is the ε-NH2 of a lysine, which has been implicated in the catalysis possibly via 
an intermediate R-NH2Cl species. 
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Nucleophilic halogenation is less common than the electrophilic route. All of the 
known enzymes involved in nucleophilic halogenation require S-adenosyl methionine 
(SAM) as a substrate.112  
In the first case, the halide (X= Cl, Br, I) attacks the sulfonium methyl group in SAM, 
in a methyltransfer reaction. The resulting product is the gaseous halomethane, as 
illustrated in Scheme 10.112 
 
Scheme 10. Halomethanes production by the action of a methyl transferase 
Nucleophilic halogenation can also involve the attack of the halide ion to the C5’ 
position of SAM, displacing methionine and introducing the halogen.112 The first 
example of this type of enzyme was reported in 2002 by O’Hagan et al., isolated from 
Streptomyces cattleya. 116  This fascinating C-F bond-forming enzyme is named 
fluorodeoxyadenosine synthetase, although it is generally referred to as ‘the 
fluorinase’.116 Scheme 11 shows the fluorinase-catalysed SN2-type attack by fluoride 
ion to the C5’ position of SAM, to generate 5’-fluoro-5’-deoxyadenosine (5’-FDA).117 
The relevant metabolic pathway will be discussed in Section 1.5. 
 
Scheme 11. C-F bond formation catalysed by the fluorinase enzyme 
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In 2009, Moore et al. reported a chlorinase analogous to the fluorinase.118 This 
nucleophilic halogenating enzyme was found in the marine organism Salinispora 
tropica, and its metabolic pathway leads to the formation of salinosporamide A, a 
potent anticancer agent.118 The first step of the metabolic pathway is presented in 
Scheme 12. More details of this pathway, and its relation to the fluorinase are 
described in Section 1.5.  
 
Scheme 12. First step to the chlorinase pathway, and Salinosporamide A 
The third class of halogenating enzymes involves halogenation by single electron 
transfer. Given that these enzymes require the presence of α-ketoglutarate as a co-
substrate, they are often called α-ketoglutarate-dependent halogenases; although they 
are also referred to as non-haem FeII- or O2-dependent halogenases.115  
Their mechanism was first investigated in the context of syringomycin E biosynthesis 
in Pseudomonas syringae.119, 120 The proposed mechanism starts with an iron complex 
in its FeII resting state. The water molecule from this original complex is substituted by 
molecular oxygen, which is then reduced, oxidising the iron to FeIV. This newly 
formed species is highly reactive and attacks the substrate, generating a radical 
intermediate. The substrate radical is able to sequester the corresponding halide from 
the complex. These mechanistic steps are shown in Scheme 13.119 
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Scheme 13. Proposed mechanism for the α-ketoglutarate-dependent halogenases119 
An important characteristic of non-haem FeII-dependent halogenases is that they can 
halogenate unactivated, aliphatic carbon centres, sometimes leading to the formation of 
unusual halogenated motifs, such as vinylhalides.121 Additionally, these halogenases 
can catalyse the transfer of multiple halogens within one active site. 122  The 
combination of these two properties results in the formation of natural products 
featuring several halogens on the same carbon atom; such is the case of trigocherrin A 
– which contains a dichlorovinyl moiety – or barbamide – containing a trichloromethyl 
group (Fig. 17).121 
 
Fig. 17 Unusual halogenated motifs generated by radical halogenation 
1.4.3 Fluorinated natural products 
Fluorine is the 13th most abundant element in the Earth’s crust, and it appears primarily 
in minerals like fluorite, apatite and cryolite. However, the concentration of fluoride 
ion in seawater is extremely low. Table 4 shows the occurrence of the different 
halogens in both seawater and the lithosphere.123 
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Table 4. Occurrence of the halogens on Earth 
Element Seawater (ppm) Litosphere (ppm) 
Fluorine 1.3 770 
Chlorine 19000 550 
Bromine 65 1.6 
Iodine 0.05 0.3 
In conjunction with low concentration in seawater, fluoride has the highest heat of 
hydration amongst the halogens (approximately 120 kcal/mol), and it follows that it is 
difficult to remove water molecules surrounding the anion and thus it is a poor 
nucleophile. Additionally, fluoride presents an extremely low oxidation potential        
(-2.87 eV), and it cannot be oxidised by haloperoxidases.124 
These properties make fluorine – or fluoride – extremely difficult to enter into 
biochemistry and be incorporated by living organisms such as plants or bacteria. The 
first fluorinated natural product to be identified was fluoroacetate, in 1943.125 Since 
then, only another five fluorine-containing structures from nature have been identified 
and isolated. In total, six types of fluorine-bearing natural products have been 
established, although the existence of some others is known although they have not 
been structurally characterised. Some reports of natural fluoro compounds have been 
discarded as unreliable.125  
Fluoroacetate, (2R,3R)-2-fluorocitrate, 4-fluorothreonine, a range of ω-fluorofatty 
acids, 5-fluoro-2,3,4-trihydroxypentanoic acid and nucleocidin have been correctly 
identified.  
 40 
 
Fig. 18 The six types of fluorinated natural products known to date 
Fluoroacetate 1, fluorocitrate 5 and the fluorofatty acids were all isolated from plants 
from Africa, and their discovery was closely related both in time and in content 
(research on fluoroacetate led to the discovery of fluorocitrate and the fluorofatty 
acids). The microbial products 2, 3, 4 and 6 came later. 
Fluoroacetate was identified in 1943 by Marais in South Africa. The discovery was 
triggered by the investigations on Dichapetalum cymosum, a highly toxic indigenous 
plant that when consumed led to the death of foraging cattle. The local name of D. 
cymosum is ‘gifblaar’, which means ‘poison leaf’.126 Those investigations led to the 
isolation of fluoroacetate, the first fluorinated natural product, which was also the 
cause of the toxicity of gifblaar. 
Fluoroacetate is also present in a variety of plants and microorganisms. As a curiosity, 
the highest level of fluoroacetate ever recorded was found in the seeds of the plant 
Dichapetalum braunii, which contained up to 8000 ppm.127,128  
Nevertheless, several animals that live and forage in areas where fluoroacetate-
producing plants are found, show resistance. An example of this behaviour has been 
observed for Sindrus albimaculatus, a caterpillar of the moth, which is capable of 
accumulating fluoroacetate. Their survival is due to an evolved resistance to the 
fluorinated toxin.129,130 
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In Australia, where this phenomenon has been extensively studied, one of the most 
striking cases is that of the emu. This seed-eating bird displays high resistance to 
fluoroacetate, with an LD50 of up to 200 mg per kg,130 whereas seed-eating birds 
grown and fed in areas where fluoroacetate is not naturally-ocurring have an LD50 of 
up to 20 mg per kg, one order of magnitude lower.130  
Given the complexity of these organisms, the exact mechanism by which they are able 
to cope with fluoroacetate is not known.131 
Kawasaki and co-workers reported a defluorination enzymatic mechanism Moraxella 
species, shown in Scheme 14. The active site of the defluorinase contains an aspartate 
residue (Asp-105). The carboxylic group of Asp-105 acts as a nucleophile and 
displaces fluoride, forming an enzyme-bound intermediate. Then, His-272 activates 
water, and the resulting hydroxide ion hydrolyses the enzyme-bound intermediate, 
releasing glycolate.132 
 
Scheme 14. Postulated enzymatic mechanism for Moraxella sp. 
More recently, an investigation by Spencer discovered another bacterial fluoroacetate 
resistance enzyme in Streptomyces cattleya. In this case, it was a fluoroacetyl-CoA 
thioesterase (FlK).133 Chang at Berkeley was able to shed some light on how this 
enzyme works by converting fluoroacetyl-CoA back to fluoroacetate, through a ketene 
intermediate (Scheme 15), and therefore avoiding the entrance of the toxin into the 
TCA cycle. 134 
 
Scheme 15. Fluoroacetyl-CoA thioesterase’s ketene intermediate 
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The toxicity of fluoroacetate is due to its in vivo conversion to (2R,3R)-2-
fluorocitrate,135 which is an inhibitor of aconitase136 – a key enzyme of the citric acid 
cycle. Scheme 16 shows the biotransformation of fluoroacetate into (2R,3R)-2-
fluorocitrate, a procedure known as ‘lethal synthesis’.137 The metabolic pathway starts 
with the action of an acetyl-CoA synthetase, which in the presence of ATP, converts 
fluoroacetate into fluoroacetyl-CoA. Fluoroacetyl-CoA is an active metabolite for the 
citric acid cycle, and is condensed with oxaloacetate by the action of a citrate synthase 
to yield 2-fluorocitrate, exclusively as the (2R,3R) stereoisomer – which is the only 
toxic diastereoisomer of the four possible isomers of 2-fluorocitrate.137,138,139  
 
Scheme 16. Biotransformation of fluoroacetate into (2R,3R)-2-fluorocitrate 
 (2R,3R)-2-Fluorocitrate is a substrate for aconitase, which catalyses its transformation 
into isocitrate, through a cis-aconitate intermediate. This intermediate is attacked by 
hydroxide ion while bound to the enzyme, leading to the formation of 4-hydroxy-
trans-aconitate, the actual inhibitor of aconitase (Scheme 17).140 
 
Scheme 17. Transformation of (2R,3R)-2-fluorocitrate through the cis-aconitate intermediate into the 
trans-aconitate aconitase inhibitor 
In 1996, Lauble and co-workers141 solved the structure of the enzyme-bound inhibitor 
generated in this ‘lethal synthesis’ (4-hydroxy-trans-aconitate), and this image is 
reproduced in Fig. 19. 
F O
O CoASH
Acetyl-CoA
synthetase
ATP AMP + PPi
F SCoA
O
Citrate
synthase
H2O CoASH
OOC COO
O
OOC COO
OOCH2C OH
F
Inhibits
aconitase
HOOC COOH
HOOC OH
F
HOOC COOH
F
COOH
HO F
HOOC
COOH
OH COOH
4-hydroxy-trans-aconitate
 43 
 
Fig. 19 4-Hydroxy-trans-aconitate bound to the enzyme with a [4Fe-4S] cluster  
In 1959, Peters reported a toxic lipid from the seeds of Dichapetalum toxicarium, 
suggesting that it probably was a long chain -fluorinated fatty acid.142 
D. toxicarium is an indigenous plant to Sierra Leone, where the local people refer to it 
as ratsbane (rat poison), a very appropriate name, given that it is also used as a 
rodenticide. When the seeds of this plant are ingested, they cause vomiting, diarrhoea, 
and paralysis of the lower limbs, amongst other ailments. The paralysis of the lower 
extremities had afflicted the natives for generations, and was the cause for the plant’s 
alternative name: ‘broke back’.143  
It was subsequently shown that the main component of the oil (source of 80% of the 
total organic fluorine present) was ω-fluorooleic acid,144,145 which co-occurred with at 
least two other components in the oil, as well as traces of fluoroacetate.146 
Nucleocidin was first isolated from Streptomyces calvus in 1957. 147  Both the 
elucidation of the structure and the biosynthesis of nucleocidin were hindered for many 
years, due to public strains being unable to produce the antibiotic. 
The elucidation of nucleocidin’s structure was not trivial. When initially isolated from 
Streptomyces calvus, a partial structure including an adenine moiety and an ester 
sulfamic acid was proposed (Fig. 20a).147 A decade later, in 1968, the preliminary 
structure was corrected to 9-(4-O-sulfamoylpentofuranosyl)adenine (Fig. 20b),148 and 
finally, in 1969, Morton et al. suggested the presence of fluorine in the C4’ position of 
the ribose, 149  with a ß-D-configuration. 150  The final structure of 4’-fluoro-5’-
sulfamoyladenosine (Fig. 20c) was confirmed by total synthesis in 1976.151 
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Fig. 20 Different structures for nucleocidin, as proposed through its structural elucidation history 
The discovery of new fluorinated natural products remained stalled for many years. In 
1986, more than 25 years after Peters’ identification of fluorofatty acids, Sanada et al. 
reported the isolation of 4-fluorothreonine and fluoroacetate, while attempting to 
improve the production of the ß-lactam antibiotic thienamycin (Fig. 21), in 
Streptomyces cattleya.152 Sanada discovered that when cultured in the presence of 
fluoride, S. cattleya was able to produce fluoroacetate, along with a novel fluorinated 
structure, which they identified as 4-fluorothreonine. This new fluorinated aminoacid 
exhibited antimicrobial activity.152 
 
Fig. 21 Antibiotic thienamycin 
In an effort to locate the source of fluoroacetate and fluorothreonine from S. cattleya, 
Tamura and his colleagues designed a range of 14C and 13C labelling experiments.153 
While most of the envisaged experiments did not show successful results, the 
incubation of [2-13C]-glycerol to the mycelium suspension caused enrichment of the 
carboxylic carbon of fluoroacetate with 13C. Further experiments with 14C-
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hydroxypyruvates showed that C-2 and C-3 are exclusively converted to fluoroacetate. 
These observations suggest that the carbon skeleton from fluoroacetate derives from 
glycerol through β-hydroxypyruvate.153 
Separately, Nieschalk and O’Hagan studied the incorporation of deuterium-labelled 
glycerol into the fluorometabolites of Streptomyces cattleya. They used 
enantiotopically labelled (R)- and (S)-[1-2H2]-glycerol, and discovered that only the 
deuterium atoms from the pro-R side of glycerol were incorporated into fluoroacetate 
and fluorothreonine (Scheme 18).154 
 
Scheme 18. Deuterium-labelled glycerol experiments in S. cattleya154 
Almost thirty years passed before the isolation of a new fluorinated metabolite with the 
identification of 5-fluoro-2,3,4-trihydroxypentanoic acid 2 from Streptomyces sp. 
MA37. The structure of this compound was confirmed by total synthesis, and is shown 
in Fig. 22.155 
 
Fig. 22 (2R,3S,4S)-5-Fluoro-2,3,4-trihydroxypentanoic acid from Streptomyces sp. MA37 
Since the discovery of fluoroacetate in 1943, there have been several reports of new 
fluoroorganic molecules that were later confirmed as either wrongly analysed or 
incorrectly identified as natural products.  
Peters and Shorthouse, reported in 1967 the observation of a ‘volatile form’ of a 
fluorometabolite, while investigating the metabolism of fluoroacetate in Acacia 
georginae.156 By 1971, these scientists suggested that the ‘volatile form’ could be a 
fluoroketone. Since monofluoroacetone had previously been found in the livers of rats 
given fluoroacetate,157 they concluded that the mysterious structure from A. georginae 
could be the same fluoroacetone 7.158 The authors were clear in expressing their doubts 
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on the identity of the ‘volatile form’. A widely accepted hypothesis is that the product 
they isolated was fluoroacetaldehyde 8, an intermediate in the fluoroacetate pathway in 
Streptomyces cattleya.159  
 
Fig. 23 Fluoroacetone versus fluoroacetaldehyde 
A more controversial case was presented with the discovery of some 5-fluorouracil 
derivatives from the sponge Phakellia fusca in the South Sea of China.160 In 2003, Xu 
et al. isolated the five 5-fluorouracil derivatives displayed in Fig. 24. 
 
Fig. 24 5-Fluorouracil derivatives isolated from the South Sea of China 
Given that derivatives 9 and 10 are well-known anti-tumour agents,161 it is most likely 
that these isolates are just the result of industrial contamination in the ocean, absorbed 
by the sponge.162,163 
More recently, the isolation of di-tert-butylfluorophenylpropionic acid 14 from 
Streptomyces sp. TC1 was reported.164 Despite the claim that the molecule contained a 
fluorine atom, no spectral evidence was provided, apart from a very broad 19F NMR 
signal in the Supporting Information of the article.164 O’Hagan et al. synthesised a 
sample of 14, and comparison with the published spectra proved the molecules to be 
different.165 Instead, they propose that the original isolate was phenolpropionic acid 15, 
a well-known antioxidant.165 Both structures are shown in Fig. 25. 
 
Fig. 25 Di-tert-butylfluorophenylpropionic acid and the phenolic derivative 
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1.5 The fluorinase 
1.5.1 Discovery and crystal structure of the first fluorinating enzyme 
The natural sources of organofluorine products have been extensively studied, both 
because of fluoroacetate’s toxicity and their rare occurrence. In 2002, O’Hagan et al. 
identified the first fluorinating enzyme, from the bacterium Streptomyces cattleya that 
produces 4-fluorothreonine.116 The enzyme is able to catalyse the formation of a 
carbon-fluorine bond by the SN2-like attack of fluoride to the C5’ position of SAM, to 
generate 5’-FDA.116 This intermediate is transformed into fluoroacetaldehyde, which is 
oxidised to fluoroacetate.116 While the production of fluoroacetate and 4-
fluorothreonine by Streptomyces cattleya was originally observed by Sanada, no 
relationship could be established at the time on the formation of these products.152 
 The biosynthetic pathway to fluoroacetate and 4-fluorothreonine in S. cattleya 
involves five enzymatic steps, and a branch point, which separates the formation of 
fluoroacetate and 4-fluorothreonine.166 The reactions are shown in Scheme 19. 
 
Scheme 19. Fluorinase pathway in Streptomyces cattleya 
The pathway shown in Scheme 19 starts with the SN2 attack of fluoride on SAM, 
catalysed by the fluorinase, to yield to 5’-FDA. 5’-FDA is then transformed into 5-
fluorodeoxyribose phosphate (5-FDRP) by the action of a purine nucleoside 
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phosphorilase (PNP). An isomerase then converts 5-FDRP into 5-fluorodeoxyribulose 
phosphate (FDRibulP), which is the substrate for the aldolase that generates 
fluoroacetaldehyde 8. Fluoroacetaldehyde is a branch point on the metabolic pathway. 
A pyridoxal phosphate (PLP) dependent transaldolase, yields 4-L-fluorothreonine in 
combination with L-threonine. Alternatively, an NAD+-dependent aldehyde 
dehydrogenase transforms fluoroacetaldehyde into fluoroacetate 1.166 
Purification and in vitro over-expression of 5’-fluoro-5’-deoxyadenosine synthase 
allowed a deeper understanding of the enzyme’s kinetics, and opened the possibility of 
reproducing the protein’s sequence by PCR, in order to determine the complete coding 
sequence for the flA gene.117 Crystallography was used to determine the structure of 
the wild-type enzyme, isolated from S. cattleya.117 Crystal structures showed that the 
fluorinase is constructed as a dimer of trimers – forming a hexamer. Each monomer 
unit is organised by the amino-terminal domain, linked to a smaller carboxy-terminal 
domain; and by a ‘distinctive, extended loop of 21 amino acid residues’.117 Fig. 26 
shows the structure of the monomeric units, the trimers and the hexamers determined 
by X-ray crystallography.117 
 
 
Fig. 26 Crystal structures of the monomeric units, trimers and hexamers of the fluorinase117 
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Structures with a bound SAM molecule show that the substrate binds to the interface 
between the C-terminal and the N-terminal domains, and the trimer holds three bound 
molecules.117  
Isotopic labelling experiments which resulted in prochiral deuterium labelling at C-5’ 
of SAM, incubated in whole-cell experiments, indicated an ‘inversion of 
configuration’ during the F- attack on the C5’ position of SAM.167 The hypothesis was 
consistent with the crystal structure, showing 5’-FDA and methionine bound to the 
enzyme, and displaying an anti relationship between the C-F bond (in red in Fig. 27) 
and the C-S bond (dotted red, Fig. 27).117  
 
Fig. 27 Crystal structure of 5’-FDA formation, in a SN2 fashion117 
1.5.3 Streptomyces sp. MA37 
In 2014, a fluorinase gene homologue was identified in a genome isolated from 
Streptomyces sp. MA37 found in Ghana. It showed an 87% analogy to the original 
fluorinase.168 In the presence of fluoride ion, the cultures of MA37 also produced 
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fluoroacetate and 4-fluorothreonine, as well as a range of unidentified fluorinated 
products, as observed by 19F-NMR spectroscopy.168 
Further investigations showed that the genome in MA37 had a high homology to that 
of Salinispora tropica, the organism with a chlorinase enzyme involved in the 
biosynthesis of salinosporamide A.118 This chlorinase is closely related to the 
fluorinase, and they work in a similar manner. The early steps of the salinosporamide 
A production are shown in Scheme 20.118 
 
Scheme 20. Early steps in the salinosporamide A chlorinase metabolic pathway118 
Unlike Streptomyces cattleya and Streptomyces sp. MA37, Salinispora tropica does 
not produce fluoroacetate or fluorothreonine. However, the first two steps of the 
metabolic pathway are analogous to those in S. cattleya. Comparison of the genome of 
S. tropica and MA37 showed functional homology amongst some of the enzymes 
involved in both metabolic pathways. 118,155 
Therefore, a metabolic pathway for the new fluorometabolites was proposed, merging 
those of S. cattleya and S. tropica, and creating a branch point in 5-FDRP (18).155 This 
is shown in Scheme 21, with the separated upper and lower branches signalled.155 
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Scheme 21. Proposed metabolic pathway for the fluorinase Streptomyces sp. MA37155 
Testing this hypothesis led to the discovery of the most-recently isolated 
fluorometabolite: (2R,3S,4S)-5-fluoro-2,3,4-trihydroxypentanoic acid (2). The identity 
of this new compound was proven by total synthesis and GC-MS analysis. So far, the 
pathway is structurally secure up to the formation of 2, but the nature of the further 
metabolites remains unknown.155 
 
Fig. 28 19F NMR analysis of a Streptomyces sp. MA37 culture, with identified molecules 1, 2 and 4 and 
several unidentified structures155 
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It is interesting to note that although the fluorinase can act as a chlorinase,169 the 
opposite does not occur, and the chlorinase is not capable of incorporating fluorine. 
Genetic engineering - carried out in a collaboration between St Andrews and the 
Scripps Institution of Oceanography - have enabled the formation of 
fluorosalinosporamide, in an engineered Salinispora tropica, by knocking out that 
chlorinase gene and replacing it with the fluorinase gene.170 
 
Fig. 29 Structure of fluorosalinosporamide 
1.5.4 Other organisms containing a fluorinase 
Since the discovery of the fluorinase in Streptomyces sp. MA37, another three 
fluorinases have been identified by genome mining. All present more than 80% 
homology to the original fluorinase in Streptomyces cattleya.168,171 
Two of the new fluorinases were found in the genomes of sequenced organisms 
(Actinoplanes sp. N902-109 and Nocardia brasiliensis). PCR amplification of the 
genes, as well as over expression and purification of the enzymes in E. coli proved that 
both fluorinases are functional.168 
Additionally, a third functional fluorinase was found in Streptomyces xinghaiensis, the 
first from a marine source. The fluorinase pathway in S. xinghaiensis leads to the 
formation of fluoroacetate, but not fluorothreonine, and the production of fluoroacetate 
is sea-salt dependent.171 
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Chapter 2. Metabolism and lipophilicity profile of a range of 
novel fluorinated motifs 
Organofluorine compounds are relevant across all fields of performance chemicals, 
including medicinal, materials and agricultural chemistry. The substitution of 
hydrogen atoms for fluorine analogues bestows new characteristics to the recipient 
molecule, often improving its pharmaco-kinetic properties.1,2,3 The exploration of new 
fluorinated motifs is therefore of interest to offer new building blocks for research 
programmes.  
In this context, lipophilicity is a key pharmaco-kinetic property, normally expressed as 
a Log P value. Lipophilicity is directly related to a drug’s efficacy, since it determines 
the permeability of the compound through the cell membrane and its distribution in 
albumin.2 Historically, medicinal chemists aim for Log P values lower than five, but 
over the years, and with the levels of exigency growing considerably, this value has 
been lowered to three.4  
Many authors have studied and discussed the effect that fluorine has on the 
lipophilicity of a drug,1,5,6 and while it is generally assumed that fluorination increases 
lipophilicity, this does not always hold.7 The extent of that affirmation was explored 
for our new fluorinated motifs, and will be an important section of this chapter.  
In drug design programmes there is an additional need to study and analyse how a 
candidate behaves within the human body, in order to assess how viable that particular 
compound would be in metabolic terms. The fungus Cunninghamella elegans has been 
used as a model for mammalian drug metabolism, and it emerges as a very useful tool, 
given its ease of evaluation.8 
Cunninghamella elegans contains a high level of oxidation enzymes of the cytochrome 
P450 class, enzymes which have a role in phase I drug metabolism.9,10 Previous reports 
with this organism also describe the appearance of conjugative metabolites, resulting 
from phase II enzymes, for more labile compounds.11  
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During the last few years, different members from the St Andrews group have 
developed and synthesised a range of novel fluorinated motifs. Among the new motifs 
there are fluorocyclopropanes and fluorocyclohexanes, and also α,α-difluoroethyl thio- 
and oxy- ethers. The study of their metabolic fate, as well as research exploring their 
lipophilicity profile, is the main objective of this Chapter.  
2.1 Derivatives of all-cis phenylfluorocyclohexane 
2.1.1 Introduction to the syntheses and potential applications of all-cis 
(fluorocyclohexyl)benzenes 
Of all the cycloalkanes, cyclohexane is the most extensively studied as a motif in 
organic chemistry. Understanding the fundamentals of cyclohexane’s conformation, by 
Barton12 and Hassel,13 was awarded the Nobel Prize for Chemistry in 1969.14 The size 
of its ring makes it optimal in terms of strain and stability. Cyclohexane moieties are 
present in many natural products. The range goes from antibiotics, such as 
streptomycin (isolated from Streptomyces – Actinomyces – griseus in 1943)15 and 
neomycin (firstly found in Streptomyces fradiae – Actinomyces fradii – in 1949)16, to 
poisons – like strychnine or its derivative brucine. Other natural products include 
chemotherapeutic drugs like doxorubicin or paclitaxel. 
 
Fig. 1 Examples of natural products featuring one cyclohexane ring 
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Fused cyclohexanes are a fundamental feature of steroids – whose nucleus is 
composed of not one, but three cyclohexane rings and one cyclopentane ring. Three 
fused cyclohexane rings also constitute adamantane, whose derivatives have been 
widely used in medical chemistry. Particularly, adamantane is found in antivirals and 
drugs against infectious diseases, in drugs to treat Central Nervous System illnesses or 
in cancer research.17  
 
Fig. 2 Examples of popular multiple cyclohexane motifs in natural products 
According to a study carried out by Aldeghi and colleagues in 2014,18 cyclohexane 
was number six in the list of ‘ten most frequent ring fragments found in marketed 
drugs’. Thus, cyclohexanes are found in drugs such as anaesthetics, like phencyclidine 
(later replaced with ketamine); antidepressants of the SNRI family such as venlafaxine 
and desvenlafaxine; or anticancer and chemotherapeutic drugs like docetaxel or 
etoposide. 
 
Fig. 3 Examples of marketed drugs containing cyclohexane motifs 
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The substitution of hydrogen for fluorine atoms has had an important impact in drug 
development.1,2,3 However, even though cyclohexane and fluorine are very commonly 
found in organic chemistry, examples in which they appear together, as 
fluorocyclohexanes, are very rare. 
In an attempt to change the classical properties of cyclohexane, the St Andrews group 
started to explore all-cis vicinal fluorocyclohexanes, with the syntheses of all-cis 
1,2,3,4-tetrafluorocyclohexane 19  (Scheme 1) and all-cis 1,2,4,5-tetrafluoro 
cyclohexane20 (Scheme 2) in 2011. The characteristic all-cis disposition of the fluorine 
atoms in these derivatives imparts exceptionally high dipole moments for aliphatic 
rings, making them interesting new motifs.19,20  
The synthesis of all-cis 1,2,3,4-tetrafluorocyclohexane 36 is shown in Scheme 1.19 
Stereochemical control was required for the formation of all-cis 1,2,3,4-
tetrafluorocyclohexane 36, sequentially converting the C-O bonds of cis 1,3-
diepoxycyclohexane 31 to C-F bonds. 
 
Scheme 1. Previous synthesis for all-cis 1,2,3,4-tetrafluorocyclohexane19 
A preparation of the isomer all-cis 1,2,4,5-tetrafluorocyclohexane 39 was published 
shortly after (Durie et al., 2012),20 as shown in Scheme 2. The procedure was more 
direct and consisted of only two steps. Diepoxidation of 1,4-cyclohexadiene with 
mCPBA, followed by fluorination of the resultant diepoxide with DAST at 70 ºC gave 
the product (39). This final step was low yielding, however overall the route proved 
practical to generate milligrams of this solid (m.p. = 107-109 ºC).20  
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Scheme 2. Published synthesis for all-cis 1,2,4,5-tetrafluorocyclohexane20 
A key characteristic of both of these structures is that they have 1,3-diaxial C—F 
bonds in the chair conformation, and ring interconversion also generates 1,3 diaxial 
conformers (Fig. 4). This special arrangement of the fluorines gives them high 
molecular dipole moments: 4.91 D for 36 and 5.18 D for 39.19,20 
 
Fig. 4 Chair conformations of 36 and 39 
This progressed to the synthesis of all-cis hexafluorocyclohexane 40 in St Andrews in 
2015.21 Cyclohexane 40 is the stereoisomer of 1,2,3,4,5,6-hexafluorocyclohexane with 
the highest energy, and one of the most polar aliphatic molecules known (µ = 6.2 D).21 
Following the St Andrews synthesis, a direct hydrogenation of hexafluorobenzene was 
developed by Glorius in Germany in 2017.22 
In practice, this all-cis arrangement creates molecules with differenciated faces: an 
electronegative cation-binding fluorine face and an electropositive anion-binding 
hydrogen face.21 They have been referred to as ‘Janus-faced’ compounds, given their 
resemblance to the Roman god of past and future Janus (usually represented with two 
faces: one overlooking the past, and one overlooking the future), as shown in Fig. 5. 
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Fig. 5 Janus-faced all-cis hexafluorocyclohexane 
The St Andrews synthesis is shown in Scheme 3, and consists of 12 steps.21 
 
Scheme 3. Synthesis for all-cis 1,2,3,4,5,6-hexafluorocyclohexane by Keddie et al.21 
The last fluorination step is particularly limiting with a yield of approximately 10%. 
This synthetic route is not appropriate for large-scale production of 40. The Münster 
synthesis is much more efficient, generating 40 in a 34% yield, in just one step.22 A 
yield that was further improved to 88%, by the addition of silica gel.23 This method 
uses a specific rhodium catalyst, as shown in Scheme 4. 
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Scheme 4. One step synthesis for all-cis 1,2,3,4,5,6-hexafluorocyclohexane 4023 
Despite the significant improvement for the synthesis of fluorocyclohexanes, and 
particularly of all-cis 1,2,3,4,5,6-hexafluorocyclohexane 40 and both isomers of all-cis 
tetrafluorocyclohexane 36 and 39, the generation of functionalised derivatives remains 
a challenge. 
Currently the most developed approach in this regard are the phenyl derivatives of all-
cis 1,2,4,5-tetrafluorocyclohexane 39.24,25,26,27 A secondary advantage deriving from 
the attachment of the phenyl ring is the higher volatily of the precursors to these 
products, which considerably facilitates their manipulation.  
As shown in Scheme 5, the syntheses of the all-cis fluorocyclohexyl derivatives start 
from biphenyl, which is transformed to 1,4-dihydro-1,1’-biphenyl (53) by means of a 
Birch reduction. The resultant diene is then treated with mCPBA to give diepoxide 54 
and then with hydrogen fluoride to generate the mixture of isomers 55 and 56 (1.6:1). 
Both isomers, once separated, are activated as their triflates and then fluorinated. 
These reactions lead to the tetra- and tri- fluorocyclohexyl derivatives (62 and 59), 
respectively.24,25,26,27 
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Scheme 5. Syntheses of derivatised fluorocyclohexanes 24,25,26,27 
Scheme 6 shows the synthesis of the tri- and di- fluoro derivatives from the same 
intermediate (57). After triflate elimination with DBU, hydrogenation of the double 
bond gives cyclohexanes 65 and 66, the latter with the loss of a fluorine atom. Once 
the hydrogenation products have been purified, they are both treated in the same 
manner with HF·pyridine, to give 59 and 58, respectively.25,26 
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Scheme 6. Route to 59 and 58 from compound 5725,26 
Finally, the carboxylic acid derivatives 60 and 63 were accessed by a four-step 
synthesis involving iodination, palladium-catalysed carbonylation and hydrolysis of 
the esters 69 and 70 to give the corresponding carboxylic acids, 60 and 63 (Scheme 
7).27 
 
Scheme 7. Synthesis of carboxylic acids 60 and 63 from 59 and 6227 
Compounds 58, 59, 60, 62 and 63 used in the following sub-sections of this Chapter 
were prepared by Dr Mohammed Salah Ayoup (University of St Andrews). 
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2.1.2 Aims and Objectives 
In order to study how the number of fluorine atoms affects the metabolic stability of 
these derivatives, all-cis tetra-, tri-, and difluorocyclohexyl benzenes 62, 59 and 58 
were selected for this study, as well as the two para-substituted benzoic acid 
derivatives 60 and 63. 
 
Fig. 6 Selected molecules for the metabolic studies with C. elegans 
The fungus Cunninghamella elegans was used to explore the metabolic vulnerability 
of each of the selected compounds, and their resultant metabolites were isolated by 
HPLC prior to full characterisation by NMR spectroscopy and mass spectrometry.  
Additionally, a reverse-phase HPLC method for the estimation of lipophilicities was 
designed and developed. 
2.1.3 Estimation of lipophilicities by the use of 19F NMR spectroscopy 
Historically, the ‘drug-likeness’ of a molecule was assessed according to a series of 
factors, which are generally formalised as the ‘Lipinski’s Rule of Five’. According to 
Lipinski, a successful candidate would not have more than five hydrogen bond donors 
and ten hydrogen bond acceptors. The molecular weight would be less than 500 Da, 
and its octanol-water partition coefficient (expressed as Log P) should be lower than 
five.28,29 
The traditional procedure to measure partition coefficients is the ‘shake-flask method’ 
between octanol and water. However, this method can be difficult to achieve 
reproducible results, and dissimilar values are often reported in literature.30  
In 2016, at the start of this project, Linclau and coworkers published an accurate 
method of estimating the Log P values of particularly polar fluorinated compounds by 
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the use of 19F NMR spectroscopy.31 This procedure is based on the ‘shake-flask 
method’, and consists of addition of the product, with an internal reference, to a 
biphasic medium of octanol and water. Then, a 19F NMR spectrum of each of the 
phases is recorded, and the peaks integrated relative to each other in the different 
phases.   
The relationship between the integration values and the Log P estimations is as 
follows.31 
First, it is necessary to define the integration ratio (ρ) for the aqueous and the octanol 
phases. In the following equations, ‘X’ refers to the compound to be measured and 
‘ref’ is the reference. 
ρ!"# = I!"#!I!"#!"# = !!C!"#!!!"#C!"#!"#  
ρ!" = I!"!I!"!"# = !!C!"!!!"#C!"!"# 
Once the integration ratio for both phases has been defined, it is possible to calculate 
the partition coefficient (P), can be calculated as follows: 
ρ!"#ρ!" = C!"#! C!"!"#C!"! C!"#!"# = P!P!"# 
P! = P!"# ρ!"#ρ!"  
log!! = log!!"# + log ρ!"#ρ!"  
Since the log P of the reference is well known, the only unknown variable is the log P 
of the compound under investigation. 
For this NMR method, the settings of both the actual NMR experiment and that for 
processing the FID are extremely relevant, such that the results are reproducible. 
According to the method, the important parameters are the frequency offset point 
(O1P) and the pulse delay time (D1). In order to obtain the best signal to noise ratio – 
and therefore a more accurate integration – the pulse delay time (D1) of the samples 
needs to be sufficiently long. These were evaluated by Linclau such that D1 for 
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octanol should be 30 s and for water, 60 s. The frequency offset point (O1P) should be 
centred on the fluorine signals, thus it varies for each sample. Other variables were 
studied but found to be less relevant, such as spectral width (SD) or the number of 
scans (NS).31 Therefore, unless otherwise stated, the number of scans was left on the 
automatic selection for the instrument (NS = 64 scans). All spectra were processed in 
the same way, using Topspin 3.5pl5.  
2.1.3.1 Calibration Experiments 
The necessity for some calibration experiments became apparent at the start of this 
project, in order to adapt the method to the selected compounds. To probe the 
suitability and reproducibility of the procedure, it was decided to run two sample 
experiments, with two molecules whose Log P values had been previously evaluated 
against 2,2,2-trifluoroethanol (TFE, 71): 1,3-difluoro-2-propanol (72) and 2-fluoro 
phenol (73).31 In his article, Linclau used both as references, depending on the 
chemical shift of the products to be assessed.31  
2.1.3.1.1 2,2,2-Trifluoroethanol (71) against 1,3-difluoro-2-propanol (72) 
2,2,2-Trifluoroethanol (TFE, 71) was chosen as the first reference compound, to 
estimate the value of 1,3-difluoro-2-propanol’s Log P. This exact experiment was 
published by Linclau, and therefore allows the reproducibility to be assessed.  
The procedure and sample preparation followed the published method,31 by adding 
TFE and 1,3-difluoro-2-propanol into a pear-shaped flask containing HPLC grade 
octanol and a stirrer bar. Finally, milliQ water was added. The flask was stirred for 3 
hours at room temperature, and the phases were left to separate overnight.  
The NMR samples were prepared carefully to avoid contamination between the 
phases. A fraction of the upper octanol layer was extracted with a 1 mL syringe and a 
needle, and some was discarded to ensure that no aqueous residues were left in the 
needle. The remaining sample were transferred into an NMR tube with d6-acetone, and 
homogenised.  
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The preparation of the lower aqueous sample required precaution to avoid octanol 
contamination. In this case, some air was taken with the syringe and needle and it was 
slowly discharged while passing through the organic layer to avoid accidentally 
collecting any octanol. The remaining air was slowly discharged into the aqueous 
phase to avoid any mixing, and a sample of the aqueous layer was taken. The needle 
and syringe were removed as efficiently as possible, and some water was discarded to 
avoid contamination. The needle was also externally wiped with a tissue. The 
remaining sample was added into an NMR tube followed by d6-acetone, and 
homogenised.  
In both cases, a full range 19F {1H} NMR spectrum was run. Manual FID processing 
led to the following results: 
ρ!"#$% = I!"I!" = 100.0060.24 = 1.62 
ρ!"#$%!& = I!"I!" = 27.08100.00 = 0.271 log!!" =  +0.36 
log P!" = log P!" + log ρ!"#ρ!"#$% = +0.36 + log 0.2711.62 = +0.36 + −0.79 = −0.43 
This value matched the one described by Linclau (log P72 = -0.42), however, the 
method of integration is important, since the automated integration readout was 
inaccurate: 
ρ!"#$% = I!"I!" = 0.99930.3405 = 2.94 
ρ!"#$%!& = I!"I!" = 0.33621.0000 = 0.3362 log!!" =  +0.36 
log P!" = log P!" + log ρ!"#ρ!"#$% = +0.36 + log 0.3362.94 = +0.36 + −0.94 = −0.58 
In Table 1, the different values obtained for 1,3-difluoro-2-propanol are displayed, in 
order to establish a comparison. 
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Table 1. Comparison of Log P values for 1,3-difluoro-2-propanol from different sources 
Source Log P value 
Literature (calculated, cLog P)* -0.36 
Linclau (experimental)31 -0.42 
This project (experimental, automatic integration) -0.58 
This project (experimental, manual integration) -0.43 
* The cLog P of -0.36 was calculated by an ACD/Labs Software V11.02 (© 1994-
2018 ACD/Labs), and it does not match experimental values. The literature value was 
also retrieved from the U.S. National Library of Medicine online database 
(http://chem.sis.nlm.nih.gov/chemidplus/)  
With these results, it became evident that the method for integrating the signals is 
extremely important, given that a very small change provokes a significant difference 
in the final value – even within the same experiment. It is also necessary to repeat 
experiments to ensure reproducibility. 
2.1.3.1.2 TFE (71) against 2-fluorophenol (73) 
The second calibration experiment was carried out with two objectives. The first was 
to ensure the reproducibility of the method; and the second, to obtain an experimental 
value for 2-fluorophenol. 2-Fluorophenol (73) has a more similar chemical shift to the 
all cis-fluorocyclohexyl motifs than TFE, and therefore, its use as a reference 
compound should lead to more accurate Log P evaluations.  
This experiment was conducted by reproducing the conditions used in the previous 
calibration test. TFE and 2-fluorophenol were added into a pear-shaped flask with 
octanol and MilliQ distilled water, and stirred for 3 hours.  
Again, the way the FID processing was carried out was crucial, leading to different log 
P values when automatic and manual integration methods were applied. Table 2 
shows the different values obtained for 2-fluorophenol depending on the conditions 
used, and those described in the literature. 
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Table 2. Comparison of Log P values for 2-fluorophenol from different sources 
Source Log P value 
Literature (cLog P)30b 1.82 
Linclau (experimental)31 1.70 
This project (experimental, automatic integration) 1.72 
This project (experimental, manual integration) 1.70 
For a second time, the manual integration showed better consistency with Linclau’s 
results. This time, the ΔLog P = 0.02 between the automated and the manual results, 
was much closer. After these calibration experiments, 2-fluorophenol 73 was 
considered as a good reference compound. 
2.1.3.2 Log P estimation of the selected all-cis fluorocyclohexanes 
2.1.3.2.1 All-cis tetrafluorocyclohexylbenzene (62) 
The chosen reference 2-fluorophenol (73) was used to determine a lipophilicity value 
for all-cis tetrafluorocyclohexylbenzene 62, using an analogous procedure to that of 
the calibration assays. 
NMR samples were prepared as usual, and run using the following settings: aqueous 
sample (NS = 64 scans, D1 = 60 s, O1P = -169 ppm); octanol sample (NS = 64 scans, 
D1 = 30 s, O1P = -169 ppm).  The centre of the spectrum, established by the frequency 
offset point (O1P), was set between the reference signal and that of compound 62, to 
ensure the best accuracy. Manual integration of the peaks led to a Log P value of 2.45. 
The experiment was repeated, and a Log P value of 2.46 was obtained, thus indicating 
good reproducibility (ΔLog P = 0.01) for both runs. After these results, the method 
was understood to be reliable if manual integration is used. However, the intensity of 
the NMR signals was quite low, given the very poor solubility of 62 in water or 
octanol. 
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2.1.3.2.2 All-cis trifluorocyclohexylbenzene (59) 
The treatment of all-cis trifluorocyclohexylbenzene (59) with 2-fluorophenol in 
octanol and water as described allowed NMR analysis (O1P = -166 ppm) of the 
phases, leading to a Log P value of 2.36. Repetition of the assay afforded a Log P 
value of 2.38. 
The close difference between these two experiments (ΔLog P = 0.02), suggests good 
reproducibility. However, the increasing error when compared with the tetrafluoro 
derivative 62 can be explained by the lower solubility of 59 in water, producing a 
lower signal to noise ratio, and influencing the integration values. 
2.1.3.2.3 All-cis difluorocyclohexylbenzene (58) 
The procedure followed for this experiment was identical to those previously 
described. However, in this case, the very low intensity of the fluorine signals (O1P =  
-168 ppm) in the aqueous phase did not allow the determination of a Log P value for 
58. The NMR experiment for the aqueous sample was increased to 128 scans instead 
of 64, however this did not improve the signal to noise ratio.  
A second assay was carried out, in order to establish whether it was possible to obtain 
a better NMR signal of the aqueous phase containing 58. To this end, the amount of 58 
was increased to 10 mg, and the amount of octanol decreased to 1.5 mL, to favour its 
solubility in water. Stirring was extended for 6 hours before leaving the phases to 
separate. However, this did not improve the concentration of 58 in the aqueous phase, 
as determined by NMR spectroscopy. 
2.1.3.2.4 All-cis tetrafluorocyclohexyl carboxylic acid (63) 
Cyclohexane 63 was available in very low amounts, given its challenging synthesis in 
the lab. Therefore, only one experiment to determine its lipophilicity was carried out. 
Examination of NMR spectra (O1P = -170 ppm) allowed a preliminary estimation of 
the Log P value as 1.36. Additionally, the solubility of 63 in water is extremely low, 
and determination of the integral values for the 19F NMR signals was unreliable. 
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2.1.3.2.5: All-cis trifluorocyclohexyl carboxylic acid (60)  
The assay to determine the lipophilicity value of 60 presented the same challenges as 
that of the previous experiment. While scarcity of product allowed only one 
experiment, its low solubility did not allow a precise manual integration. Hence, the 
recorded value (Log P = 1.46) is only a preliminary one. 
Conclusions on the use of 19 F {1H} NMR for the estimation of Log P values 
When possible, the experiments in this section were repeated at least once to ensure 
reproducibility. 
Despite the convenience of the 19F NMR method, it was not particularly successful for 
the (fluorocyclohexyl)benzene derivatives, which have Log P values higher than 2. 
The poor solubility of this family of compounds – especially in the aqueous phase – 
gave poor signal to noise ratios, which compromised the accuracy of the Log P values 
obtained. 
Thus, although the method described by Linclau31 is good for fluorinated sugars and 
other compounds of high water solubility (and low Log P), it is limited in terms of 
compounds with Log Ps in the 2 to 5 range. 
2.1.4 Determination of Log P values by reverse-phase HPLC 
An alternative method for the estimation of the Log P values was explored, this time 
by reverse-phase HPLC, based on retention time on a C18 column with an aqueous 
phase. The estimation of lipophilicity values was conducted using a Phenomenex Luna 
C18 100A (250 mm x 4.60 mm) 5µ column in a Shimadzu Prominence HPLC, based 
on the premise that Log P values are directly proportional to retention times, as stated 
by Gianinis in 2008.32  
A series of reference compounds, with known literature lipophilicity values,30 were 
evaluated (injecting 5-10 µL of 0.5 mg/mL solution in MeCN). The retention times 
(Rt) were used to calculate the capacity factors (k) with the following equation: 
Capacity factor k = Retention Time − Dead Time of the columnDead Time of the column  
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The dead time of the column is the time that takes for an unretained molecule (such as 
the solvent) to pass through. For the particular experimental conditions used, the dead 
time of the column was calculated to be 1.97 min. 
Table 3 shows the experimental values obtained and the calculations used to evaluate 
Log Ps.  Literature Log P values30 of the reference compounds are displayed in red, 
along with the experimental retention times observed for each molecule (measured in 
triplicate). Average retention times were calculated using each of the three values 
obtained, and this average value was used to calculate the capacity factor for each 
reference compound (using the equation described above). Finally, the logarithm of k 
was calculated (values shown in green). 
For this study, the experimental conditions (60:40 MeCN:water, 1mL/min) included 
supplementation of the eluents with 0.05% of TFA, in order to protonate the 
carboxylic acids, and obtain sharper peaks. The set of conditions shown in Table 3 are 
the result of multiple optimisations of the method, developed in order to give the most 
reproducible values.  
Table 3. Literature Log P,30 measured retention time (Rt) and capacity factors (k) for the references 
Reference Log P Rt 1 
(min) 
Rt 2 
(min) 
Rt 3 
(min) 
Average Rt 
(min) 
Capacity 
factor (k) 
Log k 
Phenol 1.50 3.99 3.99 3.99 3.99 ± 0.00 1.03 0.013 
2-Fluorophenol 1.71 4.18 4.18 4.18 4.18 ± 0.00 1.13 0.051 
Benzofuran 2.67 8.42 8.42 8.43 8.42 ± 0.01 3.29 0.52 
Toluene 2.73 10.27 10.27 10.27 10.27 ± 0.00 4.23 0.63 
o-Xylene 3.12 13.36 13.34 13.37 13.36 ± 0.02 5.80 0.76 
Naphthalene 3.35 12.75 12.75 12.78 12.76 ± 0.02 5.50 0.74 
Cumene 3.66 18.87 18.88 18.91 18.89 ± 0.02 8.61 0.94 
t-Butylbenzene 4.11 23.93 23.86 23.91 23.90 ± 0.04 11.16 1.05 
Butylbenzene 4.26 31.10 31.15 31.14 31.13 ± 0.03 14.84 1.17 
Anthracene 4.45 25.08 25.07 25.02 25.06 ± 0.04 11.75 1.07 
Pyrene 4.88 33.24 33.33 33.17 33.25 ± 0.08 15.92 1.20 
 83 
The calculated log k (Y-axis) values were plotted against their reported Log P values 
(X-axis) to obtain a linear regression equation, as represented in Plot 1.  
 
Plot 1. Regression line obtained for the reference compounds 
The equation obtained in Plot 1 was used to calculate the Log P values of a series of 
compounds by substitution of the logarithm of their capacity factor values in the 
equation above. Retention times, capacity factors (k) and their logarithms are shown in 
Table 4, along with the Log P values (blue), estimated by substitution of the Log k 
values in the regression equation in Plot 1. 
Table 4. Estimation of Log P (blue) by using the logarithm of the measured capacity factors (green) 
Compound LogP Rt 1 Rt 2 Rt 3 Average Rt k Logk 
62 2.58 7.78 7.78 7.72 7.76 ± 0.04 2.95 0.47 
59 2.64 8.08 8.08 8.03 8.06 ± 0.03 3.10 0.49 
63 1.50 4.28 4.27 4.28 4.28 ± 0.01 1.18 0.07 
60 1.51 4.29 4.30 4.30 4.30 ± 0.01 1.19 0.07 
58 3.30 12.68 12.68 12.61 12.66 ± 0.05 5.44 0.74 
74 2.79 8.87 8.88 8.87 8.87 ± 0.01 3.52 0.55 
52 3.76 17.82 17.81 17.71 17.78 ± 0.07 8.05 0.91 
75 4.99 46.88 46.53 46.89 46.77 ± 0.24 22.80 1.36 
76 2.28 6.45 6.45 6.45 6.45 ± 0.00 2.28 0.36 
77 3.23 12.00 11.99 12.00 12.00 ± 0.01 5.11 0.71 
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Table 4 also presents cyclohexyl and phenyl analogues of the studied compounds 
which were selected in order to establish lipophilicity comparisons, particularly to 
explore the effect of the 1,3-diaxial C—F bonds on the polarity. The effect of the 
number of fluorine atoms and the presence of the carboxylic acid group were also 
probed. For a more visual representation, structures are shown by families and in 
increasing lipophilicity order in Fig. 7.  
 
Fig. 7 Comparison of the Log P values and lipophilicity trends for selected fluorocyclohexanes and 
comparative analogues  
The lowest Log P (most hydrophilic) values are those for the tetrafluorinated 
analogues, followed by the trifluorinated and difluorinated compounds, while the 
structures without fluorine display the highest lipophilicities. It is clear that the number 
of fluorine atoms affects the lipophilicity values considerably.  
A comparison of 74 (which lacks 1,3-diaxial fluorines) with 59, shows that the diaxial 
fluorine atoms do have an effect on lipophilicity, even though not as significant as the 
complete removal of a fluorine, as is the case of 58. Hence, the increasing lipophilicity 
order goes from all-cis trifluorinated cyclohexane 59, followed by the non-cis 74 to the 
difluorinated structure 58, having 58 the highest lipophilicity of the fluoro series.  
Carboxylic acids 60 and 63 are inherently more polar than the phenyl derivatives, 
however the increasing number of fluorines leads to a progressive lowering of their 
Log Ps. 
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2.4.1.1 Conclusions on the use of a reverse-phase HPLC method to estimate 
lipophilicities 
The reverse-phase HPLC method for the estimation of lipophilicity values was very 
convenient and easy to use, although it required optimisation before obtaining a 
reliable set of values. Aqueous solubility does not constitute a problem, since the 
samples are prepared in acetonitrile, instead of an octanol-water mixture. 
The values presented were not measured at neutral pH. TFA was added to acidify the 
eluent solvents, in order to measure the carboxylic acids. However, the values of the 
phenyl derivatives were also recorded at neutral pH (with no TFA present) to study 
their variation with pH. They did not vary significantly for the non-carboxylated 
products (Table 5), indicating the method is quite robust.  
Table 5. Comparison of Log P values with and without supplemented TFA 
 
   
Log P (No TFA) 2.54 2.60 3.24 
Log P (With TFA) 2.58 2.64 3.30 
 
A clear outcome from this work has been that not only does fluorine addition lower the 
lipophilicity of cyclohexane rings, but that the lipophilicity values are below Log P = 
3.5, bringing these compounds into the range as candidates for drug scaffolds. 
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2.4.1.2 Molecular dynamics  
Molecular dynamic studies evaluating how water interacts with the cyclohexyl 
derivatives were performed in collaboration with Stefano Bosisio and Julien Michel 
(University of Edinburgh).26,33 The preferred location of water and the contribution of 
water molecules to enthalpy, entropy and free energy values was studied.26 In this 
sense, Fig. 8 illustrates a hydration profile for all-cis tetrafluoro cyclohexane 62 and its 
non-fluorinated analogue 75.26   
 
Fig. 8 Average interactions of water molecules (red) with non-fluorinated 75 (structure A) and 
tetrafluorinated 62 (structure B)26 
For both 75 and 62, there is a similar association of water to each face of the phenyl 
ring, however, the cyclohexyl rings are different. Water density around the non-
fluorinated cyclohexyl motif in 75 is quite low (A), while for in the fluorinated 
analogue 62, it is significant (B).26  
Given the opposite polarities of the faces in 62, water associates most significantly 
with the hydrogen face and less significantly with the fluorine face. The polarity of the 
ring arises from the polarised hydrogens, and therefore, hydrogen bonding to water 
rationalises the increased hydrophilicity of the hydrogen face.26  
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2.1.5 Metabolic fate in Cunninghamella elegans 
Given that the lipophilicity values for these cyclohexanes is within the medicinal 
chemistry range, a study of the metabolism of all-cis (fluorocyclohexyl)benzenes 
became an objective. This was carried out partly in collaboration with Prof. Cormac 
Murphy, at University College Dublin, including a three-month placement. The model 
organism Cunninghamella elegans was used.34,35  
The incubation, inoculation and extraction procedures of compounds 62, 59, 58, 63 
and 60 in the fungus were carried out in a standardised manner. Compounds (as a 
solution in DMF) were added to mature liquid cultures of the fungus, incubated for 3 
days, and extracted into ethyl acetate. Purification was achieved using reverse-phase 
HPLC, and the compounds characterised by NMR spectroscopy and mass 
spectrometry. A full description of the procedure can be found in the Experimental 
Chapter of this thesis. 
Additionally, and in order to ensure that the biotransformations were carried out by the 
fungus, and not as result of decomposition from being in the medium for three days, 
blanks with no C. elegans were run for all the compounds. In these experiments, only 
starting materials were recovered in all cases. 
2.1.5.1 All-cis (2,3,5,6-tetrafluorocyclohexyl)benzene (62) 
An earlier one off study on the metabolic fate of all-cis (2,3,5,6-
tetrafluorocyclohexyl)benzene 62 had been investigated in Streptomyces griseus by Dr 
Mohammed S. Ayoup (University of St Andrews). Dr. Ayoup observed the formation 
of 78 as the only metabolite.  
       
Scheme 8. Bioconversion of 62 to 78 (Dr. Ayoup, University of St Andrews) 
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In that experiment, it was obvious after observation of the bacterial culture that there 
was some form of fungal contamination present. When the experiment was repeated 
using an aseptic batch of S. griseus, only starting material was recovered. These results 
seemed to indicate that the fungal contamination in the original culture was the cause 
of the biotransformation.  
In this study, compound 62 was incubated with C. elegans. The experiment was 
carried out in triplicate to establish the reproducibility of the assays. Preliminary GC-
MS analysis of the extracts indicated the formation of a new product, compatible with 
monohydroxylation at around 30% conversion.  
 
Scheme 9. Metabolism of all-cis (tetrafluorocyclohexyl)benzene 62 in C. elegans 
Reverse-phase HPLC purification allowed the isolation of starting material (tret = 23 
min) and this new metabolite (tret = 18 min). 1H NMR spectroscopy and high-
resolution mass spectrometry were consistent with monohydroxylation, and a crystal 
structure was obtained, confirming alcohol 78 as the product. 
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Fig. 9 Crystal structure obtained by Dr. Ayoup for 78 26 
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2.1.5.2 All-cis (2,3,6-trifluorocyclohexyl)benzene (59) 
The influence of the number of fluorine atoms on the level of metabolism of the 
cyclohexanes was of interest. Therefore, it became necessary to gradually decrease the 
fluorine atoms present. Accordingly, all-cis (2,3,6-trifluorocyclohexyl) benzene 59 was 
probed. 
The experiments were carried out in triplicate and led to the same outcome, with the 
formation of one new metabolite, at a conversion of around 50% after 3 days. Full 
NMR and mass spectrometry analysis of the isolated metabolite indicated the benzyl 
hydroxylated product 79.  
 
Scheme 10. Metabolism of all-cis (2,3,6-trifluorocyclohexyl) benzene 59 in C. elegans 
2.1.5.3 All-cis (2,3-difluorocyclohexyl)benzene (58) 
Incubation of 58, which has two fluorine atoms, with C. elegans gave a complex 
mixture of products. Purification of these metabolites by reverse-phase HPLC proved 
to be challenging, given their close retention times. However, five different fluorinated 
metabolites were isolated. No starting material was recovered from these cultures, 
indicating complete conversion; and thus, suggesting the metabolic instability of this 
difluorinated derivative.  
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Fig. 10 HPLC trace (70% AcCN:Water) for the extract, after incubating 58 with C. elegans 
As shown in Fig. 10, the major metabolite remains the monohydroxylated product 84 
(pink star), but other products are the result of anti hydroxylation in C4 (blue star, 82) 
and of both syn and anti monohydroxylation at C5 (green and yellow stars, products 80 
and 83). The least anticipated product comes at tret = 16.5 min (purple star, 81). This 
metabolite features syn monohydroxylation at C5, relative to the fluorine position, and 
indicates the loss of a fluorine atom. The formation of this product would appear to 
require the action of more than one enzyme, and a pathway is suggested in Scheme 11.  
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Scheme 11. Putative pathway for the formation of monofluorinated metabolite 81 in C. elegans 
This hypothetical route starts with the observed metabolites 80 or 83 (stereoisomers), 
represented as single non-stereospecific structure 85 in Scheme 11. From here, 
oxidation to a ketone, followed by elimination of HF would offer a logical pathway. 
The conjugated double bond could then be reduced, and finally, the ketone converted 
to an alcohol. 
In order to probe this pathway, both diastereoisomers 80 and 83 were inoculated into 
fungal cultures and incubated for 72 h, but none of these assays led to the formation of 
81. Metabolites 82 and 84 were also incubated with C. elegans, but again no 
generation of 81 was observed. Presumably, these metabolites are exuded from the 
cells and do not re-enter. Thus, the origin of the monofluorinated cyclohexane remains 
ambiguous. 
2.1.5.4 All-cis 4-(2,3,5,6-tetrafluorocyclohexyl)benzoic acid (63) 
To further probe tetrafluorocyclohexane metabolism, incubation of all-cis 4-(2,3,5,6-
tetrafluorocyclohexyl)benzoic acid 63 was explored. This gave one product, which 
once again was the result of benzylic hydroxylation. The yield was low and the 
product was obtained in less than 10% conversion from the starting material. 
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Scheme 12. C. elegans incubation of  63 gave 89 
The low amount of product recovered from the culture did not allow for full NMR 
characterisation. However, it is possible to follow the disappearance of the benzylic 
hydrogen atom by 1H NMR spectroscopy. A high-resolution accurate mass was 
obtained for product 89, and was consistent with the structure. 
2.1.5.5 All-cis 4-(2,3,6-trifluorocyclohexyl)benzoic acid (60) 
Finally, and in order to complete the metabolism study, an incubation of all-cis 4-
(2,3,6-trifluorocyclohexyl)benzoic acid (60) was carried out. Again, the benzylic 
hydroxylation product was isolated (tret = 23 min). The reaction was relatively 
efficient, progressing to approximately 50% conversion in three days. 
 
Scheme 13. C. elegans incubation with 60 gave 90  
2.1.6 Enantiomeric excess analysis of all-cis (fluorocyclohexyl)benzene derivatives 
Compounds 58, 59 and 60 fed to the fungus were all racemic mixtures. It became 
relevant to assess whether C. elegans mediated hydroxylations would be more 
selective towards one enantiomer over the other.  
For chiral HPLC analysis, a sample of racemic all-cis (2,3,6-
trifluorocyclohexyl)benzene 59 was injected, to establish the optimal separation 
conditions of the enantiomers. The sample recovered from the incubation was injected 
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using the same conditions. HPLC enantiomeric analysis for racemic all-cis (2,3,6-
trifluorocyclohexyl)benzene 59, and after incubation with C. elegans (50% 
conversion) is shown in Fig. 11.  
 
Fig. 11 Chiral HPLC analysis for all-cis (2,3,6-trifluorocyclohexyl)benzene 59. The upper trace is 
racemic 59, and the lower trace is enantiomerically enriched (15% e.e.) after incubation with C. elegans 
In order to assess the enantiomeric ratio of 79, it became necessary to synthesise a 
racemic sample as a reference. The synthesis was carried out as shown in Scheme 14, 
and required a bromination step followed by introduction of the hydroxyl group by 
substitution.36  
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Scheme 14. Route to racemic 2,3,6-trifluoro-1-phenylcyclohexan-1-ol 79 
Benzylic bromination proved efficient, and allowed the required replacement of Br for 
OH. Following some recent work in the group, this last step was achieved in DMF to 
generate alcohol 79.36 A reasonable explanation for this process involves the 
participation of DMF as a nucleophile to form intermediate 92, as recently published 
by T. Bykova in the group for the tetrafluorinated ring system.36 This intermediate 
would then be attacked by the azide to release the benzylic alcohol, as shown in 
Scheme 15. 
 
Scheme 15. Putative mechanism for the generation of alcohol 79, where the oxygen source is DMF 
Racemic 2,3,6-trifluoro-1-phenylcyclohexan-1-ol 79 was analysed by chiral HPLC, 
and a good separation of the enantiomers was achieved. A sample of 2,3,6-trifluoro-1-
phenylcyclohexan-1-ol 79 produced from the incubation with C. elegans (50% 
conversion) was injected using the same conditions. This analysis (Fig. 12) indicates a 
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Fig. 12 Chiral HPLC analysis for 2,3,6-trifluoro-1-phenylcyclohexan-1-ol 79. Upper trace shows the 
racemic mixture. Lower trace presents the enantiomerically enriched (23% e.e.) 79 obtained after 
incubation with C. elegans at 50% conversion 
With these results in hand, the influence of the carboxylic acid group on enantiomeric 
selectivity was probed. However, it was not useful to inject carboxylic acid 60 directly 
onto the HPLC, as it is too polar, so it was derivatised as its methyl ester. The 
conditions and yield for this step are shown in Scheme 16, leading to quantitative 
formation of 93.37 Both the racemic and the metabolised samples were analysed by 
chiral HPLC, and led to identical racemic outcomes. 
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Scheme 16. Esterification conditions to 93 
The chiral HPLC results are presented in Fig. 13, for a 50% conversion in C. elegans. 
 
Fig. 13 Chiral HPLC analysis for 93. The upper trace shows the racemic starting material and the lower 
trace corresponds to residual 93 after incubation with C. elegans (50% conversion) 
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2.1.7 Conclusions on the work with all-cis (fluorocyclohexyl) benzenes 
C. elegans mimics human metabolism by performing Phase I modification by 
hydroxylation of xenobiotics. Lack of metabolism of an added xenobiotic would mean 
that the product is stable against metabolic degradation, and therefore, it would be 
unable to undergo Phase II metabolism and later be excreted from the organism. On 
the other hand, multiple hydroxylation, or a very active Phase I metabolism, would 
indicate poor metabolic stability, leading to low pharmaceutical efficiency. 
In this section, the influence of the number of fluorine atoms on an otherwise identical 
cyclohexane motif was established. It was successfully shown that as the number of 
fluorine atoms increases, so does the metabolic stability, which is opposite to the effect 
of the fluorines on the lipophilicity. The estimations of lipophilicity by reverse-phase 
HPLC show that the Log P values decrease considerably as the number of fluorine 
atoms increases (and the compounds become more polar). 
Both the lipophilicity and the metabolism studies are therefore promising for inclusion 
of the tetrafluoro motif in drug discovery programmes. 
Enantiomeric excess analysis showed that the fungus is not particularly selective for 
the individual chiral compounds that were presented.  
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2.2 α,α-Difluoroethyl thioethers and α,α-difluoro oxyethers  
2.2.1 Introduction to the syntheses and potential applications of α,α-difluoroethyl 
thio- and oxy- ethers 
This section focuses on α,α-difluoroethyl thioethers (R–SCF2CH3).38 This novel motif, 
introduced in St Andrews in 2018, has some similarity to both R–XCF3 and               
R–XCH2CF3 (X = S or O), moieties that are found quite widely in pharmaceutical 
drugs and agrochemicals. 
Interest in trifluoromethyl sulfides as drug scaffolds derives from their high 
lipophilicity, strong electron-withdrawing properties and improved metabolic 
stability. 39  These characteristics improve the cell membrane permeability and 
biochemical stability of the parent molecules, making them ‘privileged structural 
motifs in drug discovery’. 40 
Some examples are shown in Fig. 14, and include cefazaflur (a first generation 
cephalosporin antibiotic), toltrazuril (an antiprotozoal veterinary agent) or a losartan 
analogue (a potential hypotensive drug).41, 42 
 
Fig. 14 Examples of drugs containing a CF3S- motif 
2,2,2-Trifluoroethyl sulfide derivatives are claimed quite frequently in patents. In 
1990, for example, Uneyama patented the preparation of 2,2,2-trifluoro-1-
S
N
O OH
O
S
NNN
N
H NH
O
SCF3
Cefazaflur
(antibiotic)
N
N
H
N
O
O
O
O
SCF3
Toltrazuril
(coccidiostat)
F3CS
N
N
NK
NN
N
Losartan analogue
(hypotensive agent)
N
N
NK
NN
N
OH
Cl
Losartan
(hypotensive agent)
 99 
(phenylthio)ethanes for their use as pharmaceutical and agrochemical intermediates 
(Fig. 15a).43 More recently, Koehler and coworkers reported the preparation of several 
trifluoroethyl sulfide derivatives for pest control (Fig. 15b).44  
 
Fig. 15 Examples of trifluoroethyl sulfides in patents 
Analyses of the drug Riluzole, and its sulfuric analogue, SKA-19 (Fig. 16) were also 
performed by the St Andrews group.38 Riluzole is used to treat amyotrophic lateral 
sclerosis, as well as anxiety,38,45 while its sulfur containing analogue SKA-19 is a very 
potent anticonvulsant.38,46 
 
Fig. 16 Structures of riluzole and SKA-19, along with the expected bioisosteres 
The synthetic method used to obtain these α,α-difluoroethyl ethers is shown in Scheme 
17, and involves the double hydrofluorination of the corresponding ethynyl ethers with 
HF·pyr (70%).38  
 
Scheme 17. General procedure for the generation of selected difluorinated thio- and oxy- ethers38 
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2.2.2 Aims and Objectives 
It became an objective to assess the lipophilicity profile (Log P) of selected α,α-
difluoroethyl thio and oxy ethers (96 and 101), relative to reference compounds (Fig. 
17), given the very recent introduction of this motif.  
 
Fig. 17 Selected α,α-difluoroethyl thio and oxy ethers for the studies on lipophilicity, and the chosen 
compounds for comparison. Compopund 96 was synthesised by Dr. Tomita (University of St. Andrews), 
and compound 101 was prepared for this project. The rest of the products were commercially available 
Additionally, the metabolic stability of the difluoro motif – and therefore its metabolic 
fate – was investigated to obtain preliminary data that could inform future drug 
discovery programmes. The selected molecules are shown below (Fig. 18). 
 
Fig. 18 Selected α,α-difluoroethyl thio and oxy ethers for the studies on metabolism. Products 104 and 
105 were synthesised by Dr. Tomita and 106 was obtained by Dr. Al-Maharik (University of St. 
Andrews) 
2.2.3 Estimation of lipophilicities by the use of a reverse-phase HPLC method 
Estimation of the lipophilicity was carried out using a similar reverse-phase HPLC 
procedure similar to that used for the fluorinated cyclohexyl derivatives, without TFA 
added. 
The set of reference compounds used was the optimised range as described before, and 
shown in Table 6, with retention times established for the non-TFA added eluent 
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conditions. As expected, the changes in retention times are not significant, but re-
calibration was required to ensure accuracy. 
Table 6. Log P values for the compounds used to establish a reference curve 
Reference Log P Rt 1 (min) Rt 2 (min) Rt 3 (min) Average Rt (min) 
Capacity 
factor (k) Log k 
Phenol 1.50 4.30 4.30 4.26 4.29 ± 0.03 1.18 0.08 
2-Fluorophenol 1.71 4.20 4.21 4.50 4.30 ± 0.20 1.18 0.08 
Benzofuran 2.67 8.38 8.38 8.38 8.38 ± 0.00 3.26 0.51 
Toluene 2.73 10.26 10.27 10.25 10.26 ± 0.01 4.22 0.63 
o-Xylene 3.12 13.25 13.28 13.58 13.37 ± 0.30 5.80 0.76 
Naphthalene 3.35 12.73 12.73 12.76 12.74 ± 0.02 5.48 0.74 
Cumene 3.66 17.06 17.07 17.17 17.10 ± 0.07 7.70 0.89 
t-Butylbenzene 4.11 23.45 23.41 23.26 23.37 ± 0.11 10.89 1.04 
Butylbenzene 4.26 29.96 30.43 30.45 30.28 ± 0.32 14.41 1.16 
Anthracene 4.45 24.46 24.46 24.51 24.48 ± 0.03 11.46 1.06 
Pyrene 4.88 32.70 32.62 32.80 32.71 ± 0.09 15.65 1.19 
The values in Table 6 were used to establish a new regression curve, by plotting the 
calculated Log k against the reported Log P (Plot 2). 
 
Plot 2. Log k vs. Log P for the new neutral conditions, with no supplementation of TFA 
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This regression line was used to calculate the Log P values for the thio- and oxy- 
ethers series, as presented in Table 7. For the estimation of 101, it was necessary to 
synthesise this compound, as illustrated in Scheme 18.38 
 
Scheme 18. Synthetic procedure for the generation of 101 
 
Table 7. Measured lipophilicity values for a series of fluorinated thio- and oxy ethers 
Compound Log P Rt 1 Rt 2 Rt 3 Average Rt Capacity factor (k) Log k 
PhSCF3 (94) 3.70 17.67 17.68 17.68 17.68 ± 0.01 8.00 0.90 
PhSCH2CH3 
(95) 3.42 14.32 14.28 14.33 14.31 ± 0.03 6.28 0.80 
PhSCF2CH3 (96) 3.38 13.89 13.88 13.88 13.88 ± 0.01 6.07 0.78 
PhSCH2CF3 (97) 3.30 13.05 13.05 13.03 13.04 ± 0.01 5.64 0.75 
PhSCH3 (98) 2.87 9.61 9.61 9.62 9.61 ± 0.01 3.89 0.59 
PhOCF3 (99) 3.35 13.49 13.51 13.49 13.50 ± 0.01 5.87 0.77 
PhOCH2CH3 
(100) 2.96 10.42 10.09 10.12 10.21 ± 0.21 4.20 0.62 
PhOCF2CH3 
(101) 2.87 9.56 9.57 9.58 9.57 ± 0.01 3.87 0.59 
PhOCH2CF3 
(102) 2.83 9.28 9.28 9.48 9.35 ± 0.13 3.76 0.58 
PhOCH3 (103) 2.51 7.55 7.60 7.57 7.57 ± 0.03 2.85 0.46 
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These results are illustrated in Fig. 19, in a different format to Table 7, where a 
comparison is made between the lipophilicity and polarity trends.38 
 
Fig. 19 Lipophilicity versus polarity for a series of thio- and oxy- ethers 38 
The trends in lipophilicity and polarity observed during this investigation are 
informative. It is well-known that lipophilicity decreases upon monofluorination, but 
the trend reverses with vicinal trifluorination.47 Difluorination is generally similar to 
the values of monofluorination.1,2,3,47 In our series of thio- and oxy- ethers, the highest 
Log P values are observed with trifluoromethoxy- (99) and trifluorothio- (94) anisole; 
which contrast with the lowest Log P values of their hydrocarbon analogues anisole 
103 and thioanisole 98.38 For the compounds 95, 96 and 97; as well as their oxy 
derivatives, intermediate polarities are found. 
Partial fluorination generates orientated dipoles.47 Fluorine atoms also have a marked 
inductive effect, which results in the polarisation of their vicinal hydrogen atoms.38 
Studies on geminal α,α-difluoropropyl benzenes have concluded that the volume 
increase produced by fluorine substitution increases lipophilicity. In this way, although 
polarity is increased by the addition of a second fluorine atom, it is compensated for by 
the subsequent volume increase.47a Overall, this buffers the inductive effect and leads 
to an unchanged lipophilicity value with respect to the monofluorinated analogue, 
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although lower than the non-fluorinated derivative.47a These factors help explain the 
observed Log P values for the α,α-difluoroethyl thio (96) and oxy (101) ethers, and 
their non-fluorinated analogues (95 and 100). Additionally, these new motifs have a 
bridging sulfur or oxygen atom, both of which possess lone pairs. However, the 
negative inductive effect of the fluorine atoms will suppress lone pair donor capacity, 
and influence the lipophilicity values. 
Fig. 20 shows the electrostatic surface potential maps for the thio ether (left) and the 
oxygen ether (right).38  
 
Fig. 20 Electrostatic surface potential maps for the thio- and oxy- analogues 96 and 101. Computational 
analysis and calculations were performed by M. Bühl (University of St Andrews) 38 
Additionally, some other products were analysed in this lipophilicity study. For an 
easier reading and analysis of the results, the compounds have been organised in series 
1 to 6, in Figs. 21-23. 
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Fig. 21 Series 1 to 3. Log P values comparing the alkyl and ether chain lengths. (c) in 108 refers to a 
calculated Log P 
Series 1 reflects how the carbon chain length influences lipophilicity. The comparison 
of toluene, ethylbenzene and propylbenzene illustrates that the longer the carbon chain, 
the higher the Log P value. The same trends are observed for the oxygen and thio 
ethers in series 2 and 3. If these three series are compared, the behavioural trends are 
common, although the lipophilicity values are dissimilar. The absolute values on 
Series 1 are the highest, followed by Series 3. The oxygen ethers of Series 2 display 
the lowest lipophilicity values of the three. 
Series 4 (Fig. 22) highlights the effect of trifluorination for 2-membered chains 
attached to phenyl. Therefore, trifluoroethylbenzene 109, trifluoroanisole 99 and 
trifluorothioanisole 94 are compared. Interestingly, the non-ether 109 is the most polar. 
Series 5 and 6 are analogous to Series 4, for different length chains and different 
fluorinated motifs. 
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Fig. 22 Series 4. Log P comparisons of two-membered side chains with CF3 groups 
Series 4 shows that trifluoroethylbenzene 109 has the lowest Log P value, followed by 
the oxy and thio ether derivatives, 99 and 94 respectively. This highest lipophilicity is 
presumably due to the larger volume of sulfur, which actively softens the 
nucleophilicity of the lone pairs, reducing hydrogen bonding capacity and therefore 
resulting in a higher lipophilicity value compared to the oxygen analogue. The 
presence of the oxygen atom close to fluorine will decrease overall lipophilicity 
relative to the parent compound.48 In this case, this trend is not observed, and 
trifluoroethyl benzene 109 presents a lower Log P value than trifluoromethoxy 
benzene 99. This perhaps unexpected result can be explained by fluorine polarising the 
vicinal C-H bonds. 
 
Fig. 23 Log P comparison of three membered side chains containing PhXCH2CF3 and PhXCF2CH3 
motifs (X= C, O or S) 
Series 5 and 6 follow this behaviour too, when the sulfur and oxygen structures are 
compared. In this way, the oxy ethers emerge with the lowest lipophilicities. 
Interestingly, when the Ph-XCH2CF3 and the Ph-XCF2CH3 motifs (X= S or O) in these 
series are compared, the lipophilicity values are quite similar, indicating that they are 
good isosteres for one another. 
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2.2.4 Metabolic fate of the ethers in Cunninghamella elegans 
In order to explore the metabolic fate of these ether derivatives, three candidates were 
selected, based on their availability and low volatility. Accordingly, the selected 
compounds were (1,1-difluoroethyl)(4-methoxyphenyl)sulfane (104), (1,1-
difluoroethyl) (naphthalene-2-yl)sulfane (105) and 1-(1,1-difluoroethoxy)-4-
methoxybenzene (106). These compounds, shown in Fig. 24, were prepared in the 
University of St Andrews by Dr Tomita (104 and 105) and Dr Al-Maharik (106). 
Incubation, isolation and purification procedures followed those previously described. 
 
Fig. 24 Selected molecules for the study on metabolic fate in C. elegans 
2.2.4.1 (1,1-Difluoroethyl)(4-methoxyphenyl)sulfane (104) 
Incubation of thioether 104 in C. elegans led to the isolation of three new 
fluorometabolites, products of oxidation from the fungal CYP enzymes. 
Analysis of the extracts by 19F{1H}NMR spectroscopy showed a clear feature. While 
the starting material appears as a singlet peak for the fluorines, two of the 
fluorometabolites displayed a doublet of doublets, indicating an AB system and a 
structural change in the close environment of the fluorine atoms.   
Isolation of each peak by reverse-phase HPLC, and subsequent NMR spectroscopy and 
high-resolution mass spectrometry, revealed sulfoxides 112 and 113 and sulfone 114. 
 
Scheme 19. Fluorometabolites isolated, along with their isolation ratios 
The major product was sulfoxide 112 (tr = 24 min), followed by phenol 113 (tr = 16 
min). Sulfone 114 (tr = 21 min) was a relatively minor metabolite, at only 10% of 
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sulfoxide 112. The sulfoxides are chiral on the sulfur atom, resulting in non-
equivalence of the fluorine atoms, and hence, the observed AB system. The lower level 
of sulfone 114 could be an indication that it is the last product to be generated in the 
metabolic pathway. 
Additional to sulfur oxidation, C. elegans is also able to de-methylate the para 
methoxyl group, generating a phenol. The fact that there is no oxidation of the 
aromatic ring, nor elimination of the fluorines, seems to point towards a reasonably 
stable motif overall.  
In an effort to establish the sequence of events through which these metabolites are 
generated, a series of control experiments was carried out. It was hypothesised that 
sulfoxide 112 would be generated first. A demethylation would then act to generate 
113, which would finally be oxidised to sulfone 114 (Scheme 20a). Alternatively, the 
final steps could possibly invert in order, and generate sulfone 115 prior to 
demethylation (Scheme 20b).  
 
Scheme 20.  Hypothetical pathways for (1,1-difluoroethyl)(4-methoxyphenyl)sulfane (100) metabolism 
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In order to establish if any of these routes is valid, each of the fluorometabolites was 
separately incubated, with different rates of success. It proved difficult to establish 
outcomes by 19F{1H} NMR spectroscopy from the crude extracts, so it was necessary 
to use HPLC. Comparison of retention times and NMR analyses of the collected peaks 
proved more successful and allowed characterisation. 
Incubation of sulfoxide 112 (tr = 24 min) led to the formation of phenol 113 and 
sulfone 114, both being securely identified against previous data. No starting material 
(112) was observed either by NMR spectroscopy or HPLC, indicating full conversion. 
These results prove that oxidation of the sulfide happens first in the metabolism. 
An incubation of sulfoxide 113 (tr = 16 min) with C. elegans did not result in any 
conversion and only the starting material 113 was recovered.  
Finally, given the very low amount that was recovered from the original culture, an 
experiment with sulfone 114 did not show any new products, indicating that the 
metabolite is either exuded and not taken up by the fungus, or possibly fully 
metabolised. 
These experiments established the first step of the metabolism, and also allowed route 
A of Scheme 21 to be discarded. In an attempt to establish whether route B is valid, 
the sulfone 115 was synthesised for an incubation study (Scheme 21). Given that the 
synthesis was carried out on analytical amounts of 104 (5 mg), a complete conversion 
was estimated by NMR spectroscopy only, but the yield could not be established. 
 
Scheme 21. Synthesis of 1-((1,1-difluoroethyl)sulfonyl)-4-methoxybenzene (sulfone 115)  
Sulfone 115 was incubated with C. elegans, following the standard conditions. After 
72 h, the culture was extracted and the crude analysed. 19F{1H} NMR spectroscopy 
showed two peaks (singlets), which match the starting material 115 and sulfone 114. 
This is consistent with the last step in Route B, and gives a stronger support for Route 
B over Route A. 
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2.2.4.2 (1,1-Difluoroethyl)(naphthalene-2-yl) sulfane (105) 
In order to study the influence of the p-methoxy substituent on the metabolism of the 
thioether motif, a derivative of difluorinated 104 without the –OMe group was 
explored. (1,1-Difluoroethylphenyl)sulfane would have been the most obvious choice, 
but this compound is too volatile for the complete cycle of incubation, extraction and 
purification. Instead, the metabolic fate of (1,1-difluoroethyl) (naphthalene-2-yl) 
sulfane (105) was investigated. 
After incubation with C. elegans, 19F{1H} NMR analysis of the extract showed three 
sets of signals, indicating the formation of two sulfoxide metabolites and one sulfone 
(Scheme 22) – reproducing the observed products in the methoxy derivative 104. 
 
Scheme 22. C. elegans incubation results for 105 
Reverse-phase HPLC allowed the separation of these metabolites. NMR analysis, 
followed by high-resolution mass spectrometry enabled a preliminary identification of 
each of the structures. However, the recovery of fluorometabolites from the fungal 
culture was low, making full characterisation challenging. 
The major product (tr = 37 min) was positively identified as sulfoxide 116. The second 
most abundant fluorometabolite (tr = 13 min) is sulfoxide 117, as determined by 1H 
and 19F{1H} NMR spectroscopy, as well as high-resolution mass spectrometry. 
Unfortunately, the amount of material recovered was too low to be able to carry out 
13C NMR analysis. The 1H NMR spectrum is however quite distinctive, and points 
towards this structure. In particular, three signals in the aromatic region, between 7.27 
and 7.75 ppm, match the substitution pattern for the aromatic ring adjacent to the 
sulfur atom; while two doublets at 6.5 and 6.1 ppm correspond to protons vicinal to the 
hydroxyl groups. 
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Finally, a third fluorometabolite of general sulfone structure 118 (tr = 17 min), 
according to mass spectrometry, was recovered by HPLC. This is a very minor 
metabolite and little information was obtained for its unambiguous identification.  
2.2.4.3 1-(1,1-Difluoroethoxy)-4-methoxybenzene (106) 
Finally, in order to extend the study to the oxy ether series, difluoroethoxy ether 106 (5 
mg) was fed to cultures of C. elegans, employing the standard conditions. 
Examination of the 19F NMR spectrum of the extracts showed only residual starting 
material, although only at low levels. Isolation of the major components by HPLC and 
their subsequent analysis proved that there was a non-fluorinated metabolite present. 
This was determined to be 4-acetoxyphenol 119 (tr = 25 min), the identity of which 
was confirmed by comparison of literature NMR data. 49  
 
Scheme 23. Incubation of 106 in C. elegans, gave 4-acetoxyphenol 119 
These results were reproduced in separate experiments (4 times). However, on one 
occassion, the 19F NMR spectrum showed the formation of a new fluorine peak. HPLC 
purification showed that the main metabolite was still 4-acetoxyphenol 119, but also 
allowed the isolation of this new fluorinated compound (tr = 19 min). Unfortunately, 
the recovery from the fungal culture was once again very low, and taking into account 
that this was a very minor metabolite, only 1H and 19F NMR spectra were obtained. 
These analyses were enough to observe that the OCF2CH3 motif was intact, and that 
demethylation had occurred. A residual para substitution pattern was obvious in the 1H 
NMR spectrum, suggesting 4-(1,1-difluoro)ethoxy phenol 120. 
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In order to further establish what happened in this incubation, scale-up (3 ×25 mg) 
batches of 106 were added to three different cultures of C. elegans. The outcome of 
each was exactly the same as that for the first assays, and showed the formation of 4-
acetoxyphenol 119 along with some residual starting material, and some minor traces 
of decomposition, but no phenol 120. 
Therefore, it was determined that 1-(1,1-difluoroethoxy)-4-methoxybenzene (106) 
suffers from a rapid hydrolytic metabolism, as well as demethylation, and seems to be 
a vulnerable motif for bioactive discovery programmes, given its very low metabolic 
stability. 
2.2.5 Enantiomeric excess analysis 
The experiments with thioether derivatives (104 and 105) led to the isolation of chiral 
sulfoxide intermediates. The enantiomeric selectivity of the fungus in generating these 
chiral sulfoxide motifs was also investigated. 
Initially, a racemic mixture of 1-((1,1-difluoroethyl)sulfinyl)-4-methoxybenzene (112) 
was synthesised by addition of (bisacetoxy)iodo benzene (BAIB) and aluminium 
chloride to (1,1-difluoroethyl)(4-methoxyphenyl)sulfane (104), as illustrated in 
Scheme 24. This reaction was carried out on an analytical scale (4.7 mg), and a portion 
of the product was purified by reverse-phase HPLC. 
 
Scheme 24. Synthesis of racemic 112 
A solution of racemic sulfoxide 112 in isopropanol was analysed by chiral HPLC. The 
successful eluent conditions afforded a separation of 1 min between the enantiomers, 
and involved the use of an ID column (5% isopropanol in hexane, 1 mL per minute). 
The same conditions were used to analyse the product recovered from the fungal 
culture after incubation with 104. In this case, the fungus manages to generate 
sulfoxide 112 in 60% e.e (Fig. 25).  
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Fig. 25 Chiral HPLC traces for the racemic 112  (upper image) and the isolated enantiomerically-
enriched 112 after incubation of 104 with C. elegans (lower image) 
The same synthetic procedure was used to obtain racemic sulfoxide 116 on an 
analytical scale (Scheme 25).  
 
Scheme 25. Synthesis of racemic 116 
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The fully characterised racemate was successfully separated into its enantiomers by 
chiral HPLC (IC column with 5% isopropanol in hexane at a rate of 1 mL/min). 
Analysis of the fungal extracts indicated that, for this naphthalene derivative, the 
fungus performs the biotransformation with a 54% e.e. Although this value is slightly 
lower than that of the methoxy derivative, it is still quite selective (Fig. 26). 
 
 
 
 
 
 
Fig. 26 Chiral HPLC traces for racemic mixture 116 (upper trace) and the isolated enantiomerically-
enriched 116 after incubation of C. elegans with 105 (lower trace) 
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2.2.6 Conclusions on α,α-difluoroethyl thio- and oxy- ethers  
The lipophilicity profile of a range of α,α-difluoroethyl thioethers and α,α-difluoro 
oxyethers was estimated by reverse-phase HPLC. 
In this way, the metabolic fate of selected examples was carried out by incubations 
with C. elegans. While the sulfur thio ethers display a moderate metabolic stability, 
yielding sulfoxide and sulfone metabolites, the investigated oxy ether was readily 
metabolised to an acetate ester, indicating low metabolic stability. 
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2.3 α,β,β-(Trifluorocyclopropyl) benzene derivatives  
Cycloalkanes are present in countless natural and synthetic products, all of which 
display an ample variety of applications, from antibiotics to liquid crystals – and many 
more examples in-between. For a number of years, the St Andrews group has been 
studying the synthesis and properties of all-cis fluorocyclohexanes. Recently, the 
group has extended this work to the synthesis of partially fluorinated cyclopropanes for 
their potential in drug discovery programmes. 
2.3.1 Introduction to the syntheses and potential applications of 
fluorocyclopropanes 
The first cyclopropyl derivative reported was synthesised by W. H. Perkin in 1884.50 
Since then, the literature on cyclopropane syntheses has been continuous.51 The 
versatility of this moiety is reflected in its multiple molecular purposes; they can act as 
‘space elements’ of a specific dimension, reduce conformational flexibility, store strain 
energy to produce a thermodynamic driving force, or serve as high-energy 
intermediates in metabolism, among others. 52  In 2003, there were over 200 
pharmaceutically relevant drugs that contained at least one cyclopropylamine moiety.53 
The presence of cyclopropyl rings in natural products is also significant, and they have 
been isolated from different plants, fungus and both marine and terrestrial 
microorganisms. 
Fig. 27 shows a selection of natural products containing, at least, one cyclopropane 
moiety.54 These products display a variety of biological activities,55, 56 from antiviral,57 
antifungal58, 59, 60 and antibacterial61 to anticancer62 and anti-leishmanial.63 
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Fig. 27 Bioactive natural products containing cyclopropane motifs 
Most of these natural products have bioactive properties. Given that fluorine is often a 
relevant moiety for the control of the chemical properties in drugs, the St Andrews 
group introduced α,β,β-trifluorocyclopropanes as a new fluorinated motif in 2018 to 
act as a substituent for consideration in drug discovery.64 
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The general synthesis of α,β,β-trifluorocyclopropanes involves fluorobromination of a 
styrene derivative with NBS and HF, followed by a dehydrobromination reaction to 
yield the corresponding α-fluorostyrene. These intermediates are treated with 
TMSCF3/NaI, which generates difluorocarbene, to afford the final products, as shown 
in Scheme 26.64  
 
Scheme 26. Synthetic procedure to α,β,β-trifluorocyclopropanes as reported by C. Thomson64  
Scheme 26 presents the syntheses of 125 and 126 as carried out by C. Thomson 
(University of St Andrews).64 Samples of these were kindly donated to investigate 
their biochemical degradation and properties. 
2.3.2 Aims and Objectives 
Cyclopropane moieties are popular motifs in drug discovery programmes. The aim of 
this section is to study the preliminary viability of the new fluorocyclopropyl moiety in 
drug discovery programmes. For this, the metabolic fate of 125 and 126 as well as 
their lipophilicity profiles was studied. 
Additionally, selected n-propyl and cyclopropyl benzene derivatives were used as tools 
for a better understanding of the lipophilicity behaviour in these motifs (Fig. 28). 
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Fig. 28 Selected structures for the study of lipophilicities 
2.3.3 Estimation of lipophilicities by the use of a reverse-phase HPLC 
Log P values for the cyclopropyl derivatives 125 and 126 were calculated using the 
same reference compound set and conditions, similar to that for the thio- and oxy- 
ether derivatives in Section 2.2.3.  
In those cases, the regression line equation was y = 0.3772x – 0.493 (R2 = 0.98572). 
Using this equation, new Log P values were estimated. The experimental results are 
shown in Table 8. 
Table 8. Retention times measured in triplicates, that led to the estimation of the Log P values in blue 
Compound Log P Rt 1 Rt 2 Rt 3 Average Rt Capacity factor (k) Logk 
127 4.01 22.45 22.42 22.47 22.45 ± 0.03 10.42 1.02 
128 3.42 14.29 14.28 14.31 14.29 ± 0.02 6.27 0.80 
129 2.91 9.86 9.86 9.89 9.87 ± 0.02 4.02 0.61 
130 2.81 9.21 9.21 9.23 9.22 ± 0.01 3.69 0.57 
131 2.79 9.09 9.09 9.11 9.10 ± 0.01 3.63 0.56 
126 2.87 9.62 9.63 9.63 9.63 ± 0.01 3.90 0.59 
132 3.55 15.76 15.77 15.78 15.77 ± 0.01 7.03 0.85 
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In an attempt to facilitate a comparison between the different compounds and their 
lipophilicity values, they have been organised into three series. The first series 
analyses the influence of the different degrees of fluorination upon 
cyclopropylbenzene 141, and the second focuses on the effect of an electron-
withdrawing and an electron-donating substituents on the aromatic ring. The last series 
compares the lipophilicity values of alkyl chains and their cyclic analogues, with and 
without fluorine substitution. 
Cyclopropylbenzene 128 had a measured log P of 3.42, while the α,β,β-
trifluorocyclopropyl derivative 130’s was 2.81. The difluoro cyclopropane 129 falls in-
between these at 2.91. However, the value of the latter (129) is much closer to the 
trifluorocyclopropane 130 than to the original cyclopropane 128, thus the benzylic 
fluorine does not seem to have a very large effect on the lipophilicity, although its 
introduction slightly increases rather than decreases polarity.  
 
Fig. 29 Series 1, Log P comparisons of different degrees of fluorination on cyclopropylbenzene 
Given the different electronic properties of electron-withdrawing (EWD) and electron-
donating (ED) substituents, 131 and 126 would be expected to have different 
polarities. However, as shown in Fig. 30, it is evident that the difference from the most 
polar (nitro substituted product 131) to the least polar (methoxy substituted 126) is 
small (Log P = 0.08). This outcome contrasts with the considerable difference in the 
reported values for nitrobenzene (Log P = 1.86)65 and anisole (Log P = 2.11)66; 
indicating that the effect of the fluorine substitutions on the cyclopropane is larger than 
that of the aromatic substituents. 
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Fig. 30 Series 2, log P influence of different substituents on α,β,β-trifluorocyclopropyl benzene 
In Series 3 (Fig. 31), the n-propyl substituent has the highest lipophilicity, compared to 
that of the cyclopropyl derivatives, in both the non-fluorinated and the fluorinated 
analogues. In each case, partial fluorination lowers the lipophilicity, indicating that 
fluorination is polarising the vicinal hydrogens. Although trifluorination of n-
propylbenzene lowers the lipophilicity considerably, cyclopropyl benzene 128 is 
significantly more polar again. Hence, these partially fluorinated cyclopropyl 
derivatives become interesting for drug discovery programmes, especially when taking 
into account that their lipophilic range is below the much desired Log P < 3 for the 
trifluorinated analogue 130. 
 
Fig. 31 Series 3, comparison of cyclic and open chains of propanes, and their partially fluorinated 
derivatives 
2.3.4 Metabolic fate of partially fluorinated cyclopropanes in Cunninghamella 
elegans 
Cyclopropanes are known to metabolise when exposed to cytochrome P450 enzymes. 
Oxidation of cyclopropyl benzene 128 by cytochrome P450 enzymes was reported by 
Suckling et al. in 1982.67 In that work, carried out with a rat liver microsomal 
preparation, 2-cyclopropylphenol 134 was generated. However, this metabolite only 
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accounts for up to 10% of the products recovered. The major product was benzoic acid 
133.67,68 
 
Scheme 27. Biotransformations of cyclopropylbenzene 131 by cytochrome P450 enzymes 67,68 
The isolation of benzoic acid 133 indicates the potential for a high level of metabolic 
activity, and suggested the involvement of a series of oxidative enzymes. Model 
chemical oxidations carried out on cyclopropylbenzene with cumene hydroperoxide 
also afforded benzoic acid as a significant product.68  
Riley and Hanzlik have explored the oxidative metabolism of cyclopropylbenzene 128 
in three different microsomal P450 systems. 69  All three systems gave 1-
phenylcyclopropanol 135 by benzylic oxidation, as well as cyclopropyl-4-phenol 
136.69 One of the systems afforded cyclopropyl-2-phenol 134, as previously described 
by Suckling, but none of the microsomes led to the observation of any ring-opened 
metabolites.69 
 
Scheme 28. Reported microsomal metabolites of cyclopropylbenzene 13169 
The same three microsomal systems were used to incubate p-cyclopropylanisole (137), 
and both an O-demethylation product 136 and the benzylic oxidation metabolite 138 
were observed. Again, there was no sign of ring opening.69 
 
Scheme 29. Cytochrome P450 biodegradation of p-cyclopropylanisole 13769 
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The analogous chemical experiment, carried out by anodic oxidation, did not show any 
products.70 
Based on these studies, Vermeulen et al. rationalised the origin of the metabolites from 
cytochrome P450 oxidation.71  The computationally obtained results are shown in 
Scheme 30. 
 
Scheme 30. Rationale of cytochrome P450 products for p-cyclopropylanisole 13771 
In this Chapter, the metabolism on α,β,β-trifluorocyclopropanes was explored to 
establish the influence of the number of fluorine atoms upon biotransformation, and 
also to investigate whether different aryl substituents would alter the outcome. The 
three compounds (125, 126 and 129) shown in Fig. 32 were selected. 
 
Fig. 32 Selected fluorocyclopropanes for metabolism studies 
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2.3.4.1 (2,2-Difluorocyclopropyl)benzene (129) 
The incubation of cyclopropane 129 with C. elegans was carried out over 72 h, at 28 
ºC and 150 rpm, as previously described. Analysis of 19F{1H} NMR spectrum of the 
cell extract showed that the starting material predominated. However, there were some 
minor fluorine peaks at a similar chemical shift and with the same coupling pattern, 
indicating modification of the aromatic ring only. Another product with a very 
different chemical shift (at around 100 ppm) indicated modification of the β, β-
difluorocyclopropyl motif (Fig. 33).  
 
Fig. 33 19F{1H} NMR spectrum after incubation of 129 with C. elegans 
Given the very low level of conversion from 10 mg of starting material, no products 
could be successfully isolated by reverse-phase HPLC.  
In order to test the volatility of the metabolites, and whether that would account for the 
poor recovery, a sample of cyclopropane 129 was left to incubate at 28 ºC. Analysis of 
the crude extracts showed very low intensity signals by fluorine NMR spectroscopy. 
-155-150-145-140-135-130-125-120-115-110-105-100-95-90
-146-144-142-140-138-136-134-132-130-128-126-124
 125 
This indicated that the fluorometabolites are quite volatile and isolation from the liquid 
culture is challenging. 
A scale-up was investigated. In this case, four different C. elegans cultures with 25 mg 
each of 129 were set up for incubation. However, 19F{1H} NMR spectroscopy of the 
combined crude extracts did not show any traces of fluorine. In the end, high volatility 
resulted in an incomplete study in this case. 
2.3.4.2 1-Bromo-4-(1,2,2-trifluorocyclopropyl)benzene (125) 
1-Bromo-4-(1,2,2-trifluorocyclopropyl)benzene (125) was investigated next. After 
incubation with C. elegans, an analysis of the crude extract showed the formation of a 
minor metabolite. It was clear from the 19F NMR spectrum that the α,β,β-trifluoro 
motif had remained intact. 
Replicates of this assay showed consistent formation of that same minor metabolite, 
but attempts of isolation by HPLC proved unsuccessful. 
Purification was then explored by column chromatography. In this way, the starting 
material 125 and the minor metabolite were recovered. However, the latter could only 
be observed by 19F NMR spectroscopy, given the low levels that were produced. 
Replications did not improve the recovery and the metabolite was not identified. 
2.3.4.3 1-Methoxy-4-(1,2,2-trifluorocyclopropyl)benzene (126) 
Cultures of C. elegans were inoculated with 1-methoxy-4-(1,2,2-trifluorocyclopropyl) 
benzene (126, 5-10 mg). Analysis of the resultant extracts after three days by 19F{1H} 
NMR spectroscopy showed the formation of a new metabolite, along with residual 
starting material. The 19F{1H} NMR patterns revealed that the trifluorocyclopropyl 
motif was intact and that the modification was to the aromatic ring. Purification by 
column chromatography allowed product 150 to be isolated.  
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Fig. 34 1-methoxy-4-(1,2,2-trifluorocyclopropyl)benzene (150) 
The biotransformation with C. elegans was repeated, increasing the amount of 
cyclopropane 126 (20 mg), to facilitate the isolation and characterisation of the 
unknown fluorometabolite. Full NMR analysis, and high resolution mass 
spectrometry, confirmed the identity of the metabolite as 4-(1,2,2-
trifluorocyclopropyl)phenol (150). 
 
Scheme 31. Biotransformation carried out by C. elegans 
However, previous attempts at the synthesis of 150 had proven unsuccessful (Connor 
Thompson, University of St Andrews). In that case, the experiment was carried out by 
treatment of 1-methoxy-4-(1,2,2-trifluorocyclopropyl)benzene (126) with boron 
tribromide (Scheme 32). In this experiment, only phenol 151 was isolated. This result 
seemed to indicate that phenol 150 is unstable, certainly in the presence of BBr3. 
 
Scheme 32. Conversion of 126 to 151 by BBr3 
In order to try to obtain a sample of 150 to secure product identification, it seemed 
appropriate to repeat this experiment. In my hands, a different result was observed, as 
illustrated in Scheme 33. This generated the cyclopropanol 152, avoiding the methoxy 
ether cleavage. Clearly, the BBr3 promotes C-F bond cleavage. However, a synthesis 
of 150 proved elusive. 
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Scheme 33. Reproduction of previous experiment and new product isolated 
Two things became clear. Firstly, the fungus does not metabolise the cyclopropane 
ring, and secondly, C. elegans seems to offer a mild method for demethylating 126, as 
previously described by Riley and Hanzlik,69 and Vermeulen.71 
2.3.5 Conclusions on α,β,β-(trifluorocyclopropyl) aryl derivatives 
Lipophilicity studies with aryl α,β,β-(trifluorocyclopropyl) derivatives led to several 
observations. Firstly, open chain n-propylbenzene is more lipophilic than 
(cyclopropyl)benzene, and the same tendency is observed for their α,β,β-trifluoro 
analogues. This decrease in Log P makes the cyclopropyl moiety attractive as a 
candidate motif for drug discovery. Additionally, partial substitutions of fluorines for 
hydrogens increases the polarity further, lowering the lipophilicity values to the 2.50 – 
3.00 range. 
Metabolism studies with difluorinated aryl (cyclopropyl) derivatives were challenging 
due to the volatility of the compounds. Most successful was the incubation of 1-
methoxy-4-(1,2,2-trifluorocyclopropyl) benzene 126 with C. elegans, which led to the 
formation of 4-(1,2,2-trifluorocyclopropyl)phenol 150. Notably, the cyclopropyl ring 
was not metabolised. 
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2.4 General Conclusions on Chapter 2 
The main objectives of this Chapter were to investigate the lipophilicity profile and the 
metabolic stability of a new range of fluorinated motifs recently developed in the St 
Andrews lab. In total, three new fluorinated motifs were explored: all-cis 
(fluorocyclohexyl) benzenes (Section 2.1); α,α-difluoroethyl thio- and oxy- ethers 
(Section 2.2) and α,β,β-(trifluorocyclopropyl) benzenes (Section 2.3). 
For all of these motifs, the lipophilicity decreased upon the increasing number of 
fluorine atoms present (Fig. 35), making them interesting motifs for drug discovery 
programmes. 
 
Fig. 35 Comparison of the Log P values obtained for the motifs studied in this Chapter 
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Metabolic studies with C. elegans demonstrated that, most of the products were 
oxidised, in typical examples of phase I metabolism. In the case of the 
fluorocyclohexyl derivatives, benzylic hydroxylation was observed in all cases. An 
increase in fluorination led to a decrease in metabolism of the cyclohexyl ring. The 
difluorocyclohexane 58 showed a variety of hydroxylation patterns, proving that 
fluorine substitutions increase metabolic stability. 
The α,α-difluoroethyl thioethers were oxidised on sulfur, either to sulfoxides or 
sulfones; and a metabolic degradation route for the formation of each metabolite was 
investigated. Incubation of α,α-difluoroethyl oxyether (101) with C. elegans led to the 
isolation of 4-acetoxyphenol. These results indicate that these oxygen ether motifs are 
relatively easily metabolised (hydrolysed), and are probably not good candidates for 
drug discovery programmes, given the very low efficacy they would present with such 
rapid decomposition. 
Finally, the metabolic stability of fluorocyclopropyl derivatives was studied, with 
different levels of success. While the investigations into (2,2-difluorocyclopropyl) 
benzene (129) and 1-bromo-4-(1,2,2-trifluorocyclopropyl)benzene (125) did not lead 
to definite conclusions; 1-methoxy-4-(1,2,2-trifluorocyclopropyl)benzene (126) led to 
the isolation of demethylated phenol 150, in a transformation that proved challenging 
by chemical methods. 
Additionally, chiral analysis of some of the products and residual starting material was 
performed, with varied results. For the cyclohexyl derivatives the enantiomeric excess 
observed was low (between the 3 – 25% e.e. range); the sulfoxides from the α,α-
difluoroethyl thioethers showed e.e.’s higher than 50%.  
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Chapter 3. In vitro reconstitution of (2R,3S,4S)-5-fluoro-
2,3,4-trihydroxypentanoic acid biosynthesis 
3.1 Introduction to (2R,3S,4S)-5-fluoro-2,3,4-trihydroxypentanoic acid (2) 
biosynthesis 
In 2014, the St. Andrews group reported the isolation and characterisation of a new 
fluorinated natural product: (2R,3S,4S)-5-fluoro-2,3,4-trihydroxypentanoic acid 2 (5-
FHPA).1 This was enabled by the discovery of a fluorinase in Streptomyces sp. MA37, 
after a full genome sequence.2,3 
The fluorometabolite profile of S. sp. MA37 is more complex than that of 
Streptomyces cattleya. Fluoroacetate 1 and 4-fluorothreonine 4 are produced, but there 
was also a number of unknown fluorinated metabolites, as can be seen in the 19F NMR 
spectrum (Fig. 1).1 
 
Fig. 1 19F{1H} NMR spectrum of the fluorometabolite profile of S. sp. MA371 
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The first steps of the metabolic pathway of S. sp. MA37 are similar to those of S. 
cattleya.1 However, the metabolic pathway in S. sp. MA37 branches into two. The first 
branch leads to the formation of fluoroacetate (1) and 4-fluorothreonine (4); but the 
second generates 5-FHPA (2) and other unknown metabolites. Both branches are 
shown in Scheme 1, indicated as ‘upper’ and ‘lower’. 
 
Scheme 1. Biosynthetic pathway to the fluorometabolites in S. sp. MA37  
The process that allows the formation of 5-FHPA 2 requires four enzymes.1 It starts 
with a fluorinase reaction on SAM to generate 5’-FDA (Scheme 2).4 The fluorinase in 
S. sp. MA37 (flA1) has a gene with an 87% homology to that from S. cattleya.2 For 
expression in E. coli, a synthetic gene for flA1 was codon-optimised and over-
expressed. Additionally, a His6 tag and a TEV protease cleavage site were added into 
the synthetic gene, in order to facilitate the isolation and purification of the 
recombinant enzyme.2 Incubation with SAM and fluoride demonstrated an active 
fluorinase.2 
O
OHOH
F
O P
O
O-
O-
PNPO
OHOH
F
N
NN
N
NH2
O
OHOH
S
N
NN
N
NH2
Fluorinase
F
Isomerase
OH
OH
F
O P
O
O-
O-
O
Aldolase
O
H
F
Transaldolase (PLP)
+ L-threonine
Aldehyde (NAD+)
dehydrogenaseO
O
F
F
OH
NH3
O
O
O
O
H3N
SAM (16)
5'-FDA (17)
FAc (1)
4-FT (4)
FAld (8)
5-FDRP (18)
FDRibulP (19)
O
OHOH
F
OHF OH
O
OH OH
OH
Fdr A
Fdr CO
OHOH
F
O
UPPER
LOWER
5-FDR (26)272
BRANCH POINT
METABOLITE
Other fluorometabolites
 137 
 
Scheme 2. Fluorinase-catalysed formation of 5’-FDA (17)4 
In the metabolic pathway, 5’-FDA is then transformed into 5-FDRP, in a step 
catalysed by a purine nucleoside phosphorylase (PNP).5 PNPs are well known to 
cleave nucleoside bases and to generate the corresponding ribose phosphates; 
therefore, phosphate ions must be available in the medium.6 
 
Scheme 3. Step 2, conversion of 5’-FDA into 5-FDRP by PNP 5 
5-FDRP is a branch point of the metabolic pathway. The metabolite can now either 
follow the pathway reported for S. cattleya to generate fluoroacetate and 4-
fluorothreonine7, or ribose phosphate 18 can be transformed by a dephosphorylase 
(FdrA) into 5-FDR 26 (Scheme 4), in an analogous way to that of chlororibose in 
Salinispora tropica, as discussed in Chapter 1 (Section 1.5.3).1,8 FdrA has been 
predicted to encode a metal-dependent phosphoesterase, with a 56% identity to that 
found in S. tropica, but the information available on this protein is limited at present.1,8 
 
Scheme 4. FdrA dephosphorylates 5-FDRP to yield 5-FDR 
The final enzyme involved in this pathway to 2 is FdrC, which catalyses an oxidation 
followed by a hydrolysis. Firstly, it transforms 5-FDR into lactone 27, which is then 
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hydrolysed to the open chain carboxylic acid 5-FHPA 2.1 FdrC is an NAD+ dependent 
short chain dehydrogenase, which shares a 69% homology with the S. tropica 
analogue.1,8 A codon-optimised synthetic gene for FdrC was over-expressed in E. coli 
and purified, a process also facilitated by the addition of a His6 tag and a TEV protease 
cleavage site to the gene.1 
 
Scheme 5. Final biotransformation into 5-FHPA (2) via lactone intermediate 27 1 
3.2 Aims and Objectives 
The main objective of this Chapter is to reproduce the in vitro biotransformations that 
lead to the formation of 5-FHPA 2 from SAM and fluoride. 
Additionally, as well as reconstituting the biosynthetic pathway, optimisation of the 
conditions will be explored, in order to attempt a milligram scale-up in the production 
of 5-FHPA (2).  
3.3 In vitro reconstitution of 5-FHPA biosynthesis 
3.3.1 Transformation of fluoride to 5-FHPA (2)  
The in vitro reconstitution of the 5-FHPA biosynthesis was inspired by a previous 
reconstitution of the formation of 4-fluorothreonine from fluoride in a one-pot, five-
enzyme experiment in an NMR tube.9  
In order to reproduce the natural biosynthesis of 5-FHPA in vitro, it was necessary to 
obtain the enzymes and substrates involved in each of the four enzymatic steps. The 
recombinant fluorinase from S. cattleya used in the following sections was over-
expressed and purified by Dr Stephen Thompson (University of St Andrews).4 
Recombinant PNP from E. coli is available from Sigma Aldrich. A phytase from 
wheat, also available from Sigma Aldrich, was used in this study, instead of FdrA. The 
oxido-reductase FdrC was required to be over-expressed and this was achieved as 
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described in Section 5.6.4 (Chapter 5), following a previous protocol.1 SAM, KF and 
NAD+ are commercially available and were sourced from Sigma Aldrich.  
The four-enzyme protocol is illustrated in Scheme 6. Accordingly, SAM·2HCl was 
incubated with KF, NAD+, fluorinase, PNP, the commercial phytase from wheat and 
FrdC. The experiment was carried out in PBS buffer, at 37 ºC for 16 h. 
 
Scheme 6. Four-enzyme biotransformation of fluoride to 5-FHPA 2  
The 19F{1H} NMR spectrum carried out after incubation indicated the formation of 
three organofluorine products, which were identified as 5’-FDI, 5’-FDA and 5-FDRP, 
in order of abundance (Fig. 2A). The identity of these products was secured by 
comparison of their 19F NMR spectra to that from previous published work in the 
group.5 
In addition, five control incubations (Fig. 2B-F) were carried out to ensure the correct 
functioning of each enzyme, or to detect if any step is problematic for efficient 
turnover. In each control, one of the enzymes was removed. Therefore, Control 1 (Fig. 
2B) was run without fluorinase; Control 2 (Fig. 2C) did not contain PNP; Control 3 
(Fig. 2D) did not have phytase, and Control 4 (Fig. 2E) was lacking FdrC. Control 5 
(Fig. 2F) was carried out without NAD+. The 19F NMR spectra of these control 
experiments are shown in Fig. 2, in descending order.  
It is important to note that most of the fluorine peaks for the products involved in these 
experiments appear within a 0.5 ppm range from each other. Therefore, it is 
challenging to assign the identity of the peak without an internal reference. 1,3-
Difluoropropanol was chosen for this purpose, given that it is a fluoroorganic 
compound and its chemical shift is only 2 ppm upfield, but sufficiently remote not to 
overlap any of the studied products. Additionally, 1,3-difluoropropanol is stable in all 
the buffers and conditions used.  
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Fig. 2 Complete experiment (top) and control experiments 1 to 5 (descending order) for the  
biotransformation experiments. A) The complete experiment contained all the enzymes and cofactors, as 
well as fluoride B) Control 1. No fluorinase C) Control 2. No PNP D) Control 3. No phytase E) Control 
4. No FdrC F) Control 5. No NAD+ 
As expected, Control 1 (B) showed that without the fluorinase there is no formation of 
organofluorine compounds. Control 2 (C) indicates that the fluorinase is effective in 
the generation of 5’-FDA, although it shows a minor deaminase activity to yield 5’-
FDI (153), presumably due to enzymatic contamination. 
 
Controls 3 (D), 4 (E) and 5 (F) lead to the same outcome as that of the ‘complete 
experiment’ (A) with all the enzymes and cofactors, suggesting that step three (the 
PNP biotransformation) is blocking the overall biotransformation to 5-FHPA. 
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The same recombinant PNP from E. coli was sourced from Sigma-Aldrich, to probe 
whether the stock in the lab had been contaminated or inactive after the time stored, 
and the complete experiment was repeated. This substitution improved the 
biotransformation, and in this case did generate 5-FHPA 2, although 2 is observed at a 
low level (Fig. 3). The major product observed by 19F{1H} NMR spectroscopy is       
5-FDRP, suggesting that the problematic step is the dephosphorylation reaction 
catalysed by the phytase. 
 
Fig. 3 19F {1H} NMR spectrum of the ‘complete experiment’, showing a low formation of 5-FHPA  
Although the commercial phytase from wheat seems to have some activity in PBS 
buffer (pH = 7.4) at 37 ºC, the optimal conditions for this enzyme are at pH = 5 and   
55 ºC.10 Therefore, a new three-step, one-pot in vitro reconstitution was explored. This 
new assay involved two pH changes, as illustrated in Scheme 7. 
 
 142 
 
Scheme 7. Envisaged 3-steps 1-pot biotransformation to 5-FHPA (2) 
Since the aim was to carry out this experiment in just one pot, it became crucial to use 
a buffer that would allow the necessary changes of pH. A phosphate-citrate buffer was 
selected. At this stage, the lab received a generous donation of a PNP, immobilised in 
Sepabeads®, from GlaxoSmithKline (GSK). Unfortunately, the precise origin of this 
PNP could not be established, although it was a recombinant PNP over-expressed in 
E.coli, and possibly, of human origin. This new PNP proved very successful, and 
allowed a 100% conversion of 5’-FDA into 5-FDRP (see Section 3.3.2.2). Hence, this 
PNP was used in all future experiments. 
The three-step, one-pot experiment described in Scheme 7 started with the addition of 
SAM and KF into an eppendorf tube, followed by the buffer (at pH = 7.2). PNP and 
fluorinase were then added, and the tube was set to incubate at 37 ºC for 24 h. A gentle 
rotation was applied for a better mixture of the assay. 
After 24 h, the immobilised PNP was filtered, and the fluorinase was denatured by 
heating. The precipitated protein was then centrifuged. The clear supernatant was 
acidified to pH = 5.1 by gentle addition of citric acid. Then, the phytase was added, 
and the mixture set to incubate at 40 ºC for 48 h with gentle rotation. 
After the incubation period, the phytase reaction was stopped by raising the pH of the 
mixture to 7.2, which triggered denaturation of the phytase. The precipitated phytase 
was filtered by centrifugation, and FdrC and NAD+ were added to the supernatant. The 
biotransformation was again incubated at 37 ºC for 30 h. A 19F{1H} NMR spectrum of 
the supernatant was carried out after denaturing the enzyme. The result is shown in 
Fig. 4. This assay was successful in the formation of 5-FHPA. However, the 
conversion was not complete, and the major product was residual 5-FDRP; indicating 
that the FdrC step was not efficient. 
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Fig. 4 19F {1H}NMR spectrum of the four-enzyme biotransformation of fluoride to 5-FHPA 2, carried 
out as a one-pot experiment 
3.3.2 Individual enzymatic analysis of the biotransformation from fluoride to 5-
FHPA (2) 
In addition to the control experiments carried out in the previous section, each step of 
the biotransformation was explored individually, to establish that the enzymes are fully 
functional. A study of each on the individual steps was carried out to deconstruct the 
overall biotransformation. 
3.3.2.1 The fluorinase transformation 
The fluorinase was incubated with SAM and KF in phosphate-citrate buffer,  (pH = 
7.2, at 37 ºC, 24 h). The outcome is shown in Fig.5. The only product is 5’-FDA, with 
added 1,3-difluoro-2-propanol as a reference.  
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Fig. 5 19F {1H} NMR spectrum of the fluorinase assay 
Although the clean production of 5’-FDA is established in terms of fluorinated 
products, the actual conversion from SAM cannot be established by 19F NMR 
spectroscopy.  
3.3.2.2 The purine nucleoside phosphorylase transformation 
In the second step of the biotransformation, purine nucleoside phosphorylase (PNP) 
transforms 5’-FDA into 5-FDRP. 5’-FDA is not commercially available and was 
required to be synthesised from adenosine 154 by the three-step route illustrated in 
Scheme 8.11  
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Scheme 8. Synthetic route to 5’-FDA11  
The synthetic route started with acetonide protection of the ribose of the adenosine 
(154), a reaction that afforded 155 in 48% yield. Tosylation and fluorination at C-5’ 
were carried out in one step, leading to 156 (75%). The final deprotection step proved 
challenging - and was only successful with p-TsOH under reflux. 5’-FDA 17 was 
afforded in 39% yield.  
Incubation of synthetic 5’-FDA with the immobilised recombinant PNP (GSK) 
afforded complete conversion to 5-FDRP (Fig. 6). In order to prove the formation of 5-
FDRP (given the very similar NMR shifts) it was necessary to spike with some 5’-
FDA, which confirmed that the starting material was completely consumed and 
transformed into 5-FDRP (Fig. 6). The enzymatically-produced 5-FDRP was used as a 
substrate for the following transformation with the phytase. 
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Fig. 6 PNP-catalysed transformation of 5’-FDA into 5-FDRP. 5’-FDA present in the spectrum was 
spiked post-incubation as proof of biotransformation 
3.3.2.3 The phytase transformation 
The third enzyme involved in the biotransformation is a dephosphorylase (FdrA). 
Given the lack of availability of this dephosphorylase from S. sp. MA37, it was 
substituted for a commercial phytase from wheat (Sigma-Aldrich). This phytase had 
the inconvenience of only being active under acidic conditions and at relatively high 
temperatures; therefore, this step had to be set up using appropriate conditions. 5-
FDRP (obtained enzymatically, as discussed in Section 3.3.2.2, for the previous step) 
was incubated with the phytase in phosphate-citrate buffer (pH = 5.1), at 48 ºC for 48 
h. The 19F {1H} NMR spectrum of the reaction solution showed the formation of two 
new peaks, corresponding to the α and β anomers of 5-FDR (Fig. 7). 
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Fig. 7 Biotransformation of 5-FDRP into 5-FDR by phytase; residual 5’-FDA from spiking to the 
previous step can be observed 
3.3.2.4 The FdrC transformation 
FdrC is an NAD+-dependent short chain dehydrogenase, and is the enzyme responsible 
for the oxidation of 5-FDR to lactone 27, and then hydrolysis to 5-FHPA 2.1 A 
synthetic plasmid with the FdrC gene was transformed into E. coli (BL21 gold), prior 
to over-expression by IPTG induction, and final purification on a Ni-NTA column, 
following the protocol1 described in Section 5.6.4 (Chapter 5). Fig. 8 shows an image 
of the SDS-PAGE gel obtained from the purification of FdrC, which has a molecular 
weight of 30 kDa. Confirmation of the presence of FdrC was also obtained by MALDI 
mass spectrometry. 
 148 
 
Fig. 8 SDS-PAGE gel of over-expressed FdrC after purification on a Ni-NTA column. a) Well 1: 
Molecular weight reference ladder. b) Well 2: Soluble fraction. c) Well 3: Insoluble fraction. d) Well 4: 
Flow-through. e) Well 5: Wash buffer A, lysis buffer (20 mM Tris·HCl, 20 mM imidazole, 500 mM 
NaCl, pH=8). f) Well 6: Wash buffer B (20 mM Tris·HCl, 50 mM imidazole, 500 mM NaCl, pH=8). g) 
Well 7: Wash buffer C, elution buffer (20 mM Tris·HCl, 400 mM imidazole, 500 mM NaCl, pH=8) h) 
Well 8: Wash buffer C, elution buffer. i) Well 9: Wash buffer C, elution buffer 
Since 5-FDR is not commercially available, it was required to be synthesised. The 
method used is reported in Scheme 9, and follows a protocol previously studied in the 
group.5,11,12 The synthesis started with protection of ribose 157, to generate acetonide 
158, followed by a methanolysis protection at the anomeric carbon to give 159. 
Tosylation of the free C5 alcohol was followed by deoxofluorination to give acetonide 
161. Finally, removal of the acetonide under acidic conditions afforded 5-fluororibose 
(5-FDR, 26). This final deprotecting step is challenging, and was only achieved in a 
30% yield. The complications with the last step mainly reside in the fact that the 
reaction needs high temperature (>100 ºC), but those high temperatures cause the 
sugar to decompose. 
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Scheme 9. Synthetic procedure for the chemical synthesis of 5-FDR (26) 
For the enzymatic procedure, synthetic 5-FDR 26 was incubated with FdrC and NAD+ 
in phosphate-citrate buffer (pH = 7.2) at 37 ºC for 24 h. It can be seen by 19F {1H} 
NMR (Fig. 9) that there is residual 5-FDR (α and β anomers) in the extracts, and the 
reaction has gone to around 50% conversion.  
 
Fig. 9 Biotransformation of 5-FDR 26 into 5-FHPA 2 with FdrC 
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3.4 Optimisation of the enzymatic route  
3.4.1 Using a nucleoside hydrolase 
Both the individual experiments and the complete reconstitution from SAM and KF 
suggest that the phytase enzyme is a ‘bottle neck’, hindering the full conversion of 
fluoride to 5-FHPA 2. Additionally, it is this step that forces a change of the pH and 
results into a more complex three-step procedure. 
Therefore, the first optimisation of the route was aimed at avoiding the use of the 
phytase. A new biotransformation was envisaged, substituting the PNP and phytase for 
a nucleoside hydrolase (NH), an enzyme which can transform 5’-FDA directly into 5-
FDR, in a one-step hydrolytic reaction,13 as shown in Scheme 10.  
 
Scheme 10. Original biotransformation and alternative route using a NH  
The nucleoside hydrolase from Trypanosoma vivax (an enzyme that was available in 
the lab) was over-expressed in E. coli and purified on a Ni-NTA column, following a 
previous protocol.11 Fig. 10 shows the resultant SDS-PAGE gel after purification. The 
NH, which has a molecular weight of approximately 37 kDa, appears below the 40 
kDa mark. Confirmation of the presence of NH was also obtained by MALDI mass 
spectrometry. In order to preserve the stability and activity of the enzyme, it proved 
necessary to supplement the dialysis buffer with Ca2+ ions, since NH from T. vivax 
contains a calcium ion in its catalytic pocket, that participates in the binding to 
ribose.14 In this case, CaCl2 was used. 
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Fig. 10 SDS-PAGE gel of the production of NH after a Ni-NTA purification column. a) Well 1: 
Molecular weight reference ladder. b) Well 2: Soluble fraction. c) Well 3: Insoluble fraction. d) Well 4: 
Flow-through. e) Well 5: Wash buffer A (10 mM phosphate buffer, 20 mM imidazole, 150 mM NaCl, 
pH = 7.8). f) Well 6: Wash buffer A. g) Well 7: Wash buffer C, elution buffer (10 phosphate buffer, 500 
mM imidazole, 150 mM NaCl, pH = 7.8) h) Well 8: Wash buffer C, elution buffer. i) Well 9: Wash 
buffer C, elution buffer 
The first experiments using the recombinant NH were carried out in PBS buffer, at a 
pH of 7.4. For this, and all the subsequent assays, the order of addition was as follows: 
SAM·2HCl, KF, the appropriate buffer, fluorinase, NH, FdrC and NAD+. Incubation 
was carried out at 37 ºC, typically for 24 h. Under these conditions, the enzymatic 
reaction was significantly improved, and a complete bioconversion of fluoride to 5-
FHPA 2 was achieved. However, in the product mixture there was also residual 5’-
FDA and 5-FDR, as well as the shunt product 5’-FDI, as illustrated in Fig. 11. 
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Fig. 11 19F{1H} NMR spectrum of the production of 5-FHPA from SAM and fluoride using NH, instead 
of the PNP-phytase protocol 
A new assay was carried out in phosphate buffer (pH = 8.0), with supplementation 
with MgCl2. 19F{1H} NMR spectroscopy showed 5-FHPA, but also some residual    
5’-FDA (Fig. 12, upper). In an attempt to improve the production of 5-FHPA, the 
same experiment was repeated with an increased amount (4 times) of NH (Fig. 12, 
lower). This led to a more successful biotransformation.  
 
Fig. 12 19F{1H} NMR of 5-FHPA production from SAM and fluoride ion, carried out in phosphate 
buffer. A) 3 mg/mL of NH B) 12 mg/mL of NH 
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Table 1 summarises all the conditions used, along with the outcome of each 
experiment. The most efficient conversion used phosphate buffer and NH 
concentration of 12 mg/mL (Entry 4). 
Table 1. Summary of all conditions used for the biotransformation of fluoride to 5-FHPA 
Entry Buffer pH Mg2+ 
Incubation 
Time 
NH Conc. Outcome 
1 Tris·HCl 7.8 + 24 h 3 mg/mL 
5’-FDA:5-FHPA 
1:1.5 
2 Tris·HCl 7.8 + 24 h 6 mg/mL 
5’-FDA:5-FHPA 
2:1 
3 Phosphate 8.0 + 24 h 3 mg/mL 
5’-FDA:5-FHPA 
1.1:1 
4 Phosphate 8.0 + 24 h 12 mg/mL 
5’-FDA:5-FHPA 
1:7 
5 PBS 7.2 - 48 h 3 mg/mL Fig. 11 
 
3.4.2 Implementation of an NAD+ recycling protocol  
Since the cofactor NAD+ is consumed in the final enzymatic transformation, and it 
requires to be added in a stoichiometric amount, an NAD+ recycling system was 
considered in order to regenerate NAD+ from NADH. 
A traditional way to convert NADH into NAD+ is to use lactate dehydrogenase (LDH) 
in the transformation of pyruvate into L-lactate.15 A L-lactate dehydrogenase from 
rabbit muscle (Sigma Aldrich) was explored by incubation with fluoropyruvate (162) 
and NADH (Scheme 11), a transformation that was readily followed by 19F NMR 
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spectroscopy. The transformation was satisfactory, and showed full conversion into 
(2R)-3-fluorolactate (163) by 19F NMR spectroscopy. 
 
Scheme 11. Reduction of 3-fluoropyruvate 162 by LDH 
Given the successful generation of NAD+ with LDH, this recycling system was 
explored for the last step of the biotransformation, as shown in Scheme 12. 
 
Scheme 12. NAD+ recycling system tested for the FdrC transformation of 5-FDR into 5-FHPA 
The experiment was explored in three different buffers to establish optimal conditions. 
These were phosphate (pH = 7.8); PBS (pH = 7.4); and Tris·HCl buffer (pH = 7.8). All 
three buffers showed conversion into 5-FHPA, indicating the regeneration cycle is 
active; however, residual 5-FDR is obvious in all three. Given that none of the 
experiments carried out with 5-FDR as starting material for the FdrC transformation 
into 5-FHPA showed full conversion, it is indicative that the enzymatic turnover is 
slow, perhaps with substrate or product inhibition. 
In an attempt to avoid the saturation of FdrC, a two-step biotransformation starting 
from 5’-FDA was explored. This experiment would allow the gradual generation of 5-
FDR, and perhaps improve the overall transformation. The assay was carried out in 
Tris·HCl buffer (pH = 7.5), at 37 ºC over 20 h, and the outcome is shown in Scheme 
13. 
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Scheme 13. Assay from 5’-FDA to 5-FHPA, with LDH as NAD+ regenerating agent 
The transformation was successful, leading to full conversion into 5-FHPA (Fig. 13), 
suggesting that a slower in situ generation of 5-FDR improves the overall conversion. 
This outcome suggests that 5’-FDA (17) is more suitable than 5-FDR (26) as a starting 
point for this biotransformation to 5-FHPA (2). 
 
Fig. 13 19F {1H} NMR of 5’-FDA into 5-FHPA with an LDH recycling system of NAD+ 
Finally, the ‘complete’ transformation of fluoride into 5-FHPA with LDH as a 
recycling agent for NAD+ was explored (Scheme 14). 
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Scheme 14. Enzymatic transformation of inorganic fluoride into 5-FHPA, with NAD+ regeneration 
The experiment was run in Tris·HCl buffer (pH = 7.5) and with Mg2+ supplementation. 
Incubation was carried out at 37 ºC overnight (20 h). The outcome is shown by 19F 
NMR spectroscopy in Fig. 14.  
 
Fig. 14 19F{1H} NMR spectrum of the generation of 5-FHPA from inorganic fluoride and SAM, with 
LDH for NAD+ recycling 
This experiment starts from inorganic fluoride, and involves four enzymes, to generate 
5-FHPA. However, it was obvious that 5-FDR (α and β anomers) accumulated in the 
reaction, suggesting again a sluggish conversion of 5-FDR into 5-FHPA. 
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3.5 Scale-up of the 5-FHPA biotransformation 
Up to this point all of the experiments were carried out on an analytical scale. The next 
challenge in the optimisation process was to scale-up the production of 5-FHPA to 
milligram amounts. 
Given that the most successful biotransformation of 5-FHPA so far started from 5’-
FDA (17), initial optimisation explored the biotransformation from this metabolite (5 
mg), using LDH as the regenerating agent of NAD+ (Scheme 15). Incubations were 
carried out in Tris·HCl buffer at a pH of 7.5, 37 ºC over an extended incubation time 
(120 h). 
 
Scheme 15. Preparative scale (5 mg) of the biotransformation of 5’-FDA to 5-FHPA 
Aliquots were analysed after 24 h, 54 h and 72 h, prior to final 19F NMR analysis after 
120 h. The reaction had stopped after 24 h, when the experiment was essentially 
complete. The accumulation of 5-FDR anomers is observed again, along with a low 
level of residual 5’-FDA, as well as the product 5-FHPA (Fig. 15). The fact that 5-
FDR is the major product indicates that the final FdrC step is not fully functional – 
possibly due to an incomplete recycling of NAD+, or perhaps due to substrate 
inhibition.  
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Fig. 15 19F{1H} NMR spectrum of one of the 5 mg scale-ups after 120 h; residual 5-FDR is the major 
metabolite 
In view of the previous result, a new recycling system for NAD+ was explored using 
flavin mononucleotide (FMN, 166).16 FMN acts in conjugation with NADH, oxidising 
the cofactor back to NAD+, and generating FMNH2 by hydride transfer in a non-
enzymatic reaction.16 FMN was first tested on an analytical scale (Scheme 16). 
 
Scheme 16. Assay using FMN as a recycling agent for NAD+ 
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The experiment described in Scheme 16 was carried out in Tris·HCl buffer (pH = 7.5), 
at 37 ºC for 20 h. 19F NMR spectroscopy of the product shows the sole formation of 5-
FHPA, indicating FMN is highly efficient. The 19F {1H} NMR spectrum is shown in 
Fig. 16. 
 
Fig. 16 19F {1H} NMR shows conversion of 5’-FDA to 5-FHPA by FdrC, with FMN/NAD+ cofactor 
recycling 
After this transformation, a scale-up of the procedure was carried out using 5’-FDA (5 
mg), following the method described in above. After 24 h at 37 ºC, the only product 
that could be observed by 19F{1H} NMR was 5’-FHPA (Fig. 17), indicating a 
complete conversion of 5’-FDA to 5-FHPA. 
 
Fig. 17 Production of 5-FHPA from 5’-FDA (5 mg), with FMN as recycling agent 
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Encouraged by this result, a ‘complete’ biotransformation of 5-FHPA from fluoride 
was explored, as illustrated in Scheme 17, starting in this case with SAM (5 mg). 
 
Scheme 17. Biotransformation from SAM and KF to 5-FHPA with FMN to recycle NAD+ 
After a 24 h incubation, the only observed peak – apart from that of fluoride – was 5’-
FDA, thus the biotransformation appeared to stop at the NH step. In order to explore 
what might be the cause of this arrest, some control assays were carried out.  
An analytical reaction with 5’-FDA and the nucleoside hydrolase was conducted, to 
check whether the enzyme had lost its activity, however, there was again a full 
conversion of 5’-FDA into 5-FDR, indicating that the enzyme was still active. 
Another possibility was that the amount of SAM added (5 mg) was excessive, and 
perhaps downregulated the pathway in some way. To test this possibility, an analytical 
scale experiment from fluoride (Scheme 17) was carried out. This resulted in the 
formation of some 5-FHPA, but also in residual 5’-FDA and 5-FDR. Therefore, it was 
established again that SAM and inorganic fluoride do not serve as efficient starting 
materials for this biotransformation. 
A scale-up reaction from 5-FDR (10 mg) was carried out to study whether the single 
FMN step would be more efficient that the two-step experiment starting from 5’-FDA. 
Accordingly, 5-FDR was incubated in Tris·HCl buffer at 37 ºC and for 24 h (pH = 
7.5), in the procedure illustrated in Scheme 18. 
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Scheme 18. Biotransformation of 5-FDR to 5-FHPA 
The experiment was successful, but only progressed to about 25% conversion. 5-FDR 
remained in a ratio 3:1 with 5-FHPA. Once again, 5’-FDA proved to be the most 
efficient starting material for this enzymatic synthesis. Therefore, further experiments 
focused solely on this as a starting point for the biotransformation. 
Fresh batches of enzymes (NH and FdrC) were prepared before increasing the amount 
of starting material, to avoid the loss of activity over time. An assay was set up with 50 
mg of 5’-FDA, following the protocol illustrated in Scheme 16 (page 158). The 
experiment was incubated at 37 ºC, and monitored regularly over one week. 
Fluorine NMR analysis after 20 h of incubation showed formation of 5-FHPA, with 
residual amounts of 5’-FDA and 5-FDR. Integration of the peaks indicated that the 
ratio of 5’-FDA:5-FDR:5-FHPA was 1.3:1:1.3. After 48 h, the amount of 5’-FDA had 
considerably decreased, and 5-FHPA was already the major product in the mixture. At 
day four, the ratio 5’-FDA:5-FDR:5-FHPA was 0.1:1:1.7. This indicated that although 
the enzymes were still active, FdrC activity was decreasing, and lowering the overall 
conversion. This allowed the accumulation of 5-FDR in the mixture. One week after 
the start of the assay, the enzymes were no longer active, but the conversion into 5-
FHPA was improved from day 4. Fig. 18 shows the evolution of this experiment, at 
days 2 and 4. Notably, no 5’-FDA was left at day 4, and the ratio of 5-FDR to 5-FHPA 
was 1:2, as illustrated in Fig. 19.  
10 mg
O
OHOH
F
5-FDR (26)
OH FdrC
NAD+ NADH
F
OH
O
OH OH
OH
5-FHPA (2)
N
N
N
NH
O
O
O
P OO
O
OH
OHHO
FMN (166)
 162 
 
Fig. 18 Scale up from 5’-FDA (50 mg), at day 2 and day 4  
 
 
Fig. 19 19F {1H} NMR of the scale-up biotransformation of 5’-FDA into 5-FHPA, after one week  
 163 
At this point, all reasonable optimisations had been implemented; such as starting with 
5’-FDA, FMN as a functional recycling system for NAD+, freshly prepared enzymes, 
and the effect of different buffers, pH conditions and supplements (Mg2+).  
Enzymatic biotransformation using 5’-FDA (50 mg) successfully led to the formation 
of 5-FHPA in a 60% conversion, as determined by 19F NMR spectroscopy. 
Purification of a sample of the final product (5-FHPA, 2) proved to be extremely 
challenging, due to its very high water solubility, and no chromophore characteristics 
for HPLC detection. This remains to be optimised. 
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3.6 Conclusions 
The in vitro reconstitution of the biosynthetic pathway of 5-FHPA from fluoride was 
successfully achieved. The procedure started from SAM and inorganic fluoride, which 
were incubated with recombinant fluorinase from S. cattleya, recombinant PNP 
immobilised in Sepabeads®, a commercial phytase from wheat and the recombinant 
FdrC from a codon-optimised synthetic gene, along with NAD+. Due to the optimal pH 
for the phytase being significantly lower than that from the other enzymes, the process 
was carried out as a one-pot, three-step method; which involved two changes of pH. 
Optimal conditions for the combined chemical and enzymatic production of 5-FHPA 
involved 5’-FDA as a starting material for a two-step enzymatic synthesis that includes 
FMN as recycling agent for NAD+. 
Biotransformations from SAM and fluoride or from synthetic 5-FDR, did not result in 
a full conversion into 5-FHPA. 
Finally, a scale-up experiment for the enzymatic production of 5-FHPA was 
successfully carried out from 50 mg of 5’-FDA, in a 60% conversion. In this 
biotransformation, the enzymes NH and FdrC were used, therefore avoiding any 
change of pH. Added FMN enabled the in situ recycling of NAD+ at a catalytic level. 
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Chapter 4. Exploring the fluorinase pathway of Streptomyces 
sp. MA37 
4.1 Introduction 
Studying the biosynthesis of organofluorine compounds is a field of interest, given the 
scarcity of fluorinated natural products on Earth, and the potential to make 
organofluorines by biotransformations from fluoride. Only six fluorinated natural 
products are known.1 The most recent was isolated and characterised in 2014 from the 
bacterium Streptomyces sp. MA37, and was identified as (2R,3S,4S)-5-fluoro-2,3,4-
trihydroxypentanoic acid (5-FHPA, 2). This product was biosynthesised along with 
fluoroacetate (FAc, 1) and 4-fluorothreonine (4-FT, 4).1 Although 5-FHPA is the only 
novel fluorometabolite identified from S. sp MA37 so far, several additional fluorine 
peaks have been observed (by 19F NMR spectroscopy) in profile studies of the 
organism.  
Streptomyces sp. MA37 was collected in a fluoride rich soil in Ghana.1 Sequencing of 
its full genome led to the identification of flA1, a fluorinase gene with 87% homology 
of that of the original fluorinase (flA) from S. cattleya.1  
The original fl gene locus (S. cattleya) was first characterised in 2006 by Spencer et 
al.,2 now known as the ‘Spencer cluster’. Cloning and analysis of this DNA locus 
showed that it encoded several genes around the fluorinase (flA), that could potentially 
be involved in fluorometabolite biosynthesis.2 The genome map for this cluster, as 
well as the aminoacid length for each gene and its expected function is shown in Fig. 
1.2  
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Fig. 1 The Spencer Cluster, as published in 2006 5 
 
Fig. 2 is an illustration of the comparison between the genome maps for S. cattleya and 
S. sp. MA37.2 
 
 
Fig. 2 Aligned genome maps for S. cattleya (the Spencer Cluster) and S. sp. MA37 2 
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Table 1 displays the anticipated functions for each of the open reading frames (ORF) 
within the fluorometabolite gene cluster of S. sp. MA37 and its homology to the 
original S. cattleya.2 
Table 1. Homology between the genomic functions of S. sp. MA37 and S. cattleya2 
ORF Expected Function AA Identity (%) 
Homologue in S. 
cattleya 
ORF1 Duf109 114 - - 
ORF2 
Carboxylate/Amino Acid/ 
Amine Transporter 
316 76% SCAT_p0565 
ORF3 
YbaK/prolyl-tRNA 
synthetase 
191 81% SCAT_p0564 
flB1 5’-FDA phosphorilase 299 66% flB 
flA1 5’-FDA synthase 299 88% flA 
flFT1 
4-fluorothreonine 
transaldolase 
625 72% SCAT_p0562 
flF1 
DNA binding regulatory 
protein 
171 72% flF 
flG1 
DNA binding regulatory 
protein 
226 61% flG 
flH1 Na+/H+ antiporter 451 57% flH 
flI1 
Adenosylhomocysteine 
hydrolase 
487 82% flI 
ORF4 Duf109 fragment 94 - - 
flL1 
DNA binding regulatory 
protein 
224 57% flL 
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This section of the genome is responsible for the formation of fluoroacetate (1) and 4-
fluorothreonine (4) as observed in both S. cattleya and S. sp. MA37. However, the 
metabolic pathway in S. sp. MA37 comprises an additional branch, which starts from 
5-FDRP (18), and is expected to lead to the formation of 5-FHPA (2), as well as the 
additional unknown fluorometabolites.1 
In 2014, a second genome cluster from S. sp. MA37 was identified, and named fdr, 
since it is involved in the formation of 5-FDR.1 This cluster is located separately from 
the flA cluster. It is similar to a section of the genome that encodes the chlorinase 
pathway in Salinispora tropica.3,1 
The homology between the proteins found within the fdr cluster in S. sp. MA37, and 
their expected functions, along with the homology to S. tropica are displayed in Fig. 
3.1 
 
Fig. 3 Fdr cluster, and homology to S. tropica1 
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4.2 Aims and objectives 
It became a focus to explore further the biosynthesis of the novel fluorometabolites of 
Streptomyces sp. MA37. Our approach was to incubate advanced biosynthetic 
intermediates with cell-free extracts, to track the pathway of previously unidentified 
fluorometabolites and gain a better knowledge of their origin.  
For these purposes, it became an objective to synthesise candidate intermediates, for 
cell-free extract incubations. Metabolites immediately prior and after the putative 
branch point in the metabolic pathway (Scheme 1) were selected. 
 
Scheme 1. Putative fluorometabolic pathway in S. sp. MA37. Target molecules for incubation studies 
are highlighted in pink and green 
Accordingly, 5’-FDA (17) and 5-FDR (26) were synthesised, as indicated in Section 
3.3.2. In order to further investigate the validity of the pathway, the syntheses of 
isotopically labelled [5’,5’-2H2]-5’-fluoro-5’-deoxyadenosine 17a and [5,5-2H2]-5-
fluoro-5-deoxyribose 26a also became an aim (Fig. 4). 
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Fig. 4 Target isotopomers for feeding experiments 
4.3 Fluorometabolite profile in Streptomyces sp. MA37 
As a frame of reference, it became necessary to re-establish the production of the 
fluorometabolites from glycerol stocks of S. sp. MA37. Additionally, our collaborator 
Dr. H. Deng (University of Aberdeen), kindly supplied a fresh agar gel with plated 
bacteria. These strains were established in culture and both showed similar metabolite 
production when incubated in a fluoride-enriched medium. An example of the resultant 
19F{1H} NMR spectra of these extracts is shown in Fig. 5. Fluorometabolite 
production was good, and differed only a little from previous.1 
 
 
Fig. 5 A) Fluorometabolite production of a liquid culture of S. sp. MA37, when incubated in a fluoride-
enriched medium, produced in this study. B) Original production of fluorometabolites in S. sp. MA37, 
as published1 
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This fluorometabolite profile will form the frame of reference for this study, where a 
number of cell-free extracts and whole-cell feeding experiments will be carried out to 
explore metabolite production. 
4.4 Cell-free experiments with Streptomyces sp. MA37 
A ‘cell-free’ extract (CFE) refers to an experiment in which the cells have been 
ruptured, and the cell debris removed by centrifugation, but all the soluble elements 
inside the cell remain in the supernatant. This makes it possible to carry out incubation 
experiments with the released soluble, active enzymes. 
4.4.1 Exploratory incubations of SAM with inorganic fluoride, and 5’-FDA. 
Assignment of signals 
A cell-free extract was prepared following the procedure described in Section 5.7.2 
(Chapter 5). SAM (16) and 5’-FDA (17) were stored in 10 mM stock solutions and 
KF in a 50 mM solution, at -80 °C. Reagent solutions were thawed in ice before use. A 
first set of experiments was carried out incubating with added SAM (in the presence of 
fluoride ion) to assess fluorinase activity in the CFE. Also, 5’-FDA (17) was explored 
as a substrate to assess if the downstream metabolic enzymes remained active in the 
CFE. 
The SAM (16) and fluoride experiments were run for 16–48 h, but they did not show 
any fluorine peaks by 19F{1H} NMR spectroscopy, apart from that corresponding to 
fluoride ion. This lack of fluorometabolite production suggested that the fluorinase in 
this particular CFE was not active.  
However, incubation with 5’-FDA (17) did generate a metabolite profile, as identified 
by 19F{1H} NMR spectroscopy. A synthetic sample of 5’-FDA was added into the 
NMR tube. This confirmed that the signal at -231.0 ppm was indeed 5’-FDA. Given 
the proximity of these peaks within the spectrum – all appearing within a 0.5 ppm 
range – it is difficult to assign the peaks accurately without spiking with reference 
compounds. The 19F NMR peaks at -230.7, -230.9, and -231.0 ppm could be assigned 
to 5-FDRP (18), 5’-FDI (153) and 5’-FDA (17), respectively.4  The peak at -231.4 ppm 
is an unknown metabolite. 
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Fig. 6 19F{1H} NMR spectrum of the 5’-FDA incubation in CFE in phosphate buffer, note the false 
multiplicity of the peaks, caused by faulty shimming in the NMR spectroscope 
Given the clustering of the fluorine peaks within the spectra, an internal 19F-NMR 
reference compound was added to all of the cell free extracts to improve confidence in 
signal assignments. 1,3-Difluoro-2-propanol was selected due to its high solubility in 
water, and its proximity in chemical shift (-232.8 ppm). The internal reference 
revealed that the peaks did not always appear at the same chemical shift from different 
experiments, most probably due to differences in the protein concentration or pH of the 
different samples.  
Since, no synthetic reference samples of 5’-FDI (153) and 5-FDRP (18) were 
available, it proved necessary to prepare samples of 5’-FDI and 5-FDRP by enzymatic 
biotransformations. In addition, the same nucleoside hydrolase (NH) enzyme used in 
the Chapter 3 was employed to generate a sample of 5-FDR (26).  
Three enzymatic transformations were carried out with 5’-FDA (17), as shown in 
Scheme 2.5 The adenosine deaminase (ADA) and hydrolase (NH) reactions worked as 
expected, affording 5’-FDI (153) and 5-FDR (26), respectively.  
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Scheme 2. Enzymatic transformations performed on 5’-FDA (17) 
The purine nucleoside phosphorylase (PNP) reaction led to three fluorinated products 
(in the 19F{1H} NMR spectrum with chemical shifts at -231.0, -231.1, and -231.3 ppm, 
Fig. 7). 5’-FDI 153 (-231.1 ppm) and 5’-FDA 17 (-231.3 ppm) were established as the 
major products, and it was deduced by comparison to previous reports,7 that the minor 
signal at -231.0 ppm belonged to 5-FDRP 18 (Fig. 7). 
 
 Fig. 7 19F{1H} NMR spectrum for the PNP reaction with 5’-FDA, after 5’-FDA spiking 
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The products obtained in these enzymatic reactions were used as reference compounds 
for spiking the CFEs. With these reference compounds in hand, it was established that 
the three major peaks obtained when incubating 5’-FDA in the CFE were (from left to 
right) 5-FDRP, 5’-FDI and 5’-FDA, as illustrated in Fig. 7.  
The cell-free experiments carried out so far indicated that the enzyme activity beyond 
the branch point metabolite 5-FDRP seemed not to be active in the incubations. 
Furthermore, there did not appear to be any significant fluorinase activity. In order to 
confirm this, these experiment were repeated. A cell pellet from a new culture was 
prepared, and the CFE experiments with both SAM/KF and 5’-FDA were repeated. 
The results were similar to those carried out with the first pellet. The time (day 8) at 
which the cell pellet was harvested was also investigated. Two fresh pellets were 
prepared on days 14 and 20, respectively. The outcome after incubating SAM/KF and 
5’-FDA with the resultant CFEs did not change.  
A different buffer for the CFE preparation was explored. The experiments were run 
this time in Tris (20 mM, pH 7.5), rather than phosphate buffer. Incubation of fluoride 
ion and SAM did not progress, but incubation with 5’-FDA this time showed only one 
product by 19F NMR spectroscopy, which could be assigned to 5’-FDI (153). Fig. 8 
shows 19F{1H} NMR spectra for the experiment (upper spectrum) and the same 
experiment after spiking (lower spectrum) with the reference compound (1,3-difluoro-
2-propanol, -232.8 ppm) and 5’-FDA (-231.2 ppm). 
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Fig. 8 19F{1H} NMR spectra of the 5’-FDA CFE run in Tris buffer (upper), and the same sample after 
spiking with 5’-FDA and the reference (lower) 
In order to probe 5’-FDI (153) as an intermediate metabolite, a cell-free incubation 
was prepared, adding 5’-FDI. However, 153 did not progress to any other 
fluorometabolites, either in phosphate or Tris buffers, consistent with its presence as a 
dead end ‘shunt’ metabolite. 
In all of the cell-free experiments, the adenosine deaminase (ADA) enzyme, which 
converts 5’-FDA to 5’-FDI, proved to be more active than the PNP. Inosine was added 
into the CFE, in an attempt to inhibit the deaminase, however, the formation of 5’-FDI 
still dominated, and no new fluorometabolite peaks were obtained.  
The lack of 5-FDRP (and the increased deaminase activity of PNP) in Tris buffer was 
not unexpected, since phosphate ions are required for PNP activity. 
4.4.2 Effect of the addition of fluorinase and influence of 5’-FDA concentration 
Since fluorinase in the cell-free incubations was inactive, CFE experiments were 
explored with added recombinant fluorinase. With such a combination, incubation of 
SAM and fluoride led to the formation, for the first time, of 5’-FDA (17) and 5’-FDI 
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(153), Fig. 9. This indicated again that there was still significant adenosine deaminase 
activity in the CFE. 
 
Fig. 9 19F{1H} NMR spectrum of SAM/KF CFE, with a recombinant fluorinase  
The final concentration of 5’-FDA (17) in previous CFEs was 3 mM, which may lead 
to feedback inhibition. Thus, a new CFE was carried out with a final concentration of 
just 0.5 mM of 5’-FDA. This was more successful and new peaks appeared at -230.9,         
-231.1, -231.6, -231.7, -232.7, -233.0 and -233.5 ppm in the 19F{1H} NMR spectrum 
(Fig. 10). This was the first time that a wide range of fluorometabolites accumulated in 
a cell-free extract with 5’-FDA, and suggests that higher concentrations of 5’-FDA 
(17) shut down the biotransformations. The identity of many of the peaks in Fig. 10 
remains unknown. 
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Fig. 10 19F{1H} NMR spectrum of the 5’-FDA CFE at 0.5 mM 
In order to obtain more information regarding the effect of 5’-FDA (17) concentration 
in the CFEs, a study was carried out incubating 5’-FDA across a range of 
concentrations; 0.2, 0.4, 0.6, 0.8, 1.0, 1.5, 2.0, 2.5, 3 and 6 mM were selected. As 
shown in Fig. 11, concentrations below 3.0 mM seem to be more active, generating a 
wider range of fluorometabolites, while the assays performed at 3.0 and 6.0 mM show 
a clear predominance of 5-FDRP, 5’-FDI and remaining 5’-FDA. 
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Fig. 11 19F{1H} NMR spectra of the 5’-FDA concentration (0.2 – 6.0 mM) assays 
Fig. 11 shows an important shift in the peaks, especially in the experiments with 3.0 
and 6.0 mM 5’-FDA concentration. The pH of the solution in the NMR tubes remained 
the same, so these shifts are mostly due to a difference in the protein concentration. In 
order to make sure that the peaks correspond to the same compounds, NMR tubes of 
experiment 4 (0.8 mM) and experiment 10 (6.0 mM) where mixed. The outcome 
showed just one set of peaks, indicating that the products where the same in both 
experiments. 
In a similar line of investigation, the effects of the concentration of SAM and fluoride 
were investigated. In these experiments, a concentration ratio of 1:5 mM of SAM to an 
excess of fluoride was used (previously the ratio SAM : KF was 1:1). For the first 
time, fluorometabolites were observed without addition of a recombinant fluorinase. 
This also led to the formation of 5’-FDA and 5’-FDI, as shown in Fig. 12.  
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Fig. 12 19F{1H} NMR spectrum of the SAM and KF CFE, keeping the ratio 1:5 mM 
4.4.3 Addition of cofactors, supplements and enzymes into the CFE incubations 
Given that some of the structures and their metabolic pathways are still unknown, there 
is the possibility that the CFEs were not fully competent because the enzymes were 
lacking required cofactors. 
A range of experiments with different cofactors (Table 2), buffers and feedstocks were 
trialled. A summary of the experimental conditions used, and corresponding outcomes 
are given in Table 2. All of the CFE experiments were carried out with a pellet 
harvested on day 8 of the culture fermentation, and the CFE incubations were 
performed for 20 h at 37 °C. For the incubations involving SAM and fluoride, a 
recombinant fluorinase was added (30 µL of a 2.2 mg/mL solution), in an attempt to 
stimulate the production of fluorometabolites. 
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Table 2. Addition of different enzymes, cofactors and supplements, in both Tris·HCl and phosphate 
buffers 
Buffer Enzyme Cofactor Supplement Substrate Results 
Tris· HCl Fluorinase PLP - SAM/KF - 
Phosphate Fluorinase PLP - SAM/KF - 
Tris· HCl - PLP - FDA 5’-FDI, 5’-FDA,  
2 unknown peaks Phosphate - PLP - FDA 5’-FDI, 5-FDRP, 5’-FDA 
Tris· HCl Fluorinase NAD+ - SAM/KF - 
Phosphate Fluorinase NAD+ - SAM/KF - 
Tris· HCl - NAD+ - FDA 5’-FDI, 2 unknown 
peaks 
Phosphate - NAD+ - FDA 5’-FDI, 5-FDRP, 5’-FDA 
Tris· HCl Fluorinase ATP Mg2+ SAM/KF - 
Phosphate Fluorinase ATP Mg2+ SAM/KF - 
Tris· HCl - ATP Mg2+ FDA 5’-FDI, 5’-FDA 
Phosphate - ATP Mg2+ FDA 5’-FDI, 5-FDRP 
Tris· HCl Fluorinase FAD - SAM/KF - 
Phosphate Fluorinase FAD - SAM/KF - 
Tris· HCl - FAD - FDA 5’-FDI, 2 unknown 
peaks 
Phosphate - FAD - FDA 5’-FDI, 5-FDRP 
Tris· HCl Fluorinase NAD+, FAD, 
ATP, PLP 
Mg2+ SAM/KF - 
Phosphate Fluorinase NAD+, FAD, 
ATP, PLP 
Mg2+ SAM/KF - 
Tris· HCl - NAD+, FAD, 
ATP, PLP 
Mg2+ FDA 5’-FDI, 2 unknown 
peaks 
Phosphate - NAD+, FAD, 
ATP, PLP 
Mg2+ FDA 5’-FDI, 5-FDRP 
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In these assays, a new peak emerged at -228.8 ppm (consistent with the chemical shift 
of β-5-FDR) when 5’-FDA was incubated. There is no 5-FDRP present, but there is a 
second peak appearing at -231.3 ppm (Fig. 13). Since all of the experiments with 
cofactors and 5’-FDA led to the formation of the new peak at -228.8 ppm, it is 
probable that this peak appears as a feature of the particular culture used. 
 
Fig. 13 19F{1H} NMR spectrum of a standard sample taken from one of the CFE incubations of 5’-FDA 
with PLP in Tris buffer 
Despite the incubations with 5’-FDA leading to the production of fluorometabolites, 
none of the assays carried out with SAM and KF generated any; and none of the 
cofactors added was responsible for the generation of new fluorometabolites. 
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4.4.4 Incubation of 5-FDR. Reproduction of published experiments. 
Incubation of 5-fluoro-5-deoxyribose (5-FDR, 26) with a newly prepared cell-free 
extract gave, as expected, a range of fluorometabolites as observed previously.1 No 
fluoroacetate or 4-fluorothreonine were observed, a result entirely consistent with a 
branching pathway. The results obtained in this incubation are shown in Fig. 14.  
 
Fig. 14 19F{1H} NMR spectrum of the 5-FDR CFE incubation in phosphate buffer 
4.5 Incubation in cell-free experiments from Streptomyces cattleya 
A cell-free experiment was carried out in order to check that the protocols followed in 
this study for CFE preparation were valid. This involved a repetition of the CFE 
experiments previously reported for the historical fluoroacetate and 4-fluorothreonine 
producing organism S. cattleya,6 and involved addition of 5’-FDA (17).  
This experiment led to the efficient formation of 4-FT 4 and FAc 1, as previously 
observed and gave confidence that the protocols were correctly carried out. In 
overview, these experiments suggest that Streptomyces sp. MA37 generates a much 
more sensitive CFE than that from S. cattleya. 
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Fig. 15 19F{1H} NMR spectrum of the 5’-FDA CFE incubation in S. cattleya 
4.6 Synthesis of the deuterium labelled intermediates for feeding 
experiments 
As well as feeding experiments with 5’-FDA (17) and 5-FDR (26), prepared in 
Chapter 3, we envisaged the preparation of deuterium-labelled intermediates, as such 
compounds can facilitate tracking the origin of the fluorometabolites. Deuterium 
incorporations are readily identified by a heavy atom induced shift in the fluorine 
signals of the 19F-NMR spectrum, when compared to their non-deuterated analogues.7 
Therefore, a comparison between the spectra produced in the labelled and unlabelled 
experiments, should reveal isotopically enriched metabolites, which derived from the 
labelled precursor. Hence, [5’,5’-2H2]-5’-fluoro-5’-deoxyadenosine 17a and [5,5-2H2]-
5-fluoro-5-deoxyribose 26a became synthetic targets. 
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These compounds were selected as they are intermediate metabolites, which occur just 
before and after the proposed metabolic branch point. This branch occurs at 5-fluoro-
5-deoxyribose phosphate 18, as highlighted in Scheme 1 (page 171). The synthesis of 
[5’,5’-2H2]-5’-fluoro-5’-deoxyadenosine 17a should feed into both metabolic branches, 
whereas [5,5-2H2]-5-fluoro-5-deoxyribose 26a should only label compounds derived 
from the upper branch of the pathway, if the general hypothesis is correct.  
4.6.1 Synthesis of [5’,5’-2H2]-5’-fluoro-5’-deoxyadenosine (17a) and [5,5-2H2]-5-
fluoro-5-deoxyribose (26a) 
Given the very similar location of the isotope in the fluoromethyl groups of these two 
compounds, a common route was designed with modification only of the last step. The 
retrosynthesis is shown in Scheme 3. 
 
Scheme 3. Retrosynthesis of the isotopically labelled precursors 
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The proposed synthesis began with the protection of adenosine 154 as an acetonide, 
followed by oxidation to a carboxylic acid and then subsequent esterification. The 
deuterium isotope will be introduced by reduction of the ester moiety in the presence 
of a deuteride source. Fluorination and deprotection constitute the final steps. Varying 
the conditions of this last step should allow for the formation of either 17a or 26a. 
 
Scheme 4. Conditions and reagents used in the synthesis of [5’,5’-2H2]-5’-fluoro-5’-deoxyadenosine 
17a and [5,5-2H2]-5-fluoro-5-deoxyribose 26a 
Protection of adenosine 154 was carried out in the presence of 2,2-dimethoxypropane 
(DMP), perchloric acid and acetone. The addition of both DMP and perchloric acid 
was performed at 0 °C, and the latter was added dropwise. After purification, this gave 
acetonide 155 in 63% yield. 
The oxidation of 155 into carboxylic acid 167 with BAIB and TEMPO in a 1:1 
mixture of MeCN/water proved straightforward and 167 was precipitated from the 
reaction mixture in an 85% yield.  
This oxidation reaction was previously described for substrate 155 by Epp and 
Widlanski in 1999,8 and the mechanism, which proceeds by a radical process, is 
described by Tojo and Fernández.9 
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Scheme 5. Mechanism for the oxidation, as described by Tojo and Fernández12 
The esterification reaction from 167 to 168 using SOCl2 in MeOH was not 
straightforward. The acetonide protecting group was hydrolysed during the procedure, 
due to the acidic conditions, generating adenosine-5’-carboxylic acid methyl ester 169 
in a 90% yield. 
 
Scheme 6. Formation of denosine-5’-carboxylic acid methyl ester 169 
Esterification conditions for this substrate 167, while minimising hydrolysis of the 
acetonide group, were described by Brondyk in 1976.10 The conditions used were the 
same, but the reaction was carried out in a one-pot, two-step procedure, as shown 
Scheme 7. 
 
Scheme 7. Brondyk conditions for the esterification of 168 13 
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These new conditions worked relatively well on a small scale (100 mg of starting 
material), giving 168 in a 46% yield. However, when the reaction was scaled up, 
product isolation was hampered by a significant level of deprotected ester 169. It 
proved more efficient to progress with the deprotected adenosine 169. 
The next reaction of the sequence involved the reduction of ester 169 in the presence 
of a deuteride source (NaBD4). This afforded di-deuterated adenosine 154a in 69% 
yield. 
 
Scheme 8. Reduction of the ester 169 with NaBD4 
Alternatively, in an attempt to reduce the synthesis by two steps, and therefore 
improve the overall yield, conditions were explored to transform carboxylic acid 167 
into the di-deuterated and protected adenosine 155a, as described by Szostak and 
Procter in 2014.11 However, the reaction did not work, most likely due to the lack of 
solubility of 167 in D2O, which was both the solvent and the deuterium source. 
 
Scheme 9. Attempted SmI2 reduction of carboxylic acid 155a  
The original synthetic plan required the re-protection of [5’,5’-2H2]-adenosine 154a, a 
reaction that was carried out following the previously described procedure. In the 
event, acetonide 155a was obtained in 48% yield, and then fluorination with TBAF 
and TsF in THF at 60 °C was performed. The reaction proved straightforward and led 
to 156a in a 63% yield.  
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Scheme 10. Re-protection and fluorination reactions 
Finally, deprotection was required. In the case of [5’,5’-2H2]-5’-FDA 17a, the 
procedure also proved straightforward, and product 17a was obtained in a 35% yield. 
 
Scheme 11. Deprotection of the acetonide to give [5’5’-2H2]-17 (17a) 
Deprotection to give [5,5-2H2]-FDR 26a was monitored by 19F{1H} NMR 
spectroscopy, and the formation of the anomers of [5,5-2H2]-FDR (26a) was observed 
after 2 h in 4M HCl. Purification of this highly water soluble product was challenging 
and it proved difficult to isolate a useful sample.  
4.7 Feeding experiments in whole cell cultures of S. sp. MA37 
4.7.1 Feeding of 5’-FDA (17) 
In the first place, unlabelled 5’-FDA (17) was added into a whole cell culture as the 
sole source of fluorine. Two different experiments were carried out, to investigate 
whether the time of addition would influence the incorporation or production. 
Therefore, in one of the experiments 5’-FDA was added after inoculating the bacteria 
on day 0 of the cycle; whereas in the second experiment it was added at day 8, when 
fluorometabolite production starts, in a standard culture with inorganic fluoride in the 
medium. The experiments were then incubated for 20 days, under standard conditions. 
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Whilst the incubation inoculated at day 8 shows the formation of 4-fluorothreonine (4) 
and fluoroacetate (1) – along with residual 5’-FDA –; the incubation that had 5’-FDA 
(17) added from the start of the experiment produced a wider range of 
fluorometabolites (Fig. 16). 
 
Fig. 16 Feeding experiment in S. sp. MA37, after 18 days (inoculation of 5’-FDA on day 0) 
As shown in Fig. 16, the production of fluorometabolites is similar to that observed 
during the profiling of S. sp. MA37, suggesting that whole cells are needed in order to 
generate the full fluorometabolite profile. 
A control experiment was also run to confirm that fluorometabolite production is 
derived from the 5’-FDA present in the culture. For this, a culture of S. sp. MA37 was 
incubated for 25 days, under identical conditions, but without an external source of 
fluoride. 19F NMR spectra is clear and shows no fluorinated peaks. 
4.7.2 Feeding of [5’,5’-2H2]-5’-FDA (17a) 
After the results with unlabelled 5’-FDA 17, incubations with deuterium-labelled 
[5’,5’-2H2]-5’-FDA 17a were explored. 
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For this, three experiments were conducted. In the first experiment [5’,5’-2H2]-5’-FDA 
(17a) was added shortly after the inoculation of the media with S. sp. MA37, on day 0, 
and this was the only source of fluorine. In the second experiment, [5’,5’-2H2]-5’-FDA 
(17a) was added sequentially on days 4, 5 and 6; again as the sole source of fluorine. 
The last experiment reproduced the latter, with sequential addition of [5’,5’-2H2]-5’-
FDA (17a) on days 4, 5 and 6, but it also contained KF (0.2 mM) in the medium. 
All three assays were incubated following standard conditions, at 30 ºC and 180 rpm, 
and were sonicated, centrifuged and freeze-dried at day 12 for work up and analysed 
by 19F{1H} NMR spectroscopy. The results are shown in Fig. 17. 
 
Fig. 17 19F{1H} NMR spectra after [5’,5’-2H2]-5’-FDA (17a) incubations. A) Inoculation at day 0, no 
KF. B) Inoculation at days 4, 5 and 6, no KF. C) Inoculation at days 4, 5 and 6, 0.2 mM KF. 
The formation of [2H2]-fluoroacetate 1a, is obvious in the 19F NMR spectrum (Fig. 
17), and shows that 5’-FDA is the source of fluorine for the first branch of the 
metabolic pathway. The three signals of fluoroacetate appreciated in the spectra appear 
at an approximate shift difference of 0.6 ppm from each other, corresponding to the 
populations of fluoroacetate that contain zero, one and two deuterium atoms, and they 
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are separated due to heavy atom upfield shifts, as previously established for deuterium 
labelled glycerols into FAc and 4-FT in S. cattleya.12 
 
Fig. 18 Expansion of 19F{1H} NMR spectra for the fluoroacetate peaks observed in this study; showing 
heavy atom (2H) shifts (0.6 ppm) for populations of FAc (1), [2H1]-FAc (1b) and [2H2]-FAc (1a) 
For confirmation of the source of fluoride in the second branch – to generate 5-FDR 
(26) and 5-FHPA (2) – it is necessary to enlarge the previous spectra (Fig. 19). 
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Fig. 19 19F{1H} NMR spectra after [5’,5’-2H2]-5’-FDA (17a) incubations (expansion). A) Inoculation at 
day 0, no KF. B) Inoculation at days 4, 5 and 6, no KF. C) Inoculation at days 4, 5 and 6, 0.2 mM KF. 
The formation of deuterium incorporations into 5-FHPA (2) is clear in the third 
experiment supplemented with KF. The unlabelled 5-FHPA (2) has another peak 0.6 
ppm upfield from this one, which suggests the formation of 5-[2H1]-5-FHPA, and a 
further peak at approximately 1.2 ppm upfield from the unlabelled 5-FHPA is 
consistent with the formation of 5-[2H2]-5-FHPA (2a). 
Thus, it is concluded that 5’-FDA (17) is a precursor for 5-FHPA (2). The other 
unidentified compounds also seem to be similarly labelled, consistent with 5’-FDA 
being a common precursor. The inability to prepare 5-[2H2]-5-FDR (26a) precluded 
this experiment; however, incubation with unlabelled 5-FDR 26 (Section 4.4.4, page 
184) in CFEs did not generate FAc (1) nor 4-FT (4), indicating that it is uniquely 
formed only after the branch point. 
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4.8 Conclusions  
In conclusion, the cell-free extracts of S. sp. MA37 proved to have poor fluorinase 
activity, when incubated with SAM and fluoride. Recombinant fluorinase was required 
to be added to generate a fluorometabolite profile.  
The experiments that used 5’-FDA as a substrate led to the production, almost 
exclusively, of 5’-FDI; due to the dominance of an adenosine deaminase activity in the 
CFE. It proved important to have low 5’-FDA concentration, especially below 3 mM 
to generate a range of products. 
An incubation experiment with 5’-FDI showed that this substrate was not metabolised 
in the CFE incubation, and it is concluded that it is a shunt metabolite.  
CFE incubation with 5-FDR reproduced the original observation,1 leading to the 
formation of numerous fluorometabolites. However, no FAc (1) or 4-FT (4) were 
generated, suggesting its role beyond the branch point. 
Incubations of 5’-FDA (17) in live cultures led to the formation of a series of 
metabolites consistent with those observed in the metabolite profile of S. sp. MA37. 
Reproduction of this experiment with [5’,5’-2H2]-5’-FDA (17a) allowed the 
confirmation that 5’-FDA is the universal source of all of the fluorometabolites for 
both branches of the metabolic pathway. Further experiments are needed for the 
identification of all of the isotopically labelled fluorinated peaks appearing in the 
spectra. 
A synthesis of [5,5-2H2]-5-FDR (26a) was attempted, but yields were low, and its high 
water solubility precluded its isolation at a suitable level for a feeding experiment. 
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Chapter 5. Experimental 
5.1 General Procedures and Methods 
5.1.1 Chemistry general procedures 
All reactions were carried out in flame-dried glassware, which was cooled under argon 
gas. Air and/or humidity-sensitive reactions were carried out under an argon 
atmosphere. ‘Room temperature’ refers to conditions between 18 – 25 °C. Evaporation 
or concentration refers to the removal of solvent on a rotary evaporator attached to a 
diaphragm pump. 
The reagents used were obtained from Alfa Aesar, Acros, Fisher, Fluorochem or 
Sigma Aldrich; and were used without any extra purification, unless stated otherwise. 
Anhydrous THF, DCM and Et2O were obtained from an MBRAUN SPS-800 Solvent 
Purification System by passage through two drying columns and were dispensed under 
an argon atmosphere. Anhydrous methanol and acetonitrile were distilled from 
calcium hydride in a recycling still, and were dispensed under an argon atmosphere.1  
Analytical thin layer chromatography (TLC) was carried out on aluminium-backed 
silica gel 60 TLC plates with F254 indicator (Merck KGaA). Visualisation of 
compounds was achieved under UV light (254 or 365 nm), or by staining with 
anisaldehyde-sulfuric acid solution or potassium permanganate solution, and 
subsequent thermal development. Preparative silica gel column chromatography was 
carried out with Geduran® Si 60 Silica Gel (40-63 µm, flash silica, Merck KGaA) 
under a positive pressure of compressed air, eluting with solvents as supplied. 
HPLC analysis or semi-preparative purification were performed in a Shimadzu 
Prominence (SIL-20A HT autosampler, CL-20AT ternary pump, DGU-20A3R solvent 
degasser, SPD 20A UV detector and CBM-20A controller module), with the column 
specified in each case. 
Proton (1H) and proton-decoupled nuclear magnetic resonance spectra (19F{1H}, 
13C{1H}) were recorded on Bruker Avance III 500 or Bruker Avance III HD 500 (500 
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MHz 1H, 476 MHz 19F, 126 MHz 13C) spectrometers. Chemical shifts (∂) are 
expressed in ppm, and are quoted relative to the residual solvent signal. Proton 
coupling constants (J) are given in Hertz (Hz), and quoted to the nearest 0.1 Hz. 
Identical coupling constants are averaged. When necessary, two-dimensional spectra 
(COSY, HSQC, HMBC) were used for the assignments of otherwise challenging 
signals. 
Optical rotations were measured on a Perkin Elmer 341 polarimeter in a 1 dm cell at 
λ= 589 nm (wavelength for the sodium D-line). Specific rotations are given in implied 
units of 10-1 deg cm2 g-1 and concentrations are given in g/100 mL. 
High-resolution mass spectra were recorded using electrospray ionisation (ESI), on a 
Micromass LCT Spectrometer or on a ThermoFisher Excalibur Orbitrap Spectrometer 
from solutions of the analyate in methanol, acetonitrile or water. The Mass 
Spectrometry Service at the University of St Andrews was in charge of these results. 
Melting points were measured on a Griffin MPA 350.BM2.5 apparatus or an 
Electrothermal IA9100 machine, and are uncorrected.  
IR spectra were measured on an IRAffinity -1S Shimadzu Infra Red Spectrometer with 
diamond ATR attachment. Absorption maxima are reported in wavenumbers (cm-1). 
X-ray diffraction data were collected by Prof. A. Slawin or Dr. David Cordes 
(University of St Andrews) on a Mercury 70 diffractometer which uses graphite 
monochromated Mo-Kα radiation at 100 K. Structures were analysed on 
CrystalMaker. All the published structures have been deposited in CCDC. Please see 
Appendix for the complete account of the crystallographic data. 
Frozen aqueous solutions were freeze-dried in a Christ Alpha 1-2 Plus freeze drier. 
 
 
 
 
 199 
5.1.2 Biology general procedures 
All glassware used for biological purposes was autoclaved in advance, and used inside 
a laminar flow cupboard (Gallenkamp). Plasticware was also sterilised by autoclaving, 
unless using new sterile material. Media was also sterilised by autoclaving. 
Reagents used were purchased from Sigma-Aldrich, Alfa Aesar, Acros Organic or 
Fisher, with no further purification or treatment, unless otherwise stated. The synthetic 
and codon-optimised FdrC DNA plasmid dry was ordered from DNA2.0 (Gene 
140635).2 ADA enzyme from bovine spleen and PNP – recombinant, expressed in E. 
coli - are commercially available by Sigma-Aldrich. A second recombinant PNP was 
obtained from GSK. Phytase from wheat was commercially available by Sigma-
Aldrich. NH enzyme was over-expressed and purified from a recombinant plasmid 
from T. vivax expressed in E. coli3 and recombinant fluorinase was provided by Dr. 
Stephen Thompson (University of St. Andrews).4 These enzymes and plasmids were 
stored at -20 to -80 °C.  
Glycerol stocks of Streptomyces sp. MA37 were kindly provided by Dr. Long Ma 
(University of St. Andrews), and Dr. Hai Deng (University of Aberdeen) generously 
provided a Petri plate of S. sp. MA37. 
All biological samples were flash-frozen and stored at -80 °C in a New Brunswick 
Scientific -80 °C freezer, and thawed in ice or at 4 °C before use. 
Stock solutions of the substrates and cofactors used in the CFE reactions were made; 
the concentration of these solutions was of 10 mM, except for KF, which was 50 mM. 
Incubations of less than 1.5 mL were carried out in a BTD Dry Block Heating System 
for microtubes (Grant), while bigger volumes or incubations requiring shaking were 
carried out into an I26 Incubator Shaker (New Brunswick Scientific). 
Cell lysis was achieved in most cases by sonication with a Vibra Cell apparatus 
(Sonics & Materials Inc.), or performed in a one-shot cell disrupter (Constant 
Systems). Centrifugation was carried out on a Beckmann Avanti Centrifuge, at the 
conditions specified for each case.  
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Sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) was run 
using NuPAGETM 4-12% Bis Tris gels (Novex) in MOPS SDS running buffer, in a gel 
tank (XCell Sure LockTM, Invitrogen, Novex Mini-Cell) connected to a Bio-Rad Power 
Pac 300 operating at a constant current of 125 mA for 50 minutes (Amersham 
Pharmacia biotech EPS 301). Protein samples for SDS-PAGE were prepared as 
follows, depending on their solubility. Soluble samples were prepared as a mixture of 
the corresponding solution (10 µL), SDS buffer (7.5 µL) and the lysis buffer used as 
specified for each case (20 µL). Insoluble samples were prepared taking a pinhead 
amount of the solid sample, and mixing it with urea solution (50 µL, 8 M) and SDS 
buffer (12.5 µL). The gels were stained by soaking in Instant BlueTM reagent 
overnight. 
Optical density was measured at 600 nm in a WPA cell density meter. Protein 
concentrations, expressed in mg mL-1, were determined using a Nanodrop ND-1000 
spectrophotometer at 280 nm (Thermo Fisher Scientific). The extinction coefficients 
used were calculated by introducing the corresponding protein sequence into the 
ProtParam tool on the ExPASy Proteomics server (www.expasy.org). 
Protein identification was analysed by an AB Sciex MALDI-TOF instrument, samples 
not giving conclusive data in this instrument were analysed by nanoLC-ESI MSMS 
using the Q-STAR XL. Whole protein mass spectroscopy was performed on the AB 
Sciex 4800 MALDI-TOF instrument. 
Analytical analysis was carried out in the same way than for the chemical samples, as 
previously described. 
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5.2 Synthetic preparation of compounds 
5.2.1 Racemic ((1R,2R,3R,6S)-1-bromo-2,3,6-trifluorocyclohexyl)benzene (91) 
 
Racemic all-cis (2,3,6-trifluorocyclohexyl)benzene (59, 0.200 g, 0.93 mmol, 1 equiv.) 
was dissolved in CCl4 (2 mL). NBS (210 mg, 1.12 mmol, 1.5 equiv.) was added to the 
solution. CH3CN (0.1 mL) was added for better solubilisation of 59. The reaction 
mixture was heated at 90 °C for 48 h. The mixture was concentrated under pressure 
and redissolved in water (10 mL). The aqueous phase was extracted with Et2O (3 x 10 
mL). The combined organic phases were dried over Na2SO4 anhydrous, filtered and 
concentrated under reduced pressure. This procedure gave product 91 in quantitative 
yield and no further purification was needed. 1H NMR (500 MHz, chloroform-d) δH 
7.68 (2H, dq, J = 8.3, 1.2 Hz, H-Ar), 7.44 (2H, m, H-Ar), 7.37 (1H, m, H-Ar), 5.74 
(1H, dddt, J = 49.3, 8.3, 2.6, 1.2 Hz, H-γ), 5.5 (2H, m, H-β, H-ζ), 2.46 (3H, m, H-δeq, 
H-ε), 2.01 (1H, dq, J = 8.3, 5.9, 4.2 Hz, H-δax) 19F{1H} NMR (470 MHz, chloroform-
d) δF -189.8 (dd, J = 14.7, 18.5 Hz), -188.8 (d, J = 14.7 Hz), -171.8 (d, J = 18.5 Hz) 
13C NMR (126 MHz, chloroform-d) δC 138.0 (C-Ar), 129.0 (d, J = 15.5 Hz), 126.3  
(C-Ar), 90.4 – 86.5 (m, C-γ), 25.0 (dd, J = 22.4, 12.1 Hz, C-ε), 20.1 (dd, J = 20.4, 4.0 
Hz, C-δ) HRMS (ESI+) m/z calc. for C12H12BrF3Na [M+Na]+ 314.9972, found 
314.9956. 
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5.2.2 Racemic (1R ,2S ,3R ,6S)-2,3,6-trifluoro-1-phenylcyclohexan-1-ol  (79) 
 
(1-Bromo-2,3,6-trifluorocyclohexyl)benzene (91, 40 mg, 0.14 mmol, 1 equiv.) was 
dissolved in DMF (2 mL). NaN3 (25 mg, 0.30 mmol, 2 equiv.) was added and the 
mixture was heated to 80 °C for 18 h. The reaction was cooled to r. t. and quenched 
with water (50 mL). The aqueous phase was extracted with Et2O (3 x 50 mL). The 
combined organic phases were washed with brine (3 x 50 mL), dried over Na2SO4 
anhydrous, filtered and concentrated under reduced pressure. Further purification was 
carried out by column chromatography (100% petroleum ether), yielding hydroxylated 
79 as a yellow oily product in 31% yield. 1H NMR (500 MHz, chloroform-d) δH 7.72 
(2H, dd, J = 7.6, 1.7 Hz), 7.46 (2H, dd, J = 8.4, 6.6 Hz), 7.40 (1H, m), 5.17 (2H, m), 
4.90 (dd, J = 45.8, 3.2 Hz, 1H), 2.22 (3H, m), 1.95 (1H, m) 19F{1H} NMR (470 MHz, 
chloroform-d) δF -189.1 (F, d, J = 23.0 Hz), -191.6 (F, m),   -207.7 (F, m) 13C NMR 
(126 MHz, chloroform-d) δC 140.8, 127.3 (m), 90.0 (m), 73.8, 24.7 (dd, J = 21.8, 12.3 
Hz), 20.0 (dd, J = 20.3, 4.4 Hz) HMRS (ESI+) m/z calc. for C12H13OF3Na [M+Na]+ 
253.0816, found 253.0812. NMR signals were assigned for 79 in the metabolic assays 
(Section 5.3.2.2). 
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5.2.3 Racemic methyl 4-((1S,2S,3R,6S)-2,3,6-trifluorocyclohexyl)benzoate (93) 
 
4-(2,3,6-trifluorocyclohexyl)benzoic acid 60 (5 mg, 1 equiv.) was dissolved in a 
mixture CH3CN (200 µL) and methanol (150 µL). H2SO4 (conc., 50 µL) was added 
dropwise. The mixture was stirred at 80 °C for 16 h. The reaction mixture was cooled 
and quenched with Na2CO3 (20% sol., added dropwise until pH 7.0). The neutral 
solution was extracted with DCM (3 x 1 mL). The combined organic phases were 
washed with water (3 x 3 mL), dried over anhydrous Na2SO4, filtered and under 
reduced pressure, resulting in methyl ester 93 in quantitative yield. No further 
purification was required. The enantiomerically enriched 60 recovered from the 
incubation with C. elegans was esterified following the same procedure, and the 
characterisation matches the racemic data. 1H NMR (500 MHz, chloroform-d) δH  8.03 
(d, J = 8.4 Hz, 2H, H-Ar), 7.60 – 7.52 (m, 2H, H-Ar), 5.10 (dd, J = 51.6, 8.6 Hz, 1H, 
H-γ), 4.88 (dt, J = 47.7, 2.9 Hz, 1H, H-β), 4.74 – 4.54 (m, 1H, H-ζ), 3.92 (s, 3H, 
OCH3), 2.76 (t, J = 37.4 Hz, 1H, H-α), 2.51 – 2.29 (m, 2H, H-ε), 2.00 (dt, J = 13.2, 4.0 
Hz, 1H, H-δeq), 1.83 – 1.62 (m, 1H, H-δax) 19F{1H} NMR (470 MHz, CDCl3) δF          
-183.0,  -191.0, -209.5 (dd, J = 26.8, 13.2 Hz) 13C NMR (126 MHz, CDCl3) δC 166.9 
(CO), 142.4 (C-Ar), 129.6 (d, J = 70.0 Hz, C-ζ), 92.4 – 86.9 (m, C-Ar), 52.2, 48.4 (d, J 
= 5.4 Hz, C-α), 29.7 (OCH3), 28.5 (dd, J = 22.5, 12.1 Hz, C-ε), 20.4 (dd, J = 20.4, 3.6 
Hz, C-δ) HMRS (ESI+) m/z calc. for C14H16O2F3 [M+H]+ 273.1099, found 273.1098. 
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5.2.4 (E)-((1,2-dichlorovinyl)oxy)benzene (108) 
 
A solution of phenol 107 (5.20 g, 53 mmol) and ground sodium hydroxide (2.13 g, 
53.0 mmol) in DMSO (50 mL) was stirred at room temperature for 2 h. 1,1,2-
Trichloroethylene (4.80 mL, 53.0 mmol) is added, and the reaction mixture is stirred at 
r.t. for 18 h. The reaction mixture was quenched with addition of water (200 mL) and 
the aqueous phase was extracted thrice with CH2Cl2 (3 x 150 mL). The combined 
organic phases were washed with brine, dried over MgSO4, filtered and evaporated 
under reduced pressure. Flash column chromatography in petroleum ether of the crude 
yields to the formation the title compound 108 (4.17 g, 22 mmol, 41% yield) as a 
colourless oil. 1H NMR (500 MHz, chloroform-d): δH 7.45 – 7.33 (m, 2H, H-Ar), 7.22 
– 7.15 (m, 1H, H-Ar), 7.8 (dt, J = 7.8, 1.1 Hz, 2H, H-Ar), 5.97 (s, 1H, CClH).  The 
data were in good agreement with the literature values.5 
 
 
 
 
 
 
 
 
 
 
108
O
Cl
Cl
 205 
5.2.5 (Ethynyloxy)benzene (109) 
 
A solution of (E)-1-(1,2-dichlorovinyl)oxybenzene 108 (2.17 g, 11.5 mmol) in Et2O 
(120 mL) was cooled to -78 °C and stirred for 30 min. nBuLi (18 mL, 46.00 mmol, 2.5 
M) was added dropwise and stirred at -78 °C for 1 h. The mixture is left to reach – 40 
°C over the course of 1 h, and stirred at -40 °C for 2 h. The reaction mixture was 
quenched by addition of water (100 mL) at cold temperature. The organic phase was 
separated, and the aqueous phase extracted thrice with Et2O (3 x 100 mL). The 
combined organic phases were washed successively with a saturated solution of 
ammonium chloride and brine, dried over MgSO4 and evaporated under reduced 
pressure. No further purification was required. Ethynyl(oxy)benzene 109 was obtained 
as a brown oil (1.17 g, 9.90 mmol, 86 % yield). 1H NMR (500 MHz, chloroform-d): 
δH 7.42 – 7.34 (m, 2H, H-Ar), 7.30 (dt, J = 7.9, 1.1 Hz, 2H, H-Ar), 7.22 – 7.12 (m, 1H, 
H-Ar), 2.09 (s, 1H, CCH). The data were in good agreement with the literature values.5 
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5.2.6 (1,1-Difluoroethoxy)benzene (101) 
 
Ethynyl(oxy)benzene 109 (1 g, 8.47 mmol) was added into a 50 mL Teflon round-
bottom flask and dissolved into CH2Cl2 (5 mL). The solution was cooled to -78 °C and 
stirred for 15 min. HF·py (6 mL, 67.8 mmol) was added to the flask and the reaction 
mixture was stirred for 18 h and left to reach room temperature. The reaction was 
quenched by slow addition of the solution into a saturated solution of NaHCO3 (150 
mL). The resulting mixture was extracted thrice with CH2Cl2 (3 x 200 mL). The 
combined organic layers were washed with brine, dried over MgSO4 and evaporated 
under reduced pressure. The residue was further purified by washing with CuSO4 (7%, 
25 mL) and extracting with Et2O (3 x 25 mL), which afforded the pure product 101 as 
a colourless oil with a 75% conversion. 1H NMR (500 MHz, chloroform-d): δH 7.36 – 
7.30 (m, 2H, H-Ar), 7.22 – 7.15 (m, 3H, H-Ar), 1.92 (t, J = 13.3 Hz, 3H, CF2CH3) 19F 
NMR (471 MHz, chloroform-d): δF -64.4 (q, J = 13.2 Hz, 2F) 13C NMR (126 MHz, 
chloroform-d): δC 129.3 (C-Ar), 125.4 (C-Ar), 124.0 (t, J = 261.5 Hz, CF2CH3), 121.8 
(C-Ar), 22.8 (t, J = 32.0 Hz, CF2CH3) HMRS (CI) C8H9OF2 [M+H]+ calculated for 
159.0621, found 159.0626. 
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5.2.7 1-((1,1-Difluoroethyl)sulfonyl)-4-methoxybenzene (115) 
 
(1,1-Difluoroethyl)(4-methoxyphenyl)sulfane 104 (5 mg, 0.025 mmol) was added to a 
round bottom flask containing a stirring bar, and dissolved in CH2Cl2 (1.5 mL). 
mCPBA was added to the solution (21 mg, 0.122 mmol), and the mixture was stirred at 
r.t. overnight. The reaction was quenched by addition of a saturated solution of 
NaHCO3. The aqueous phase was extracted with CH2Cl2 (3 x 3 mL). The combined 
organic phases were combined, dried over Na2SO4, filtered and concentrated under 
reduced pressure, yielding to 115 with 100% conversion. Further purification was 
carried out by column chromatography, starting with 100% petroleum ether, followed 
by 15% EtOAc in petroleum ether, affording 115 in quantitative yield. 1H NMR (500 
MHz, chloroform-d): δH 7.84 (d, J = 8.6 Hz, 2H, H-Ar), 7.02 (d, J = 8.6 Hz, 2H, H-Ar), 
3.91 (s, 3H, OCH3), 2.02 (t, J = 18.3 Hz, 3H, CF2CH3) 19F NMR (471 MHz, 
chloroform-d): δF -97.3 (s) 13C NMR (126 MHz, chloroform-d): δC 165.2, 133.1, 
122.9, 114.7, 55.8 (OCH3), 16.6 (t, J = 22.2 Hz, CF2CH3) HMRS (ESI) C9H11F2O3S 
[M+H]+ calculated for 236.0310, found 236.0390; [M+Na]+ calculated for 259.0211, 
found 259.0216. 
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5.2.8 Racemic 1-((1,1-difluoroethyl)sulfinyl)-4-methoxybenzene (112) 
 
(1,1-Difluoroethyl)(4-methoxyphenyl)sulfane 104 (5 mg, 0.025 mmol) was added to a 
round bottom flask with a stirring bar and dissolved in a mixture of DCM (3 mL) and 
methanol (0.3 mL). The solution was stirred at room temperature until homogenisation 
(5 min). AlCl3 (1.8 mg, 0.012 mmol) was added, and the solution stirred for 5 min, 
prior to the addition of BAIB (7.3 mg, 0.025 mmol). The reaction was left to stir 
overnight. After 16 h, the solvents were evaporated under reduced pressure. The 
remaining mixture showed the formation of 112 with 66% conversion from the starting 
material 104. Further purification was achieved by reverse-phase HPLC in a 
Phenomenex Luna SP column, with 60:40 AcCN:water (supplemented with 0.05% 
TFA) at a flow rate of 1 mL/min. The product 112 was isolated at tret = 24 min, which 
was consistent with the metabolic experiment’s data. 1H NMR (500 MHz, chloroform-
d): δH 7.65 (d, J = 8.9 Hz, 2H, H-Ar), 7.08 (d, J = 8.9 Hz, 2H, H-Ar), 3.89 (s, 1H, 
OCH3), 1.81 (t, J = 18.4 Hz, 1H, CF2CH3) 19F NMR (471 MHz, chloroform-d): δF       
-93.4 (d, J = 225.1 Hz), -97.1 (d, J = 225.1 Hz). Data is consistent with the full 
characterisation carried out for 112 from the metabolic assays (Section 5.3.3.1). 
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5.2.9 Racemic 2-((1,1-difluoroethyl)sulfinyl)naphthalene (116) 
 
(1,1-Difluoroethyl)(naphthalene-2-yl) sulfane 105 (5 mg, 0.022 mmol) was added to a 
round bottom flask with a stirring bar and dissolved in a mixture of DCM (3 mL) and 
methanol (0.3 mL). The solution was stirred at room temperature until homogenisation 
(5 min). AlCl3 (1.5 mg, 0.011 mmol) was added, and the solution stirred for 5 min, 
prior to the addition of BAIB (11.1 mg, 0.022 mmol). The reaction was left to stir 
overnight. After 16 h, the solvents were evaporated under reduced pressure. Further 
purification was achieved by reverse-phase HPLC in a Phenomenex Luna SP column, 
with 60:40 AcCN:water (supplemented with 0.05% TFA) at a flow rate of 1 mL/min, 
which afforded 116 in 30% yield. The product 116 was isolated at tret = 37 min, which 
was consistent with the metabolic experiments’ data. 1H NMR (500 MHz, chloroform-
d): δH 8.28 (s, 1H, H-Ar), 8.01 (d, J = 8.7 Hz, 1H, H-Ar), 7.99 – 7.92 (m, 2H, H-Ar), 
7.69 (ddt, J = 8.7, 2.6, 1.3 Hz, 1H, H-Ar), 7.67 – 7.60 (m, 2H, H-Ar), 1.77 (t, J = 18.5 
Hz, 3H, CF2CH3) 19F NMR (471 MHz, chloroform-d): δF -92.9 (d, J = 227.0 Hz),        
-96.0 (d, J = 227.0 Hz); 13C NMR (126 MHz, chloroform-d) δC 145.9 (C-Ar, visible in 
HMBC), 135.1 (s, C-Ar), 133.6 (t, J = 218.8 Hz, CF2), 129.3 (s, C-Ar), 128.8 (s, C-
Ar), 128.5 (s, C-Ar), 128.1 (s, C-Ar), 127.5 (s, C-Ar), 126.8 (s, C-Ar), 121.0 (s, C-Ar), 
111.7 (C-Ar, visible in HMBC), 16.5 (t, J = 22.1 Hz, CF2CH3); HRMS (ESI+) m/z 
calc. for C12H11OF2S [M+H]+ 241.0420, found 241.0491. 
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5.2.10 2,2-Difluoro-1-(4-methoxyphenyl)cyclopropan-1-ol (152) 
 
1-Methoxy-4-(1,2,2-trifluorocyclopropyl)benzene (126, 10 mg, 0.050 mmol) was 
added into a round bottom flask containing a stirring bar, and put under vacuum for 15 
min. to ensure dryness. 126 was dissolved in DCM (2 mL), and the solution was 
cooled to 0 ºC by placement in an iced water bath. BBr3 was added (50 µL, 0.500 
mmol), and the reaction was stirred until completion (2 h., 90% conversion). The 
reaction was quenched by addition of water (2 mL), and the pH adjusted to 7 by 
dropwise addition of a saturated NaHCO3 solution. The aqueous phase was extracted 
with DCM (3 x 5 mL); and the combined organic phases were dried over anhydrous 
Na2SO4, filtered and concentrated under reduced pressure. Further purification of the 
reaction was carried out by column chromatography, using the following conditions: 
1.) 100% petroleum ether. 2.) 15% EtOAc in petroleum ether. 3.) 30% EtOAc in 
petroleum ether. 4.) 50 % EtOAc in petroleum ether. Column chromatography 
afforded 152 as an oil. 1H NMR (500 MHz, chloroform-d) δH 7.40 (2H, d, J = 8.3 Hz, 
H-Ar), 6.89 (2H, d, J = 8.3 Hz, H-Ar), 3.82 (3H, s, OCH3), 2.20 (1H, ddd, J = 13.4, 
9.6, 4.5 Hz, CF2CH2), 2.06 (1H, td, J = 9.6, 4.5 Hz, CF2CH2); 19F NMR (471 MHz, 
CDCl3): δF -127.0 (d, J = 147.0Hz), -132.3 (d, J = 147.0 Hz); 13C NMR (126 MHz, 
chloroform,-d) δC 160.1 (s, C-4), 130.7 (s, C-3), 128.3 (s, C-1), 114.3 (s, C-2), 109.2 (t, 
J = 293.6 Hz, CF2), 55.4 (s, OCH3), 27.3 (t, J = 10.6 Hz, CH2); HRMS (ESI-) m/z calc. 
for C10H9O2F2 [M-H]- 199.0576, found 199.0574. 
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5.2.11 2’,3’-O-Isopropylideneadenosine (155) 
 
2,2-Dimethoxypropane (23 mL, 187 mmol, 10 eq.) and HClO4 (2 mL, 1.5 eq., 70% 
aqueous) were added dropwise to a suspension of adenosine 154 (5 g, 18.7 mmol, 1 
eq.) in acetone (160 mL) at 0 °C. The mixture was stirred at 0 °C for 6 h and left to 
warm to room temperature for 18 h. The reaction was quenched by addition of aqueous 
saturated NaHCO3 solution (12 mL). The solvent was removed under reduced 
pressure, and the crude mixture was adsorbed onto silica gel. Purification of the 
residue over silica gel, eluting with petroleum ether and acetone (20:80), afforded 155 
(3.6 g, 63%) as a white solid: mp 208-210 °C (MeOH); [α]D= -102.0 (c = 0.05 in 
MeOH); 1H NMR (500 MHz, methanol-d4) δH 8.35 (1H, s, H-2), 8.22 (1H, s, H-8), 
6.18 (1H, d, J = 3.5 Hz, H-1’), 5.30 (1H, dd, J = 6.1 Hz, 3.5 Hz, H-2’), 5.07 (1H, dd, J 
= 6.1 Hz, 2.3 Hz, H-3’), 4.40 (1H, ddd, J = 3.7 Hz, 3.7 Hz, 2.3 Hz, H-4’), 3.81 (1H, 
dd, J = 12.1 Hz, 3.7 Hz, H-5’), 3.74 (1H, dd, J = 12.1 Hz, 3.7 Hz, H-5’), 1.64 (3H, s, 
C(CH3)2), 1.40 (s, 3H, C(CH3)2); 13C NMR (126 MHz, methanol-d4) δC 156.0 (C-5), 
152.4 (C-2), 148.5 (C-4), 140.4 (C-8), 119.2 (C-6), 114.2 (C(CH3)2), 91.4 (C-1’), 86.5 
(C-4’), 83.8 (C-2’), 81.5 (C-3’), 62.1 (C-5’), 26.2 (C(CH3)2), 24.2 (C(CH3)2); HRMS 
(ESI+) m/z calc. for C13H17N5O4H+ [M+H]+ 308.1353, found 308.1344. 
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5.2.12 2’,3’-O-Isopropylidene-5’-fluoro-5’-deoxyadenosine (156) 
 
Tosyl fluoride (490 mg, 2.69 mmol) was set to dry under vacuo for 2h, prior to the 
addition of 2’,3’-O-Isopropylideneadenosine (155) and a stirrer bar. The solid mixture 
was set to dry for further 30 min, before solution into THF (50 mL). TBAF (5.4 mL, 
5.37 mmol) was added dropwise, and the mixture was set to reflux overnight at 60 ºC. 
The solution was then allowed to cool to r.t., and was concentrated with silica gel 
under reduced pressure. Purification of 156 was carried out by dry-loading the 
resulting mixture into a chromatographic column, and eluting with 1:1 petroleum 
ether:acetone. 156 was recovered as a white solid in 75% yield. 1H NMR (500 MHz, 
methanol-d4) δH 8.25 (1H, s, H-2), 8.24 (1H, s, H-8), 6.27 (1H, d, J = 2.5 Hz, H-1’), 
5.51-5.38 (1H, m, H-2’), 5.14 (1H, dd, J = 6.2 Hz, 3.1 Hz, H-3’), 4.73-4.55 (2H, m, H-
5’), 4.54-4.45 (1H, m, H-4’), 1.63 (3H, s, C(CH3)2), 1.41 (s, 3H, C(CH3)2); 19F NMR 
(471 MHz, methanol-d4): δF – 230.4. Data matches literature reports.6 
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5.2.13 5’-Fluoro-5’-deoxyadenosine (5’-FDA, 17) 
 
2’,3’-O-Isopropylidene-5’-fluoro-5’-deoxyadenosine 156 (417 mg, 1.35 mmol) was 
added to a round bottom flask with a stirring bar, and dissolved in a mixture of THF (5 
mL) and water (5 mL). Hydrated p-toluenesulfonic acid (369 mg, 1.62 mmol) was 
added, and the mixture was set to reflux at 63 ºC. After 6 h, the reaction has gone to 
completion. THF was evaporated under reduced pressure, and saturated NaHCO3 (50 
mL) was added. The aqueous phase was extracted with EtOAc (3 x 100 mL), and the 
combined organic phases were dried over anhydrous Na2SO4, filtered and concentrated 
under vacuum. Further purification was carried out by dry-loading the resulting 
mixture into a chromatographic column, and eluting with 10% MeOH in DCM. 
Purification afforded 17 as a white solid in 39% yield. 1H NMR (500 MHz, methanol-
d4) δH 8.24 (1H, s, H-2), 8.23 (1H, s, H-8), 6.09 (1H, d, J = 4.4 Hz, H-1’), 4.81-4.72 
(1H, m, H-3’), 4.72 (2H, ddd, J = 47.0, 20.6, 3.1 Hz, H-5’), 4.64-4.59 (1H, m, H-4’), 
4.26 (1H, ddt, J = 28.1, 5.7, 3.1 Hz, H-2’); 19F NMR (471 MHz, deuterium oxide): δF  
-231.3. Data matches literature reports.6,7 
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5.2.14 2,3-O-Isopropylidene-1-methoxy ribose (159) 
 
Ribose (157, 2.5 g, 16.6 mmol) was added into a round bottom flask containing a 
stirring bar and dissolved in acetone (200 mL). The suspension was cooled to 0 ºC in 
an iced water bath. 2,2-Dimethoxypropane (5.1 mL, 41.5 mmol) was added, followed 
by dropwise addition of H2SO4 (70%, 1.6 mL, 25 mmol). The reaction was stirred and 
warmed to r.t. overnight. The mixture is bright orange. Without quenching, MeOH (3.5 
mL) was added. The reaction was stirred at r.t. for further 3 h. Then, the reaction was 
quenched at 0 ºC by addition of a saturated solution of NaHCO3 (10 mL), producing a 
suspension. The solid was filtered off, and the solution concentrated under reduced 
pressure. The residue was dissolved in Et2O (100 mL) and water (100 mL). The 
aqueous phase was extracted with Et2O (3 x 100 mL), and the combined organic 
phases were dried over anhydrous Na2SO4, filtered and concentrated under reduced 
pressure, giving 159 in 83% yield and a white powder. Further purification was not 
required. 1H NMR (500 MHz, methanol-d4) δH 4.92 (1H, s, H-1), 4.72 (1H, d, J = 6.0 
Hz, H-2), 4.59 (1H, d, J = 6.0 Hz, H-3), 4.19 – 4.14 (1H, m, H-4), 3.60 – 3.50 (2H, m, 
H-5), 3.34 (3H, s, OCH3), 1.45 (3H, s, C(CH3)2), 1.33 (3H, s, C(CH3)2); 13C NMR 
(126 MHz, methanol-d4) δC 111.93 (C(CH3)2), 109.3 (C-1), 87.3 (C-4), 85.1 (C-3), 
81.7 (C-2), 62.8 (C-5), 53.8 (OCH3), 25.3 (C(CH3)2), 23.6 (C(CH3)2). Experimental 
data matched previous literature data.8 
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5.2.15 2,3-O-Isopropylidene-1-methoxy-5-tosyl ribose (160) 
 
2,3-O-Isopropylidene-1-methoxy ribose (159, 2.4 g, 11.8 mmol) was added into a 
round bottom flask and dissolved in THF (200 mL). Tosyl fluoride (3 g, 17.6 mmol) 
was added to the solution, followed by dropwise addition of TBAF (35 mL, 35.2 
mmol). The mixture was stirred under reflux (60 ºC) overnight. Purification was 
carried out by dryloading the reaction’s residue into a chromatographic column, and 
eluting with 10% EtOAc in petroleum ether, which afforded a crystalline white solid 
(160) in 63% yield. 1H NMR (500 MHz, chloroform-d) ∂H 7.80 (2H, d, J = 8.3 Hz,   
H-Ar), 7.37 (2H, d, J = 8.3 Hz, H-Ar), 4.92 (1H, s, H-1), 4.59 (1H, dd, J = 6.0, 1.2 Hz, 
H-2), 4.53 (1H, d, J = 6.0 Hz, H-3), 4.31 (1H, td, J = 7.2, 1.1 Hz, H-4), 4.01 (2H, dd,   
J = 7.2, 1.9 Hz, H-5), 3.22 (3H, s, OCH3), 2.45 (3H, s, Ts-CH3), 1.44 (3H, s, C(CH3)2), 
1.28 (3H, s, C(CH3)2). Experimental data matches previous literature data.8 
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5.2.16 5-Fluoro-5-deoxy-2,3-O-isopropylidene-1-methoxy ribose (161) 
 
2,3-O-Isopropylidene-1-methoxy-5-tosyl ribose (160, 1.5 g, 4.2 mmol) was added to a 
round bottom flask containing a stirring bar and dissolved in AcCN (18 mL). TBAF (5 
mL, 5 mmol) was added dropwise. The solution was stirred under reflux (80 ºC) for 4 
h. The solution was evaporated with silica gel under reduced pressure and dryloaded 
into a chromatographic column (eluted with 30:1 Petroleum ether:EtOAc), which gave 
161 as a white solid in 80% yield. 1H NMR (500 MHz, chloroform-d) δH 4.99 (1H, d, 
J = 2.4 Hz, H-1), 4.71 – 4.68 (1H, m, H-2), 4.59 (1H, d, J = 6.0 Hz, H-3), 4.46 – 4.30 
(3H, m, H-4, H-5), 3.33 (3H, s, OCH3), 1.49 (3H, s, C(CH3)2), 1.32 (3H, s, C(CH3)2). 
19F NMR (471 MHz, CDCl3) δF -225.0 (s). Experimental data matches previous 
literature data.8 
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5.2.17 5-Fluoro-5-deoxoribose (5-FDR, 26) 
 
5-Fluoro-5-deoxy-2,3-O-isopropylidene-1-methoxy ribose (161, 90 mg, 0.44 mmol) 
was dissolved in H2SO4 (0.02 M,  1 mL, 0.02 mmol), and set under reflux (98 ºC) for 
1.5 h. The cooled solution was neutralised to pH = 7 by dropwise addition of a 
saturated solution of BaCO3. The suspension was filtered through a pad of celite and 
cotton, and the solution was freeze-dried over night. This afforded 26 as a colourless 
oil in 30% yield. 1H NMR (500 MHz, deuterium oxide) δH 5.32 (1H, d, J = 4.0 Hz, H-
α anomer), 5.18 (1H, d, J = 1.7 Hz, H-β anomer), other signals could not be interpreted 
due to overlap. 19F NMR (471 MHz, deuterium oxide) δF -228.7 (s, β anomer), -231.0 
(s, α anomer); 13C NMR (126 MHz, methanol-d4) δC 101.1 (C-1, β anomer), 96.5 (C-1, 
α anomer), 83.3 (d, J = 168.8 Hz, C-5, β anomer), 82.9 (d, J = 168.8 Hz, C-5, α 
anomer), 81.0 (d, J = 19.6 Hz, C-4, α anomer) 80.5 (d, J = 19.6 Hz, C-4, β anomer), 
75.0 (C-2, β anomer), 70.6 (C-2, α anomer), 69.4 (d, J = 6.5 Hz, C-3, β anomer), 69.2 
(d, J = 6.5 Hz, C-3, α anomer). Experimental data matches previous literature data.8 
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5.2.18 2’,3’-O-Isopropylidene adenosine-5’-carboxylic acid (167) 
 
BAIB (11.2 g, 34.2 mmol, 2.2 eq.) and TEMPO (0.5 g, 3.3 mmol, 0.2 eq.) were added 
to a solution of 155 (4.8 g, 15.6 mmol, 1 eq.) in a mixture of H2O:CH3CN (1:1, 40 
mL). The mixture was stirred at room temperature for 18 h. The suspension was 
filtered, and the residue was washed with water (20 mL), acetone (20 mL) and ether 
(20 mL) successively. The residue was dried under vaccum, furnishing 167 (4.3 g, 
85%) as a white solid: mp 260–265 °C (dec.); 1H NMR (500 MHz, DMSO-d6) δH 8.26 
(1H, s, H-8), 8.09 (1H, s, H-2), 7.29 (2H, s, NH2), 6.33 (1H, s, H-1’), 5.54 (1H, dd,      
J = 6.0, 1.9 Hz, H-3’), 5.47 (1H, d, J = 6.0 Hz, H’-2), 4.69 (1H, d, J = 1.9 Hz, H-4’), 
1.53 (3H, s, C(CH3)2), 1.36 (3H, s, C(CH3)2); 13C NMR (126 MHz, DMSO-d6) δC 
171.2 (C-5’), 156.5 (C-2), 152.8 (C-5), 149.6 (C-4), 140.8 (C-8), 119.2 (C-6), 113.1 
(C(CH3)2), 89.9 (C-1’), 85.9 (C-4’), 84.3 (C-3’), 83.9 (C-2’), 27.0 (C(CH3)2), 25.4 
(C(CH3)2); m/z (ESI+) 322 ([M+H]+, 100%); HRMS (ESI+) m/z calc. for 
C13H15N5O4H+ [M+H]+ 322.1151, found 322.1136. 
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5.2.19 Adenosine-5’-carboxylic acid methyl ester (169) 
 
Thionyl chloride (0.6 mL, 17.1 mmol, 5 eq.) was added dropwise to a suspension of 
167 (1.1 g, 3.4 mmol, 1 eq.) in methanol (30 mL) that was stirred at 0°C for 30 min. 
The mixture stirred for 18 h, gradually warming to room temperature. The white 
suspension was concentrated and the residue was purified over silica gel, eluting with 
methanol and DCM (10:90), to afford 169 (0.9 g, 94%) as a white solid: mp 110-115 
°C; [α]D= -110.0 (c = 0.07 in MeOH); 1H NMR (500 MHz, methanol-d4) δH 8.86 (1H, 
s, H-8), 8.43 (1H, s, H-2), 6.30 (1H, d, J = 6.1 Hz, H-1’), 4.68 (1H, d, J =  2.7 Hz,     
H-4’), 4.64 (1H, dd, J = 6.1, 4.5 Hz, H-2’), 4.47 (1H, dd, J = 4.5, 2.7 Hz, H-3’), 3.37 
(3H, s, OCH3); 13C NMR (126 MHz, methanol-d4) δC 171.4 (C-5’), 150.6 (C-5), 149.0 
(C-4), 144.3 (C-2), 142.4 (C-8), 118.8 (C-6), 88.5 (C-1’), 83.2 (C-4’), 75.3 (C-2’), 73.6 
(C-3’), 51.8 (-OCH3); m/z (ESI+) 296 ([M+H]+, 100%); HRMS m/z (ESI+) calc. for 
C11H13N5O5H+ [M+H]+ 296.0989, found 296.0981. 
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5.2.20 5’,5’-2H2-Adenosine (154a) 
 
NaBD4 (160 mg, 4.1 mmol, 5 eq.) was added in small portions to a solution of 169 
(240 mg, 0.8 mmol, 1 eq.) in ethanol (25 mL) at 0 °C. The mixture was stirred at 0 °C 
for 5 min and heated under reflux for 48 h. The mixture was concentrated to a powder, 
the residue was dissolved in water and the pH was adjusted to 6.5 by dropwise 
addition of HCl (1M). Concentration of the mixture afforded 154a (152 mg, 69%) as a 
white powder: mp 170-175 °C (MeOH); 1H NMR (500 MHz, methanol-d4) δH 8.33 
(1H, s, H-8), 8.20 (1H, s, H-2), 5.98 (1H, d, J = 6.4 Hz, H-1’), 4.76 (1H, dd, J = 6.4, 
5.1 Hz, H-2’), 4.34 (1H, dd, J = 5.1, 2.6 Hz, H-3’), 4.18 (1H, d, J = 2.6 Hz, H-4’); 13C 
NMR (126 MHz, methanol-d4) δC 156.2 (C-5), 152.1 (C-2), 148.6 (C-4), 140.6 (C-8), 
119.6 (C-6), 89.9 (C-1’), 86.7 (C-4’), 74.0 (C-2’), 71.3 (C-3’), 61.7 (C-5’); m/z (ESI+) 
292 ([M+Na]+, 100%); HRMS (ESI+) m/z calc. for C10H11D2N5O4H+ [M+H]+ 
270.1166, found 270.1164. 					
N
NN
N
NH2
O
OHOH
HO
154a
DD
 221 
5.2.21 [5’,5’-2H2]-2’,3’-O-Isopropylideneadenosine (155a) 
 
2,2-dimethoxypropane (3.3 mL, 27.4 mmol, 10 eq.) and HClO4 (330 µL, 1 mmol, 1.5 
eq.) were added successively to a solution of 154a (740 mg, 2.7 mmol, 1 eq.) in 
acetone (22.4 mL) at 0 °C. The mixture was stirred at 0 °C for 6 h, and stirred for 18 h, 
gradually warming to room temperature. The reaction was quenched with aqueous 
saturated NaHCO3 solution (1.5 mL) and concentrated. The resultant white solid was 
purified over silica gel, eluting with petroleum ether and acetone (20:80), to yield 155a 
(400 mg, 48% yield) as a white powder: mp 208-210 °C (MeOH); [α]D -96.4 (c = 0.06 
in MeOH); 1H NMR (500 MHz, methanol-d4) δH  8.35 (1H, s, H-8), 8.22 (1H, s, H-2), 
6.18 (1H, d, J = 3.5 Hz, H-1’), 5.30 (1H, dd, J = 6.1, 3.5 Hz, H-2’), 5.06 (1H, dd,         
J = 6.1, 2.3 Hz, H-3’), 4.39 (1H, d, J = 2.3 Hz, H-4’), 1.64 (3H, s, C(CH3)2), 1.40 (3H, 
s, C(CH3)2); 13C NMR (126 MHz, methanol-d4) δC 156.1 (C-5), 152.4 (C-2), 148.6 (C-
4), 140.4 (C-8), 119.3 (C-6), 113.9 (C(CH3)2), 91.5 (C-1’), 86.6 (C-4’), 83.9 (C-2’), 
81.6 (C-3’), 61.3 (C-5’)26.2 (C(CH3)2), 24.1 (C(CH3)2); m/z (ESI+) 332 ([M+Na]+, 
100%); HRMS (ESI+) m/z calc. for C13H15D2N5O4H+ [M+H]+ 310.1479, found 
310.1466. 
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5.2.22 5’-Deoxy-5’-fluoro-5’,5’-2H2-2’,3’-O-isopropylideneadenosine	(156a)	
 
TsF (337 mg, 1.9 mmol, 1.5 eq.) and TBAF (4 mL, 3.9 mmol, 3 eq., 1.0 M solution in 
THF) were added to a solution of 155a (400 mg, 1.3 mmol, 1 eq.) in THF (40 mL). 
The mixture was heated under reflux for 18 h. The solution was cooled, and 
concentrated and purified over silica gel, eluting with petroleum ether and acetone 
(50:50), to afford 156a, 156b and 156 (250 mg, 63%) as a colourless solid: mp 130-
135 °C (MeOH); [α]D= -58.0 (c = 0.05 in MeOH); 1H NMR (500 MHz, methanol-d4) 
δH 8.24 (1H, s, H-8), 8.23 (1H, s, H-2), 6.26 (1H, d, J = 2.5 Hz, H-1’), 5.42 (1H, dd,    
J = 6.3 Hz, 2.5 Hz, H-2’), 5.13 (1H, dd, J 6.3 Hz, 3.1 Hz, H-3’), 4.48 (1H, dd, J = 24.5, 
3.1 Hz, H-4’), 1.65 (3H, s, C(CH3)2), 1.47 (3H, s, C(CH3)2); 19F{1H} NMR (470 MHz, 
methanol-d4) δF -230.4 (156), -231.1 (156b), -231.7 (156a); 13C NMR (126 MHz, 
methanol-d4) δC 156.0 (C-5), 152.6 (C-2), 148.9 (C-4), 139.8 (C-8), 119.0 (C-6), 114.1 
(C(CH3)2), 90.4 (C-1’), 85.4 (C-2’), 84.2 (C-4’), 83.0 (m, C-5’), 80.7 (C-3’), 26.0 
(C(CH3)2), 24.1 (C(CH3)2); m/z (ESI+) 312 ([M+H]+, 100%); HRMS (ESI+) m/z calc. 
for C13H14D2FN5O3H+ [M+H]+ 311.1444, found 311.1422. 
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5.2.23 5’-Deoxy-5’-fluoro-5’,5’-2H2-adenosine (17a) 
 
p-TsOH·H2O (44 mg, 0.3 mmol, 1.2 eq.) was added to a solution of 5’,5’-2H2-5’-
deoxy-5’-fluoro-adenosine 156a (80 mg, 0.3 mmol, 1 eq.) in a mixture of MeOH:H2O 
(1:1, 3 mL). The mixture was heated to 60 °C for 2 h and was cooled and concentrated. 
The residue was purified over silica gel, eluting with MeOH and DCM (10:90), to give 
17a (29 mg, 35%) as a white solid: mp 130-135 °C (H2O); [α]D= -25.1 (c = 0.18 in 
MeOH); 1H NMR (500 MHz, methanol-d4) δH 8.38 (1H, s, H-8), 8.35 (1H, s, H-2), 
6.13 (1H, d, J = 4.7 Hz, H-1’), 4.61 (1H, dd, J = 4.7, 1.2 Hz, H-2’), 4.42 (1H, dd,         
J = 5.1, 1.2 Hz, H-3’), 4.27 (1H, dd, J = 28.7, 5.1 Hz, H-4’); 19F{1H} NMR (470 MHz, 
methanol-d4) δF -232.5 (17), -233.1 (17b), -233.7 (17a); 13C NMR (126 MHz, 
methanol-d4) δC 155.9 (C-5), 152.7 (C-2), 149.1 (C-4), 139.3 (C-8), 119.0 (C-6), 88.5 
(C-1’), 83.1 (C-4’), 81.1 (m, C-5’), 74.3 (C-2’), 69.5 (C-3’); m/z (ESI+) 272 ([M+H]+, 
100%); HRMS (ESI+) m/z calc. for C10H10D2FN5O3H+ [M+H]+ 272.1123, found 
272.1116. 
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5.3 Fluorometabolite production in Cunninghamella elegans 
5.3.1 General procedures for the works with C. elegans 
5.3.1.1 Preparation of liquid cultures of C. elegans and inoculation of the 
corresponding xenobiotics 
Sterile Saboraud Dextrose (Sigma Aldrich) medium (45 mL) was inoculated with 
fungal homogenate (5 mL) at room temperature. Alternatively, inoculation was carried 
out directly from fungal gel plates into the SD liquid medium (50 mL). The cultures 
were left to grow for 72 h, at 28 °C with rotary agitation (150 rpm). 
All xenobiotics were added dissolved in DMF (50 µL) to grown cultures (50 mL, 72 h 
or prior incubation), and left to incubate for extra 72 h at 28 °C and 150 rpm.  
5.3.1.2 Extraction and purification of the metabolites 
After the incubation period, the xenobiotic-supplemented liquid cultures were 
centrifuged using a Sorvall apparatus at 4 °C. The supernatant was separated from the 
fungal debris and extracted with organic solvents; usually EtOAc (3×50 mL), unless 
otherwise stated. The organic phase was concentrated under reduced pressure, and the 
solid residues redissolved in EtOAc (1mL). The fungal cells were stored at −20 °C. 
For the fluorocyclohexyl derivatives, an aliquot of the concentrate (100 µL) was added 
to MSTFA (50 µL) for TMS derivatisation of the hydroxyl groups (1 h, 100 ºC) prior 
to analysis by GCMS. Further analysis of the extracts was done by 1H and 19F NMR.  
Purification of the samples was mainly performed by reverse phase HPLC, using either 
a semi-preparative Kingsorb Phenomenex or a semi-preparative Luna Phenomenex. 
Usual conditions included 70:30 of AcCN:water,  60:40 AcCN:water, or 50:50 
AcCN:water, as indicated for each compound. Both water and acetonitrile were 
supplemented with 0.05% TFA, unless otherwise expressed. Some of the metabolites 
required the use of column chromatography, as described in the corresponding 
experimental procedures. Analysis of the resulting metabolites and remaining starting 
materials was carried out by full NMR characterisation (1H, 19F, 13C, COSY, HSQC 
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and HMBC), and high-resolution accurate mass spectrometry. X-ray structures were 
obtained when possible. 
5.3.2 Fluorometabolite production in C. elegans in all-cis fluorocyclohexyl 
benzene derivatives 
5.3.2.1 All-cis (2,3,5,6-tetrafluorocyclohexyl)benzene (62) 
 
All-cis (2,3,5,6-tetrafluorocyclohexyl)benzene (62) was dissolved in DMF (50 µL) and 
added to a mature culture of C. elegans. The compound was left to incubate with the 
fungus for 72 h. at 28 ºC and 180 rpm. After 72 h, the fungus was centrifuged down, 
and the supernatant was extracted with EtOAc (3 x 50 mL). The combined organic 
phases were dried over Na2SO4, filtered and evaporated under reduced pressure. 
Purification of the metabolite and residual starting material was achieved by reverse-
phase HPLC, in a semi-preparative Kingsorb, and eluting with a mixture of 70:30 
AcCN:water, both supplemented with 0.05% of TFA, at a flow rate of 1 mL/min. This 
afforded 78 at a tret = 18 min, and residual starting material 62 at tret = 23 min. 
(1s, 2R, 3S, 5R, 6S)-2,3,5,6-tetrafluoro-1-phenylcyclohexan-1-ol (78) 
1H NMR (500 MHz, chloroform-d) δH 7.71 (2H, dd, J = 7.5, 1.8 Hz,   
H-Ar), 7.47 (3H, m, H-Ar), 5.10 (4H, m, H-β, H-γ, H-ε, H-ζ), 2.87 (1H, 
m, H-δeq), 2.49 (1H, m, H-δax), 2.01 (1H, s, -OH) 19F{1H} NMR (470 
MHz, chloroform-d) δF -207.7 (2F, dd, J = 7.6, 5.1 Hz), -198.8 (2F, dd, 
J = 7.6, 5.0 Hz) 13C NMR (126 MHz, chloroform-d) δC 138.7 (C-Ar, 
visible in HMBC), 129.7 (C-Ar), 129.3 (C-Ar), 126.1 (C-Ar), 90.5-85.2(C-β, C-γ, C-ε, 
C-ζ), 73.2 (C-α, visible in HMBC), 26.8 (C-δ) HRMS (ESI–) m/z calc. for C12H11OF4 
[M–H]– 247.0746, found 247.0750. 
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5.3.2.2 All-cis (2,3,6-trifluorocyclohexyl)benzene (59) 
 
All-cis (2,3,6-trifluorocyclohexyl)benzene (59) was dissolved in DMF (50 µL) and 
added to a mature culture of C. elegans. The compound was left to incubate with the 
fungus for 72 h. at 28 ºC and 180 rpm. After 72 h, the fungus was centrifuged down, 
and the supernatant was extracted with EtOAc (3 x 50 mL). The combined organic 
phases were dried over Na2SO4, filtered and evaporated under reduced pressure. 
Purification of the metabolite and residual starting material was achieved by reverse-
phase HPLC, in a semi-preparative Kingsorb, and eluting with a mixture of 70:30 
AcCN:water, both supplemented with 0.05% of TFA, at a flow rate of 1 mL/min. This 
afforded 79 at a tret = 19 min, and residual starting material 59 at tret = 24 min. 
(1R, 2S, 3R, 6S)-2,3,6-trifluoro-1-phenylcyclohexan-1-ol (79) 
1H NMR (500 MHz, chloroform-d) δH 7.72 (2H, dd, J = 7.8, 1.6 Hz,   
H-Ar), 7.44 (3H, m, H-Ar), 5.15 (2H, m, H-γ, H-ζ), 4.90 (1H, d,             
J = 45.6 Hz, H-β), 2.32 (1H, m, H-δax), 2.22 (1H, m, H-εax), 2.11 (1H, 
m, H-εeq), 1.96 (1H, m, H-δeq), 1.87 (1H, s, -OH) 19F{1H} NMR (470 
MHz, chloroform-d) δF -207.7 (F, dd, J = 24.3, 13.5 Hz), -191.6 (F, d, J = 13.5 Hz), -
189.1 (F, d, J = 24.3 Hz) 13C NMR (126 MHz, chloroform-d) δC 140.8(C-Ar), 129.1 
(C-Ar), 126.2 (C-Ar), 90.8 (C-ζ, dd, J = 200.7, 12.2 Hz), 90.5 (C-β, d, J= 183.3 Hz), 
88.6 (C-γ, dd, J = 200.7, 21.6 Hz), 73.8 (C-α, visible in HMBC), 24.7 (C-ε, dd, J = 
21.6, 12.2 Hz), 19.9 (C-δ, d, J = 20.5 Hz) HRMS (ESI+) m/z calc. for C12H13OF3Na+ 
[M+Na]+ 253.0816, found 253.0807. 
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5.3.2.3 All-cis (2,3-difluorocyclohexyl)benzene (58) 
 
All-cis (2,3-difluorocyclohexyl)benzene (58) was dissolved in DMF (50 µL) and 
added to a mature culture of C. elegans. The compound was left to incubate with the 
fungus for 72 h. at 28 ºC and 180 rpm. After 72 h, the fungus was centrifuged down, 
and the supernatant was extracted with EtOAc (3 x 50 mL). The combined organic 
phases were dried over Na2SO4, filtered and evaporated under reduced pressure. 
Purification of the metabolite and residual starting material was achieved by reverse-
phase HPLC, in a semi-preparative Kingsorb, and eluting with a mixture of 70:30 
AcCN:water, both supplemented with 0.05% of TFA, at a flow rate of 1 mL/min. This 
afforded 80 at a tret = 16 min, 81 at a tret = 16.5 min, 82 at a tret = 17.5 min, 83 at a tret = 
18 min and 84 at a tret = 22 min. 
(1S, 2S, 3)-2,3-difluoro-1-phenylcyclohexan-1-ol (84) 
 1H NMR (500 MHz, chloroform-d) δH 7.56 (2H, m, H-Ar), 7.41 (2H, m, 
H-Ar), 7.35 (1H, m, H-Ar), 5.05 (1H, m, H-γ) 4.78 (1H, dd, J = 50.7, 8.9 
Hz, H-β), 2.26 (1H, m, H-ζ), 2.03 (1H, m, H-δeq), 1.89 (1H, m, H-δax), 
1.82 (2H, m, H-ε), 1.75 (1H, d, J = 15.1 Hz, H-ζ) 19F{1H} NMR (470 
MHz, chloroform-d) δF -205.3 (F, d, J = 16.4 Hz), -189.8 (F, d, J = 16.3 
Hz) 13C NMR (126 MHz, chloroform-d) δC 144.2 (C-Ar, visible in HMBC), 129.0 
(C-Ar), 128.2 (C-Ar), 125.5 (C-Ar), 91.7 (C-β, dd, J = 198.4, 15.9 Hz), 89.7 (C-γ, dd, 
J = 196.2, 18.1 Hz), 74.7 (C-α, visible in HMBC), 31.2 (C-ζ), 25.1 (C-δ, dd, J = 21.9, 
3.1 Hz), 17.9 (C-ε, d, J = 11.9 Hz) HRMS (ESI+) m/z calc. for C12H18ONF2 
[M+NH4]+ 230.1351, found 230.1355. 
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(1S, 2R, 3S, 4R)-2,3-difluoro-4-phenylcyclohexan-1-ol (82) 
 1H NMR (500 MHz, chloroform-d) δH 7.35 (5H, m, H-Ar), 5.04 (1H, dd,  
J = 60.8, 9.1 Hz, H-β) 4.41 (1H, dddd, J = 47.7, 26.8, 9.3, 2.3 Hz, H-γ), 
4.25 (1H, m, H-δ), 2.77 (1H, ddd, J = 35.7, 13.2, 4.2 Hz, H-α), 2.22 (1H, 
m, H-εax), 2.10 (1H, m, H-ζax), 1.82 (1H, dddd, J = 14.0, 6.1, 3.0, 1.6 Hz, 
H-ζeq) 1.54 (1H, qd, J = 13.2, 4.2 Hz, H-εeq) 19F{1H} NMR (470 MHz, 
chloroform-d) δF -210.6 (F, d, J = 17.0 Hz), -195.36 (F, d, J = 17.4 Hz) 13C NMR (126 
MHz, chloroform-d) δC 140.2 (C-Ar, visible in HMBC), 128.6 (C-Ar), 127.7 (C-Ar), 
127.3 (C-Ar), 95.8 (C-γ, dd, J = 184.6, 18.2 Hz), 92.4 (C-β, dd, J = 181.8, 16.3 Hz), 
68.7 (C-δ, dd, J = 18.8, 3.0 Hz), 45.68 (C-α, dd, J = 19.2, 5.2 Hz), 30.45 (C-ε, d, J = 
7.7 Hz), 24.24 (C-ζ, d, J = 4.4 Hz) HRMS (ESI+) m/z calc. for C12H14OF2Na [M+Na]+ 
235.0910, found 235.0903. 
(1S, 3R, 4S, 5R)-3,4-difluoro-5-phenylcyclohexan-1-ol (83) 
1H NMR (500 MHz, chloroform-d) δH 7.32 (5H, m, H-Ar), 5.00 (2H, 
m, H-β, H-γ) 4.46 (1H, s, H-ε), 3.25 (1H, ddd, J = 36.2, 13.4, 4.2 Hz,  
H-α), 2.19 (3H, m, H-δ, H-ζax), 1.82 (1H, d, J = 14.2 Hz, H-ζeq) 19F{1H} 
NMR (470 MHz, chloroform-d) δF -217.5 (F, d, J = 16.0 Hz), -193.9 
(F, d, J = 16.0 Hz) 13C NMR (126 MHz, chloroform-d) δC 140.3 (C-Ar, 
visible in HMBC), 128.6 (C-Ar), 128.1 (C-Ar), 127.2 (C-Ar), 92.0 (C-β, dd, J = 199.6, 
17.1 Hz), 88.3 (C-γ, dd, J = 199.6, 19.4 Hz), 66.2 (C-ε, d, J = 15.3 Hz), 39.6 (C-α, dd, 
J = 24.7, 5.8 Hz), 32.6 (C-δ, C-ζ, m) HRMS (ESI+) m/z calc. for C12H18ONF2 
[M+NH4]+ 230.1351, found 230.1356. 
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(1R, 3R, 4S, 5R)-3,4-difluoro-5-phenylcyclohexan-1-ol (80) 
1H NMR (500 MHz, chloroform-d) δH 7.36 (2H, m, H-Ar), 7.30 (3H, 
m, H-Ar), 4.91 (1H, dd, J = 52.6, 8.4 Hz, H-β), 4.61 (1H, m,  H-γ), 
3.89 (1H, m, H-ε), 2.66 (1H, m, H-α), 2.40 (1H, dq, J = 10.1, 4.9 Hz, 
H-δeq), 2.04 (3H, m, H-δax, H-ζ) 19F{1H} NMR (470 MHz, 
chloroform-d) δF -213.6 (F, d, J = 16.1 Hz), -186.8 (F, d, J = 16.1 Hz) 
13C NMR (126 MHz, chloroform-d) δC 139.8 (C-Ar), 128.7 (C-Ar), 127.9 (C-Ar), 
127.3 (C-Ar), 90.6 (C-β, dd, J = 160.8, 16.8 Hz), 89.1 (C-γ, dd, J = 160.8, 19.2 Hz), 
67.1 (C-ε, d, J = 15.3 Hz), 41.7 (C-α, dd, J = 25.9, 6.8 Hz), 35.1 (C-δ, dd, J = 21.6, 2.9 
Hz), 34.5 (C-ζ, d, J = 3.5 Hz) HRMS (ESI+) m/z calc. for C12H18ONF2 [M+NH4]+ 
230.1351, found 230.1356. 
(1S, 3R, 4R)-4-fluoro-3-phenylcyclohexan-1-ol (81) 
1H NMR (500 MHz, chloroform-d) δH 7.33 (5H, m, H-Ar), 4.79 (1H, 
ddd, J = 49.0, 3.8, 1.9 Hz, H-β), 3.85 (1H, m, H-ε), 2.78 (1H, m, H-α), 
2.24 (1H, m, H-γax), 2.07 (2H, m, H-ζ), 1.94 (1H, m, H-δeq), 1.70 (2H, 
m, H-δax, H-γeq) 19F{1H} NMR (470 MHz, chloroform-d) δF -197.5 (F, 
s) 13C NMR (126 MHz, chloroform-d) δC 141.5 (C-Ar, visible in 
HMBC), 128.5 (C-Ar), 128.0 (C-Ar), 126.8 (C-Ar), 90.4 (C-β, d, J = 175.5 Hz), 70.1 
(C-ε, s), 45.9 (C-α, d, J = 19.9 Hz), 35.5 (C-ζ, d, J = 2.9 Hz), 29.7 (C-γ, d, J = 21.4 
Hz), 19.1 (C-δ, s) HRMS (ESI+) m/z calc. for C12H19ONF [M+NH4]+ 212.1445, found 
212.1445. 
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5.3.2.4 All-cis 4-(2,3,5,6-tetrafluorocyclohexyl)benzoic acid (63) 
 
All-cis 4-(2,3,5,6-tetrafluorocyclohexyl)benzoic acid (63) was dissolved in DMF (50 
µL) and added to a mature culture of C. elegans. The compound was left to incubate 
with the fungus for 72 h. at 28 ºC and 180 rpm. After 72 h, the fungus was centrifuged 
down, and the supernatant was extracted with EtOAc (3 x 50 mL). The combined 
organic phases were dried over Na2SO4, filtered and evaporated under reduced 
pressure. Purification of the metabolite and residual starting material was achieved by 
reverse-phase HPLC, in a semi-preparative Kingsorb, and eluting with a mixture of 
50:50 AcCN:water, both supplemented with 0.05% of TFA, at a flow rate of 1 
mL/min. This afforded 89 at a tret = 24 min, and starting material 63 at a tret = 28 min. 
4-((1s, 2R, 3S, 5R, 6S)-2,3,5,6-tetrafluoro-1-hydroxycyclohexyl)benzoic acid (89) 
19F NMR (470 MHz, methanol-d4) δF -210.0 (2F, m), -200.0 (2F, dd, J 
= 44.9 Hz) HRMS (ESI-) m/z calc. for C13H11O3F4 [M]-H 291.0644, 
found 291.0651. 
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5.3.2.5 All-cis 4-(2,3,6-trifluorocyclohexyl)benzoic acid (60) 
 
All-cis 4-(2,3,6-trifluorocyclohexyl)benzoic acid (60) was dissolved in DMF (50 µL) 
and added to a mature culture of C. elegans. The compound was left to incubate with 
the fungus for 72 h. at 28 ºC and 180 rpm. After 72 h, the fungus was centrifuged 
down, and the supernatant was extracted with EtOAc (3 x 50 mL). The combined 
organic phases were dried over Na2SO4, filtered and evaporated under reduced 
pressure. Purification of the metabolite and residual starting material was achieved by 
reverse-phase HPLC, in a semi-preparative Kingsorb, and eluting with a mixture of 
50:50 AcCN:water, both supplemented with 0.05% of TFA, at a flow rate of 1 
mL/min. This afforded 90 at a tret = 23 min, and starting material 60 at a tret = 27.5 min. 
 
4-((1R, 2S, 3R, 6S)-2,3,6-trifluoro-1-hydroxycyclohexyl)benzoic acid (90) 
1H NMR (500 MHz, methanol-d4) δH 8.06 (2H, m, H-Ar-a’), 7.85 (2H, 
d, J = 8.5 Hz, H-Ar-b’), 5.11 (2H, m, H-γ, H-ζ), 4.79 (1H, d, J = 46.9 
Hz, H-β), 2.21 (3H, m, H-ε, H-δeq), 1.91 (1H, m, δax) 19F{1H} NMR 
(470 MHz, methanol-d4) δF -209.9 (F, dd, J = 23.0, 12.8 Hz), -192.9 (F, 
d, J = 12.8 Hz), -191.2 (F, d, J = 23.0 Hz) 13C NMR (126 MHz, 
methanol-d4) δC 169.4 (COOH, visible in HMBC), 149.1 (C-Ar, visible 
in HMBC), 132.0 (C-Ar, visible in HMBC), 129.0 (C-Ar), 126.6 (C-Ar), 91.2 (C-ζ, dd, 
J = 203.6, 15.5 Hz), 90.8 (C-β, d, J = 178.3 Hz), 88.5 (C-γ, dd, J = 198.2, 19.9 Hz), 
73.0 (C-α, visible in HMBC), 24.5 (C-ε, dd, J = 34.4, 12.6 Hz), 19.7 (C-δ, dd, J = 
24.1, 4.1 Hz) HRMS (ESI-) m/z calc. for C13H12O3F3 [M]-H 273.0739, found 
273.0743. 
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5.3.3 Fluorometabolite production in C. elegans in α,α-difluoroethyl thio- and 
oxy- ethers 
5.3.3.1 (1,1-Difluoroethyl)(4-methoxyphenyl)sulfane (104) 
 
(1,1-Difluoroethyl)(4-methoxyphenyl)sulfane (104) was dissolved in DMF (50 µL) 
and added to a mature culture of C. elegans. The compound was left to incubate with 
the fungus for 72 h. at 28 ºC and 180 rpm. After 72 h, the fungus was centrifuged 
down, and the supernatant was extracted with DCM (3 x 50 mL) and Et2O (3 x 50 
mL). The combined organic phases were dried over Na2SO4, filtered and evaporated 
under reduced pressure. Purification of the metabolite and residual starting material 
was achieved by reverse-phase HPLC, in a Phenomenex Luna, and eluting with a 
mixture of 60:40 AcCN:water, both supplemented with 0.05% of TFA, at a flow rate 
of 1 mL/min. This afforded 112 at a tret = 24 min, 113 at a tret = 16 min and 114 at a tret 
= 21 min. 
1-((1,1-Difluoroethyl)sulfinyl)-4-methoxybenzene (112) 
1H NMR (500 MHz, chloroform-d) δH 7.64 (2H, d, J = 8.9 Hz, 
H-Ar), 7.06 (2H, d, J = 8.9 Hz, H-Ar), 3.88 (3H, s, OCH3), 1.75 
(3H, t, J = 18.4 Hz, CF2CH3); 19F{1H} NMR (470 MHz, 
chloroform-d) δF -94.2 (d, J = 225.8 Hz), - 97.6 (d, J = 225.8 
Hz); 13C NMR (126 MHz, chloroform-d) δC 163.1 (s, C-4), 128.1 (t, J = 323.8 Hz, 
CF2), 127.6 (s, C-2), 114.8 (s, C-3), 55.6 (s, OCH3), 16.5 (t, J= 22.3 Hz, CF2CH3); 
HRMS (ESI+) m/z calc. for C9H11O2F2S [M+H]+ 221.0448, found 221.0440. 
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4-((1,1-Difluoroethyl)sulfinyl)phenol (113) 
1H NMR (500 MHz, chloroform-d) δH 7.60 (2H, d, J = 8.9 Hz, 
H-Ar), 7.01 (2H, d, J = 8.9 Hz, H-Ar), 1.75 (3H, t, J = 18.4 Hz, 
CF2CH3); 19F{1H} NMR (470 MHz, chloroform-d) δF -94.1 (d,    
J = 225.1 Hz), - 97.6 (d, J = 225.1 Hz); 13C NMR (126 MHz, 
chloroform-d) δC 159.7 (s, C-4), 127.9 (s, C-2), 125.4 (t, J = 276.2 Hz, CF2, visible in 
HMBC), 116.4 (s, C-3), 16.5 (t, J= 22.3 Hz, CF2CH3); HRMS (ESI+) m/z calc. for 
C8H9O2F2S [M+H]+ 207.0291, found 207.0286. 
4-((1,1-Difluoroethyl)sulfonyl)phenol (114) 
1H NMR (500 MHz, chloroform-d) δH 7.87 (2H, d, J = 8.9 Hz, 
H-Ar), 7.01 (2H, d, J = 8.9 Hz, H-Ar), 2.02 (3H, t, J = 18.3 Hz, 
CF2CH3); 19F{1H} NMR (470 MHz, chloroform-d) δF -97.2 (s); 
13C NMR (126 MHz, chloroform-d) δC 161.8 (s, C-4), 133.5 (s, C-3), 123.6 (t,             
J = 262.9 Hz, CF2, visible in HMBC), 116.3 (s, C-2), 16.6 (t, J = 22.4 Hz, CF2CH3); 
HRMS (ESI+) m/z calc. for C8H8O3F2SNa [M+Na]+ 245.0060, found 245.0055; 
HRMS (ESI-) m/z calc. for C8H7O3F2S [M-H]- 221.0084, found 221.0087. 
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5.3.3.2 (1,1-Difluoroethyl)(naphthalene-2-yl) sulfane (105) 
 
(1,1-Difluoroethyl)(naphthalene-2-yl) sulfane (105) was dissolved in DMF (50 µL) 
and added to a mature culture of C. elegans. The compound was left to incubate with 
the fungus for 72 h. at 28 ºC and 180 rpm. After 72 h, the fungus was centrifuged 
down, and the supernatant was extracted with DCM (3 x 50 mL) and Et2O (3 x 50 
mL). The combined organic phases were dried over Na2SO4, filtered and evaporated 
under reduced pressure. Purification of the metabolite and residual starting material 
was achieved by reverse-phase HPLC, in a Phenomenex Luna, and eluting with a 
mixture of 60:40 AcCN:water, both supplemented with 0.05% of TFA, at a flow rate 
of 1 mL/min. This afforded 116 at a tret = 37 min, 117 at a tret = 13 min and 118 at a tret 
= 17 min. 
2-((1,1-Difluoroethyl)sulfinyl)naphthalene (116) 
1H NMR (500 MHz, chloroform-d): δH 8.28 (s, 1H), 8.01 (d,       
J = 8.7 Hz, 1H), 7.99 – 7.92 (m, 2H), 7.69 (ddt, J = 8.7, 2.6, 1.3 
Hz, 1H), 7.67 – 7.60 (m, 2H), 1.77 (t, J = 18.5 Hz, 3H); 19F NMR 
(471 MHz, chloroform-d): δF -92.9 (d, J = 227.0 Hz), -95.6 (d, J = 227.0 Hz); HRMS 
(ESI+) m/z calc. for C12H11OF2S [M+H]+ 241.0420, found 241.0491. Data is consistent 
with the full characterisation carried out for 116 from chemical reaction (Section 
5.2.9). 
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6-((1,1-Difluoroethyl)sulfinyl)naphthalene-1,4-diol (117) 
1H NMR (500 MHz, chloroform-d): δH 7.81 (1H, d, J = 7.9 Hz, 
H-Ar), 7.61 (1H, d, J = 7.9 Hz, H-Ar), 7.44 (1H, s, H-Ar), 6.50 
(1H, d, J = 11.0 Hz, H-Ar), 6.12 (1H, d, J = 11.0 Hz, H-Ar), 1.80 
(3H, t, J = 18.4 Hz, CF2CH3); 19F NMR (471 MHz, chloroform-
d): δF -93.2(d, J = 226.9 Hz), -96.7 (d, J = 226.9 Hz); HRMS (ESI-) m/z calc. for 
C12H9O3F2S [M-H]- 271.0246, found 271.0245. 
General (1,1-difluoroethyl)sulfinyl)naphthalene (118) 
19F NMR (471 MHz, chloroform-d): δF -96.8 (s); m/z calc. 
for C12H10O4F2S [M]+ 288, found 288. 
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5.3.3.3 1-(1,1-Difluoroethoxy)-4-methoxybenzene (106) 
    
1-(1,1-Difluoroethoxy)-4-methoxybenzene (106) was dissolved in DMF (50 µL) and 
added to a mature culture of C. elegans. The compound was left to incubate with the 
fungus for 72 h. at 28 ºC and 180 rpm. After 72 h, the fungus was centrifuged down, 
and the supernatant was extracted with EtOAc (3 x 50 mL). The combined organic 
phases were dried over Na2SO4, filtered and evaporated under reduced pressure. 
Purification of the metabolite and residual starting material was achieved by reverse-
phase HPLC, in a Phenomenex Luna, and eluting with a mixture of 60:40 
AcCN:water, both supplemented with 0.05% of TFA, at a flow rate of 1 mL/min. This 
afforded 119 at a tret = 25 min, and 120 at a tret = 19 min. 
4-Acetoxyphenol (119) 
1H NMR (500 MHz, chloroform-d) δH 6.95 (2H, d, J = 8.9 Hz, 
H-Ar), 6.82 (2H, d, J = 8.9 Hz, H-Ar), 2.28 (3H, t, J = 18.4 Hz, 
COCH3); 13C NMR (126 MHz, chloroform-d) δC 160.8 (s, CO, 
visible in HMBC), 122.7 (s, C-Ar), 116.1 (s, C-Ar), 21.1 (s, COCH3). Data is in good 
agreement with the literature values.9 
4-(1,1-Difluoro)ethoxy phenol (120) 
1H NMR (500 MHz, chloroform-d) δH 6.75 (2H, d, J = 2.7 Hz, 
H-Ar), 6.64 (2H, d, J = 2.7Hz, H-Ar), 1.87 (3H, t, J = 13.3 Hz, 
CF2CH3); 19F{1H} NMR (470 MHz, chloroform-d) δF -64.6 (s); 
13C NMR (126 MHz, chloroform-d) δC 114.4 (s, C-Ar), 110.1 (s, C-Ar), 22.5 (t, J = 
32.0 Hz, CF2CH3). Low amounts did not allow a full characterisation. 
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5.3.4 Fluorometabolite production in C. elegans in α,β,β-(trifluorocyclopropyl) 
benzene derivatives 
5.3.4.1 1-Methoxy-4-(1,2,2-trifluorocyclopropyl)benzene (126) 
 
1-Methoxy-4-(1,2,2-trifluorocyclopropyl)benzene (126) was dissolved in DMF (50 
µL) and added to a mature culture of C. elegans. The compound was left to incubate 
with the fungus for 72 h. at 28 ºC and 180 rpm. After 72 h, the fungus was centrifuged 
down, and the supernatant was extracted with EtOAc (3 x 50 mL). The combined 
organic phases were dried over Na2SO4, filtered and evaporated under reduced 
pressure. Purification of the metabolite and residual starting material was attempted by 
column chromatography, starting with 100% petroleum ether and following with 10% 
EtOAc, 20% EtOAc, 30% EtOAc and 50% EtOAc, finishing with 100% EtOAc wash. 
The purification allowed the isolation of 150.  
4-(1,2,2-trifluorocyclopropyl)phenol (150) 
1H NMR (500 MHz, chloroform-d) δH 7.36 (2H, dt, J = 8.7, 1.3 
Hz, H-Ar), 6.88 (2H, dt, J = 8.7, 1.3 Hz, H-Ar), 2.14-1.93 (2H, 
m, CH2); 19F{1H} NMR (470 MHz, chloroform-d) δF -135.7 (dd, 
J = 166.9, 9.1 Hz), -142.5 (d, J = 166.9 Hz), -175.3 (s); 13C NMR (126 MHz, 
chloroform-d) δC 157.4 (s, C-Ar, visible in HMBC), 129.6 (s, C-Ar), 123.6 (s, C-Ar, 
visible in HMBC), 115.4 (s, C-Ar), 32.7 (d, J = 175.0 Hz, CF), 29.6-29.0 (m, CF2), 
22.1 (m, CH2); HRMS (ESI-) m/z calc. for C9H6OF3 [M-H]- 187.0376, found 
187.0372. 
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5.4 Enantiomeric excess analysis 
5.4.1 Enantiomeric excess analysis in all-cis fluorocyclohexyl derivatives 
5.4.1.1 All-cis (2,3,6-trifluorocyclohexyl)benzene (59) 
HPLC data for compound 59: Chiralcel IC (95:5 hexane:IPA, flow rate 1 
mLmin-1, 211 nm, 30 °C), tR (A): 6.2 min, tR (B): 7.0 min. 57:43 ee.  
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5.4.1.2 2,3,6-Trifluoro-1-phenylcyclohexan-1-ol (79) 
HPLC data for compound 79: Chiralcel ID (95:5 hexane:IPA, flow rate 
1 mLmin-1, 211 nm, 30 °C), tR (A): 13.5 min, tR (B): 31.0 min; 38:62 ee. 
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5.4.1.3 All-cis methyl 4-(2,3,6-trifluorocyclohexyl) benzoate (93) 
 
HPLC data for compound 93: Chiralcel IC (95:5 hexane:IPA, flow rate 1 
mLmin-1, 211 nm, 30 °C), tR (A): 24.1 min, tR (B): 28.1 min; 48:52 ee. 
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5.4.2 Enantiomeric excess analysis for α,α-difluoroethyl thioethers 
5.4.2.1 1-((1,1-Difluoroethyl)sulfinyl)-4-methoxybenzene (112) 
HPLC data for compound 112: Chiralcel ID (95:5 hexane:IPA, 
flow rate 1 mLmin-1, 254 nm, 30 °C), tR (A): 15.6 min, tR (B): 16.5 
min; 20:80 ee. 
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5.4.2.2 2-((1,1-Difluoroethyl)sulfinyl)naphthalene (116) 
HPLC data for compound 116: Chiralcel IC (95:5 hexane:IPA, 
flow rate 1 mLmin-1, 254 nm, 30 °C), tR (A): 18.9 min, tR (B): 
16.5 min; 23:77 ee. 
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5.5 Estimation of lipophilicities  
5.5.1 Estimation by 19F NMR 
5.5.1.1 General procedures for the estimation of Log P by 19F NMR10 
The compounds to be measured were added into a pear-bottom flask containing equal 
amounts of octanol and water. The mixture was stirred at r.t. and the layers allowed to 
separate overnight.  
The NMR samples were prepared carefully to avoid contamination between the 
phases. A fraction of the upper octanol layer (0.8 mL) was taken with a 1 mL syringe 
and a needle, and 0.3 mL were discarded to ensure that no aqueous residue was left in 
the needle. The remaining sample (0.5 mL) was transferred into an NMR tube. D6-
acetone (0.1 mL) was added to the tube, and it was stoppered and carefully sealed with 
Parafilm®. The tube was inverted (20 times) to ensure homogenisation. 
For the preparation of the lower aqueous sample, some air was taken with the syringe 
and needle and it was slowly discharged while passing through the organic layer to 
avoid accidentally collecting any octanol. The remaining air was slowly discharged 
into the aqueous phase, and a sample of the aqueous layer was taken (0.8 mL). The 
needle and syringe were removed as fast as possible, and 0.3 mL of water were 
discarded to avoid contamination. The needle was also externally wiped with a tissue. 
The remaining sample (0.5 mL) was added into an NMR tube, followed by d6-acetone 
(0.1 mL). The tube was stoppered and sealed with Parafilm® prior to inversion (20 
times) for homogenisation. 
The settings of both the actual NMR experiment and that of the processing of the FID 
were carried out as follows. The pulse delay time (D1) were evaluated by Linclau such 
that D1 for octanol should be 30 s and for water, 60 s.10 The frequency offset point 
(O1P) should be centred on the fluorine signals, so it will vary for each sample.  
All spectra were processed in the same way, using Topspin 3.5pl5. The sequence of 
commands was as follows: 1. Open spectrum 2. efp 3. Window function à LB (line 
broadening) = 2 4. efp  5. si = 256 k 6. efp 7. pH 8. bas (Interval baseline correction) 9. 
.pp à Delete à Integrate à D. 
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For the spectra analysis, it was first necessary to define the integration ratio (ρ) for the 
aqueous and the octanol phases. In the following equations, ‘X’ is the compound to be 
measured and ‘ref’ is the reference. 
ρ!"# = I!"#!I!"#!"# = !!C!"#!!!"#C!"#!"#  
ρ!" = I!"!I!"!"# = !!C!"!!!"#C!"!"# 
Once the integration ratio for both phases has been defined, the partition coefficient 
(P) was calculated as follows: 
ρ!"#ρ!" = C!"#! C!"!"#C!"! C!"#!"# = P!P!"# 
P! = P!"# ρ!"#ρ!"  
logP! = logP!"# + log ρ!"#ρ!"  
Since the log P of the reference is well known, the only unknown variable is the log P 
of the compound. 
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5.5.1.2 Calibration Experiments 
2,2,2-Trifluoroethanol (71) to estimate 1,3-difluoro-2-propanol (72) 
2,2,2-Trifluoroethanol (TFE, 5 mg, 3.6 µL, 71) and 1,3-difluoro-2-propanol (5 mg, 
4.03 µL, 72) were added into a pear-shaped flask containing octanol (2 mL, HPLC 
grade) and a stirrer bar. Finally, water was added (2 mL, milliQ). The flask was stirred 
for 3 hours at room temperature, and the phases were left to separate overnight. NMR 
samples were prepared as previously described. Full range 19F {1H} NMRs were run, 
the number of scans (NS) were set to the automatic 64 scans, and the O1P was set as  -
155 Hz. The FID processing was carried out with Topspin as previously described, 
following the parameters indicated above and integrating each signal manually. This 
led to the following results: 
ρ!"#$% = I!"I!" = 100.0060.24 = 1.62 
ρ!"#$%!& = I!"I!" = 27.08100.00 = 0.271 log!!" =  +0.36 
log P!" = log P!" + log ρ!"#ρ!"#$% = +0.36 + log 0.2711.62 = +0.36 + −0.79 = −0.43 
TFE (71) to estimate 2-fluorophenol (73) 
TFE (5 mg, 3.6 µL, 71) and 2-fluorophenol (5 mg, 3.98 µL, 73) were added into a 
pear-shaped flask containing octanol (2 mL, HPLC grade) and a stirring bar. MilliQ 
water was added (2 mL) and the flask was stirred for 3 hours at room temperature. The 
octanol and aqueous phases were left to separate overnight. A full range 19F {1H} 
NMR was run, with NS = 64 scans and the O1P adjusted to -105 Hz.  
ρ!"#$% = I!"I!" = 1.00100.00 = 0.01 
ρ!"#$%!& = I!"I!" = 23.03100.00 = 0.2303 log!!" =  +0.36 
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log P!" = log P!" + log ρ!"#ρ!"#$% = +0.36 + log 0.23030.01 = +0.36 + 1.36 = +1.72 
5.5.1.3 Estimation of Log P values 
All-cis tetrafluorocyclohexylbenzene (62) 
2-Fluorophenol (5 mg, 3.98 µL, 73) and all-cis tetrafluorocyclohexylbenzene (5.32 
mg, 62) were added into a pear-shaped flask containing octanol (2 mL, HPLC grade) 
and a stirring bar. MilliQ water was added (2 mL) and the flask was vigorously stirred 
for 3 hours at room temperature. The octanol and aqueous phases were left to separate 
overnight. NMR samples were run using the following settings: aqueous sample (NS = 
64 scans, D1 = 60 s, O1P = -169 ppm); octanol sample (NS = 64 scans, D1 = 30 s, 
O1P = -169 ppm), leading to the following calculations and results: 
ρ!"#$% = I!"I!" = 16.65 + 16.71100.00 = 0.3336 
ρ!"#$%!& = I!"I!" = 95.58 + 90.94100.00 = 1.8652 log!!" =  +1.70 
log P! = log P!"# + log ρ!"#ρ!"#$% = +1.70 log 1.86520.3336 = +1.70 + 0.747 = 2.45 
A second assay was run with 2-fluorophenol (5 mg, 3.98 µL, 73) and 62 (6.46 mg), 
obtaining the following results: 
ρ!"#$% = I!"I!" = 19.66 + 16.30100.00 = 0.3596 
ρ!"#$%!& = I!"I!" = 1.0598 + 0.98731.00 = 2.0471 log!!" =  +1.70 
log P!" = log P!" + log ρ!"#ρ!"#$% = +1.70 log 2.04710.3596 = +1.70 + 0.755 = 2.46 
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All-cis trifluorocyclohexylbenzene (59) 
2-Fluorophenol (5 mg, 3.98 µL, 73) and all-cis trifluorocyclohexylbenzene (5.25 mg, 
59) were added into a pear-shaped flask containing octanol (2 mL, HPLC grade) and a 
stirrer bar. MilliQ water was added (2 mL) and the flask was vigorously stirred for 3 
hours at room temperature. The octanol and aqueous phases were left to separate 
overnight. 
NMR samples were run using the following settings: aqueous sample (NS = 64 scans, 
D1 = 60 s, O1P = -166 ppm); octanol sample (NS = 64 scans, D1 = 30 s, O1P = -166 
ppm), leading to the following calculations: 
ρ!"#$% = I!"I!" = 0.1202 + 0.1039 + 0.10791.00 = 0.332 
ρ!"#$%!& = I!"I!" = 0.5156 + 0.5078 + 0.48651.00 = 1.5099 log!!" =  +1.70 
log P!" = log P!" + log ρ!"#ρ!"#$% = +1.70 + log 1.50990.332 = +1.70 + 0.658 = +2.36 
The experiment was repeated with 2-fluorophenol (5mg, 3.98 µL, 73) and 59 (5 mg), 
leading to: 
ρ!"#$% = I!I!"# = 0.1266 + 0.0938 + 0.11301.00 = 0.3334 
ρ!"#$%!& = I!I!"# = 0.5415 + 0.5365 + 0.50311.00 = 1.5811 log!!"# =  +1.70 
log P! = log P!"# + log ρ!"#ρ!"#$% = +1.70 log 1.58110.3334 = +1.70 + 0.675 = +2.38 
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All-cis difluorocyclohexylbenzene (58) 
2-Fluorophenol (5 mg, 3.98 µL, 73) and all-cis difluorocyclohexylbenzene (4.97 mg, 
58) were added into a pear-shaped flask containing octanol (2 mL, HPLC grade) and a 
stirring bar. MilliQ water was added (2 mL) and the flask was vigorously stirred for 3 
hours at room temperature. The octanol and aqueous phases were left to separate 
overnight. NMR samples were run using the following settings: aqueous sample (NS = 
64 scans, D1 = 60 s, O1P = -168 ppm); octanol sample (NS = 64 scans, D1 = 30 s, 
O1P = -168 ppm). The very low intensity of the fluorine signals in the aqueous phase 
did not allow the determination of a Log P value for this compound.  
All-cis tetrafluorocyclohexyl carboxylic acid (63)  
HPLC grade octanol (2 mL) was added to a pear-shaped flask containing a stirring bar, 
prior to addition of 2-fluorophenol (2.5 mg, 2 µL, 73) and 63 (1.01 mg). MilliQ grade 
water was added to the mixture (2 mL), and it was stirred for 3 h at r.t. The phases 
were left to separate overnight. NMR samples were prepared as previously described, 
employing the following parameters: aqueous sample (NS = 64 scans, D1 = 60 s, O1P 
= -170 ppm); octanol sample (NS = 64 scans, D1 = 30 s, O1P = -170 ppm). 
!!"#$% = !!"!!" = 0.4964 + 0.43841.00 = 0.9348 
!!"#$%!& = !!"!!" = 0.2174 + 0.20531.00 = 0.4227 log!!" =  +1.70 
log P!" = log P!" + log ρ!"#ρ!"#$% = +1.70 + log 0.42270.9348 = +1.70 + −0.345 = +1.36 
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All-cis trifluorocyclohexyl carboxylic acid (60)   
HPLC grade octanol (2 mL) was added to a pear-shaped flask containing a stirring bar, 
prior to addition of 2-fluorophenol (2.5 mg, 2 µL, 73) and 60 (1.39 mg). MilliQ grade 
water was added to the mixture (2 mL), and it was stirred for 3 h at r.t. The phases 
were left to separate overnight. NMR samples were prepared as previously described, 
employing the following parameters: aqueous sample (NS = 64 scans, D1 = 60 s, O1P 
= -166 ppm); octanol sample (NS = 64 scans, D1 = 30 s, O1P = -166 ppm). 
!!"#$% = !!"!!" = 0.2429 + 0.1877 + 0.26791.00 = 0.6985 
!!"#$%!& = !!"!!" = 14.40 + 13.39 + 12.72100.00 = 0.4051 log!!" =  +1.70 
log P!" = log P!" + log ρ!"#ρ!"#$% = +1.70 + log 0.40510.6985 = +1.70 + −0.237 = +1.46 
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5.5.2 Estimation by reverse-phase HPLC 
5.5.2.1 General procedures for the estimation of Log P values by reverse-phase 
HPLC 
The estimation of lipophilicity values was conducted using a Phenomenex Luna C18 
100A (250 mm × 4.60 mm) 5µ column in a Shimadzu Prominence HPLC. A series of 
reference compounds were injected (5–10 µL of 0.5 mg/mL in AcCN) and their 
retention times (Rt) plotted against their Log P values to obtain a line equation.  
When possible, the value for the references used is the one recommended by Hansch 
and Leo (1987, 1995) or Sangster (1989).11,12,13 
The characteristic retention times (Rt) of each of the reference molecules was used to 
calculate their capacity factor (k), using the following equation: 
Capacity factor k = Retention Time − Dead Time of the columnDead Time of the column  
Where the dead time of the column is the time that takes for an unretained molecule 
(such as the solvent) to pass through the column, and in this case is of 1.97 min. 
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5.5.2.2 Conditions for cyclohexyl derivatives (Section 2.1.4) 
The retention times of all the compounds were measured using 60:40 AcCN:water as 
eluent, both supplemented with 0.05% TFA. The flow rate was of 1 mL/min. The 
retention time for each reference compound was measured in triplicates, to allow the 
calculation of an average retention time, which was used to calculate the 
corresponding capacity factor (k). 
Reference Log P Rt 1 
(min) 
Rt 2 
(min) 
Rt 3 
(min) 
Average Rt 
(min) 
Capacity 
factor (k) 
Log k 
Phenol 1.50 3.99 3.99 3.99 3.99 ± 0.00 1.03 0.013 
2-Fluorophenol 1.71 4.18 4.18 4.18 4.18 ± 0.00 1.13 0.051 
Benzofuran 2.67 8.42 8.42 8.43 8.42 ± 0.01 3.29 0.52 
Toluene 2.73 10.27 10.27 10.27 10.27 ± 0.00 4.23 0.63 
o-Xylene 3.12 13.36 13.34 13.37 13.36 ± 0.02 5.80 0.76 
Naphthalene 3.35 12.75 12.75 12.78 12.76 ± 0.02 5.50 0.74 
Cumene 3.66 18.87 18.88 18.91 18.89 ± 0.02 8.61 0.94 
t-Butylbenzene 4.11 23.93 23.86 23.91 23.90 ± 0.04 11.16 1.05 
Butylbenzene 4.26 31.10 31.15 31.14 31.13 ± 0.03 14.84 1.17 
Anthracene 4.45 25.08 25.07 25.02 25.06 ± 0.04 11.75 1.07 
Pyrene 4.88 33.24 33.33 33.17 33.25 ± 0.08 15.92 1.20 
 
The logarithm of each capacity factor was plotted against their literature Log P value 
to afford the equation of a line. For these conditions, y = 0.3693x – 0.4835, with a 
correlation coefficient of R2 = 0.9617. 
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The retention time of each of the products to study was measured thrice, and the 
average retention time used for the calculation of the corresponding capacity factor. 
The logarithm of the capacity factor was used with the previous equation to yield the 
Log P values of each compound. 
 
Compound LogP Rt 1 Rt 2 Rt 3 Average Rt k Logk 
62 2.58 7.78 7.78 7.72 7.76 ± 0.04 2.95 0.47 
59 2.64 8.08 8.08 8.03 8.06 ± 0.03 3.10 0.49 
63 1.50 4.28 4.27 4.28 4.28 ± 0.01 1.18 0.07 
60 1.51 4.29 4.30 4.30 4.30 ± 0.01 1.19 0.07 
58 3.30 12.68 12.68 12.61 12.66 ± 0.05 5.44 0.74 
74 2.79 8.87 8.88 8.87 8.87 ± 0.01 3.52 0.55 
52 3.76 17.82 17.81 17.71 17.78 ± 0.07 8.05 0.91 
75 4.99 46.88 46.53 46.89 46.77 ± 0.24 22.80 1.36 
76 2.28 6.45 6.45 6.45 6.45 ± 0.00 2.28 0.36 
77 3.23 12.00 11.99 12.00 12.00 ± 0.01 5.11 0.71 
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5.5.2.2 Conditions for thio- and oxy- ethers (Section 2.2.3) and fluorocyclopropyl 
derivatives (Section 2.3.3) 
The retention times of all the compounds were measured using 60:40 AcCN:water as 
eluent, with a flow rate of 1 mL/min. No TFA was used for the estimation of these Log 
P values.  
The table below displays the experimental results for these conditions, where the 
retention time for each of the reference compounds was measured three times, in order 
to calculate an average retention time. The calculated average was used to estimate the 
capacity factor (k) and its logarithm. This log k plotted against the known Log P value 
gave an equation of the line for the calculation of the unknown lipophilicities. 
 
Reference Log P Rt 1 (min) Rt 2 (min) Rt 3 (min) Average Rt (min) 
Capacity 
factor (k) Log k 
Phenol 1.50 4.30 4.30 4.26 4.29 ± 0.03 1.18 0.08 
2-Fluorophenol 1.71 4.20 4.21 4.50 4.30 ± 0.20 1.18 0.08 
Benzofuran 2.67 8.38 8.38 8.38 8.38 ± 0.00 3.26 0.51 
Toluene 2.73 10.26 10.27 10.25 10.26 ± 0.01 4.22 0.63 
o-Xylene 3.12 13.25 13.28 13.58 13.37 ± 0.30 5.80 0.76 
Naphthalene 3.35 12.73 12.73 12.76 12.74 ± 0.02 5.48 0.74 
Cumene 3.66 17.06 17.07 17.17 17.10 ± 0.07 7.70 0.89 
t-Butylbenzene 4.11 23.45 23.41 23.26 23.37 ± 0.11 10.89 1.04 
Butylbenzene 4.26 29.96 30.43 30.45 30.28 ± 0.32 14.41 1.16 
Anthracene 4.45 24.46 24.46 24.51 24.48 ± 0.03 11.46 1.06 
Pyrene 4.88 32.70 32.62 32.80 32.71 ± 0.09 15.65 1.19 
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The equation used was y = 0.3772x – 0.493, with a correlation factor of R2 = 0.9857.  
 
The experimental retention times, the calculated capacity factors and their logarithms 
are shown in the table below, along with the Log P values (blue), estimated by 
substitution of the log k values in the regression line equation. 
Compound LogP Rt 1 Rt 2 Rt 3 Average Rt Capacity factor (k) Logk 
PhSCF3 (94) 3.70 17.67 17.68 17.68 17.68 ± 0.01 8.00 0.90 
PhSCH2CH3 
(95) 3.42 14.32 14.28 14.33 14.31 ± 0.03 6.28 0.80 
PhSCF2CH3 (96) 3.38 13.89 13.88 13.88 13.88 ± 0.01 6.07 0.78 
PhSCH2CF3 (97) 3.30 13.05 13.05 13.03 13.04 ± 0.01 5.64 0.75 
PhSCH3 (98) 2.87 9.61 9.61 9.62 9.61 ± 0.01 3.89 0.59 
PhOCF3 (99) 3.35 13.49 13.51 13.49 13.50 ± 0.01 5.87 0.77 
PhOCH2CH3 
(100) 2.96 10.42 10.09 10.12 10.21 ± 0.21 4.20 0.62 
PhOCF2CH3 
(101) 2.87 9.56 9.57 9.58 9.57 ± 0.01 3.87 0.59 
PhOCH2CF3 
(102) 2.83 9.28 9.28 9.48 9.35 ± 0.13 3.76 0.58 
PhOCH3 (103) 2.51 7.55 7.60 7.57 7.57 ± 0.03 2.85 0.46 
 
 
 
y	=	0.3772x	-	0.493	R²	=	0.98572	
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Compound Log P Rt 1 Rt 2 Rt 3 Average Rt Capacity factor (k) Logk 
127 4.01 22.45 22.42 22.47 22.45 ± 0.03 10.42 1.02 
128 3.42 14.29 14.28 14.31 14.29 ± 0.02 6.27 0.80 
129 2.91 9.86 9.86 9.89 9.87 ± 0.02 4.02 0.61 
130 2.81 9.21 9.21 9.23 9.22 ± 0.01 3.69 0.57 
131 2.79 9.09 9.09 9.11 9.10 ± 0.01 3.63 0.56 
126 2.87 9.62 9.63 9.63 9.63 ± 0.01 3.90 0.59 
132 3.55 15.76 15.77 15.78 15.77 ± 0.01 7.03 0.85 
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5.6 Enzymatic biotransformations (Chapter 3) 
5.6.1 Preparation of buffers  
5.6.1.1 Phosphate-citrate buffer 
The phosphate-citrate buffer was prepared by mixing Na2HPO4 (0.2 M; 53.7 g of 
Na2HPO4·7H2O in 1 L) and citric acid (0.1 M, 19.2 g in 1 L). The volume needed for 
each pH is described in the following table.14 
0.2 M Na2HPO4 (mL) 0.1 M citrate (mL) pH 
5.4 44.6 2.6 
7.8 42.2 2.8 
10.2 39.8 3.0 
12.3 37.7 3.2 
14.1 35.9 3.4 
16.1 33.9 3.6 
17.7 32.3 3.8 
19.3 30.7 4.0 
20.6 29.4 4.2 
22.2 27.8 4.4 
23.3 26.7 4.6 
24.8 25.2 4.8 
25.7 24.3 5.0 
26.7 23.3 5.2 
27.8 22.2 5.4 
29.0 21.0 5.6 
30.3 19.7 5.8 
32.1 17.9 6.0 
33.1 16.9 6.2 
34.6 15.4 6.4 
36.4 13.6 6.6 
40.9 9.1 6.8 
43.6 6.5 7.0 
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5.6.1.2 Phosphate buffer (1 M, pH = 7.8) 
Stock solution A (potassium dihydrogenphosphate, 1 M) was mixed with stock 
solution B (potassium phosphate, dibasic, 1 M) until pH = 7.8. Other phosphate buffers 
with different pH were prepared from the same stock solutions, in different 
proportions. 
5.6.1.3 Tris·HCl buffer  
A 1M solution of Tris buffer was prepared by addition of Trizma® base (60.6 g) to 
distilled water (0.3 L), which was stirred for homogenisation. The pH was adjusted by 
dropwise addition of HCl (conc.), to the required value – as described per each 
experiment. The volume was adjusted to a total of 0.5 L by addition of distilled water. 
The corresponding concentrations of the Tris buffer were obtained by addition of the 
stock 1 M solution to the required volume of water. 
When necessary, the buffer was supplemented with Mg2+ by addition of the required 
volume of a 1 M MgCl2 stock solution. 
5.6.1.4 Buffers for the Purification of FdrC 
1 M Tris·HCl (pH = 8,), 1 M imidazole (pH = 8) and 1 M NaCl stock solutions were 
required for the preparation of the washing buffers employed during FdrC purification 
with a Ni-NTA column. 
5.6.1.4.1 FdrC ‘Wash Buffer A’ or ‘lysis buffer’: 20 mM Tris·HCl, 20 mM 
imidazole and 500 mM NaCl (pH = 8) 
Buffer A was prepared by addition of Tris·HCl buffer (10 mL, 1 M, pH = 8), 
imidazole (10 mL, 1 M, pH = 8) and NaCl (250 mL, 1 M) to a beaker. The solution 
was homogenised by stirring, and the final volume was adjusted to 500 mL by addition 
of distilled water. 
5.6.1.4.2 FdrC ‘Wash Buffer B’: 20 mM Tris·HCl, 50 mM imidazole and 500 mM 
NaCl  (pH = 8) 
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Buffer B was prepared by addition of Tris·HCl buffer (5 mL, 1 M, pH = 8), imidazole 
(12.5 mL, 1 M, pH = 8) and NaCl (125 mL, 1 M) to a beaker. The solution was 
homogenised by stirring, and the final volume was adjusted to 250 mL by addition of 
distilled water. 
5.6.1.4.3 FdrC ‘Wash Buffer C’ of ‘elution buffer’: 20 mM Tris·HCl, 400 mM 
imidazole and 500 mM NaCl (pH = 8) 
Buffer C was prepared by addition of Tris·HCl buffer (5 mL, 1 M, pH = 8), imidazole 
(100 mL, 1 M, pH = 8) and NaCl (125 mL, 1 M) to a beaker. The solution was 
homogenised by stirring, and the final volume was adjusted to 250 mL by addition of 
distilled water. 
5.6.1.4.4 FdrC ‘Dialysis buffer’: 20 mM Tris·HCl, 100 mM NaCl (pH = 8) 
Tris·HCl buffer (80 mL, 1 M, pH = 8) and NaCl (400 mL, 1 M) were added to a 5 L 
beaker and homogenised by stirring. The final volume was adjusted to 4 L by addition 
of distilled water, and the final pH adjusted to 8. 
5.6.1.5 Buffers for the Purification of Nucleoside Hydrolase 
5.6.1.5.1 ‘Wash Buffer A’ or ‘lysis buffer’: 10 mM phosphate buffer, 20 mM 
imidazole and 150 mM NaCl (pH = 7.8) 
Phosphate buffer (5 mL, 1 M, pH = 7.8), imidazole (10 mL, 1 M, pH = 7.8) and NaCl 
(75 mL, 1 M) were added to a beaker and homogenised. The final volume was 
adjusted to 500 mL by addition of distilled water. 
5.6.1.5.2 ‘Wash Buffer B’ or ‘elution buffer’: 10 mM phosphate buffer, 500 mM 
imidazole and 150 mM NaCl (pH = 7.8) 
Phosphate buffer (5 mL, 1 M, pH = 7.8), imidazole (250 mL, 1 M, pH = 7.8) and NaCl 
(75 mL, 1 M) were added to a beaker and homogenised. The final volume was 
adjusted to 500 mL by addition of distilled water. 
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5.6.1.5.3 NH ‘Dialysis buffer’: 20 mM HEPES, 1 mM CaCl2, 150 mM NaCl (pH = 7) 
HEPES buffer (80 mL, 1 M, pH = 7), CaCl2 (4 mL, 1 M) and NaCl (600 mL, 1 M) 
were added to a 5 L beaker and homogenised. The pH was adjusted to 7.0 and the final 
volume was adjusted to 4 L by addition of distilled water. 
5.6.2 Media preparation 
5.6.2.1 Lysogeny Broth Medium (LB or Luria Broth Medium) for E. coli  
Tryptone (10 g), yeast extract (5 g) and sodium chloride (10 g) were dissolved in 
distilled water (900 mL). The pH was adjusted to 7.25 by dropwise addition of NaOH 
(1 M). The appropriate antibiotic (ampicillin for NH and kanamycin for FdrC) was 
inoculated as specified for each case, and the final volume adjusted to 1000 mL. The 
medium was sterilised by autoclaving. 
5.6.2.1 Lysogeny Broth Agar for E. coli 
Tryptone (10 g), yeast extract (5 g), sodium chloride (10 g) and agar (15 g) were 
dissolved in distilled water (900 mL). The pH was adjusted to 7.25 by dropwise 
addition of NaOH (1 M). The appropriate antibiotic (ampicillin for NH and kanamycin 
for FdrC) was inoculated as specified for each case, and the final volume adjusted to 
1000 mL. The medium was sterilised by autoclaving. 
5.6.3 Over-expression and purification of nucleoside hydrolase (NH)6,15 
An overnight inoculum culture of E. coli containing the nucleoside hydrolase synthetic 
plasmid from T. vivax3 was prepared out of the glycerol stocks in LB with ampicillin 
(50 mg/mL), and incubated at 37 ºC. 
Induction cultures were prepared (6 x 1 L) from the overnight inoculum culture, in LB 
medium supplemented with ampicillin (1 mL of 50 mg/mL per litre of LB). The 
cultures were incubated at 37 ºC until O.D. was approximately 0.6 and then cooled in 
ice for 30 min. IPTG (0.3 mM) was added, and the cultures were incubated at 25 ºC for 
24 h. Cells were then harvested by centrifugation. 
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The cell pellet was resuspended in lysis buffer, containing Roche Complete Protease 
Inhibitor and deoxyribonuclease (0.1 mg/mL). The sample was sonicated 6 times (15 
secs at 10 mA amplitude each time), putting in ice at every interval. Alternatively, best 
results are achieved using the ‘one-shot’ cell disrupter. The cells and lysate were kept 
in ice at all times. The cell lysate was centrifuged (8000 rpm, 4 ºC) and filtered 
through a 0.45 µM filter paper. 
The clear lysate was purified by passing through a Ni2+ column. The lysate was 
allowed to pass through the column under gravity, leading to the nucleoside hydrolase 
being bound to the Ni2+ resin. The column was washed with lysis buffer (2 x 100 mL) 
and elution buffer (3 x 100 mL). 
Samples of the soluble lysate, the insoluble cell debris, the flow-through from the 
column, and the different washes were taken and prepared to run through an SDS-
PAGE gel. NuPage buffer was added to each collected sample. The samples were 
boiled for 10 min. at 95 ºC and centrifuged (13000 rpm, 5 min.). An aliquot (7 µl) of 
each sample was loaded to an SDS-PAGE gel, along with ladder marker (10 µl), and 
the gel was run at 200 V for 50 min. The gel was removed from the case and stained 
with instant blue stain for 40 min. 
The first and second washes with buffer C were diluted into an imidazole-free buffer, 
loaded into dialysis tubing and set to dialyse against the corresponding buffer (20 mM 
(4-2-hydroxyethyl)-1-piperazineethanesulphonic acid (HEPES), 1 mM CaCl2, 150 
mM NaCl, pH = 7) at 4 ºC overnight. 
The protein in the dialysis tubing was transferred to a Vivaspin concentrator 
(Vivascience) and was concentrated up to approximately 2 mL. The protein 
concentration was measured using a NanoDrop 1000 spectrophotometer. 
5.6.4 Transformation, over-expression and purification of FdrC2 
The competent cells (BL21 gold) were thawed on ice for 10 min, and aliquoted (100 
µL) into pre-chilled 14-mL BD Falcon polypropylene round-bottom tubes, aliquoting 
an additional sample for a control of the transformation. The competent cells were 
gently mixed by tapping of the tubes.  
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The DNA plasmid (0.5 µL) was added to each transformation reaction and swirled 
gently by tapping. For the control transformation reaction, the pUC18 control plasmid 
(1 µL) was added to the separate 100 µL aliquot of the competent cells and swirled 
gently. 
Each reaction was incubated on ice for 30 minutes. Meanwhile, LB medium was pre-
heated at 42 ºC in a heat block. Each transformation reaction was transferred from the 
ice to the heat block at 42 ºC for a heat pulse of 20 s, and incubated in ice again for 2 
min. 
The pre-heated LB medium (0.9 mL) was added into a sterile eppendorf, along with 
each transformation reaction, and incubated at 37 ºC for 1 h, shaking at 225 rpm. The 
cells from each transformation were concentrated by centrifugation, the supernatant 
being carefully removed with a pipette, and the cells from each transformation reaction 
were dissolved in minimal amounts of LB medium for plating onto LB agar dishes, 
which contained kanamycin. 
For the pUC18 control transformation, a pool of medium (195 µL) was placed on an 
LB-ampicillin agar plate. An aliquote of the control transformation reaction (5 µL) was 
added to the pool of medium and spread using a sterile spreader. 
The plates with the transformation reactions and the control were incubated overnight 
at 37 ºC. 
To conclude the transformation procedure, a liquid overnight culture was prepared 
from an isolated E. coli colony from the agar plate. For this, the LB medium (15 mL) 
was added to a 50 mL falcon tube, followed by kanamycin (15 µL of a 50 mg/mL 
solution in water). The isolated E. coli colony was scratched off the agar plate with a 
micropipette tip and swirled into the medium. The culture was incubated at 37 ºC 
overnight. 
For the over-expression of the cells, the overnight culture (1 mL) was used to inoculate 
LB medium (1 L) containing kanamycin (1 mL of a 50 mg/ml kanamycin solution) and 
set to incubate at 37 ºC until the cell density reached an absorbance at 0.6 at 600 nm. 
The culture was then cooled on ice for 30 min. A final concentration of 0.3 mM IPTG 
(from a 1 M stock solution) was added as induction procedure for FdrC over-
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expression. The incubation was continued at 25 °C for 24 h. The cells were harvested 
by centrifugation (3200 rpm for 15 min at 4°C). The supernatant was removed and the 
cell pellet was frozen at -80 ºC.  
To prepare glycerol stocks, 1000 µL of the 0.6 OD culture (before the addition of 
IPTG 1 M) were taken and added to 50% glycerol solution (400 µL). The mixture was 
stirred with a pipette and aliquoted to eppendorf tubes (200 µL each). The samples 
were flash-frozen in liquid nitrogen and kept at -80 ºC. 
Purification was carried out on a Ni2+ column. For this, the cell pellet was thawed at 
room temperature, and the cells were resuspended in lysis buffer (100 mL) with 5mg 
of DNAse and 1 protease cocktail pill. The cell suspension was lysed using a one-shot 
cell disrupter. The lysate was centrifuged (15000 rpm for 20 min) at 4 °C. The soluble 
fraction was filtered through a 0.45 µM filter and kept on ice. Samples (20 µL) of the 
soluble and insoluble lysate were reserved for the SDS-PAGE gel. 
The Ni2+ column (4 mL of sepharose-Ni beads) was washed with 3 column-volumes 
(CV) of water and then equilibrated with buffer A (5 CV). The soluble lysate was 
allowed to flow-through, reserving a sample (20 µL) for the SDS-PAGE gel. The 
column was washed with buffer A (2 x 1 CV), and a sample of each reserved on ice. 
Buffer B (2 x 1 CV) was eluted afterwards, followed by buffer C (3 x 1 CV), 
collecting samples for the SDS gel. 
NuPage buffer was added to each collected sample (see below for the corresponding 
amounts for the soluble and insoluble aliquots). The samples were boiled for 10 min. 
at 95 ºC and centrifuged (13000 rpm, 5 min.). An aliquot (7 µL) of each sample was 
loaded to an SDS-PAGE gel, along with ladder marker (10 µL), and the gel was run at 
200 V for 50 min. The gel was removed from the case and stained with instant blue 
stain for 40 min. 
The fractions eluted with buffer B and buffer C were diluted with Tris·HCl buffer (50 
mL, 20 mM, pH = 8) and loaded into dialysis tubing and set to dialyse against dialysis 
buffer (20 mM Tris–HCl pH 8.0, 100 mM NaCl) overnight at 4 ºC. 
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The protein was concentrated using a Vivaspin 10 KDa, by centrifuging at 4500 rpm 
for 30 minutes at 4 ºC, and repeating the procedure until a total volume of 
approximately 2 mL. The enzyme concentration was measured using OD280 nm 
(Nanodrop).   
5.6.5 Individual enzymatic assays 
5.6.5.1 Incubation of SAM (16) and fluoride with the fluorinase 
SAM·2HCl  (16, 1 mM) and KF (10 mM) were incubated for 24 h at 37 °C with a 
solution of fluorinase (0.5 mg/mL) in phosphate-citrate buffer (pH = 7.2). The 
fluorinase was denatured by heating (95 ºC, 10 min) and centrifuged (13000 rpm, 5 
min). The supernatant was analysed by 19F{1H} NMR. 19F{1H} NMR (470.40 MHz, 
deuterium oxide) δF -231.1 (5’-FDA, 17). 
5.6.5.2 Incubation of 5’-FDA (17) with purine nucleoside phosphorylase (PNP) 
5’-FDA (17, 1 mM) was added to an eppendorf tube and dissolved in phosphate-citrate 
buffer (pH = 7.6). PNP (approx. 5 mg, immobilised) was added, and the 
biotransformation incubated at 37 ºC for 16 h. The PNP was centrifuged and the 
supernatant was analysed by 19F{1H} NMR. 19F{1H} NMR (470.40 MHz, deuterium 
oxide) δ -230.7 (5-FDRP, 18). 
5.6.5.3 Incubation of 5-FDRP (18) with phytase 
5-FDRP (18, obtained enzymatically in Section 5.6.5.2) was incubated with phytase 
(120 mg) in phosphate-citrate buffer (pH = 5.1) at 48 ºC for 48 h. The phytase was 
denatured by heating (100 ºC, 10 min) and centrifuged. The supernatant was analysed 
by 19F{1H} NMR. 19F{1H} NMR (470.40 MHz, deuterium oxide) δF -228.3 (5-FDR, 
26),  -230.4 (5-FDR, 26), -230.7 (5-FDRP, 18), -230.8 (5’-FDA, spiked, 17). 
5.6.5.4 Incubation of 5-FDR (26) with FdrC 
Synthetic 5-FDR (26, 1 mM) was incubated with FdrC (2.7 mg/mL) in phosphate-
citrate buffer (pH = 7.1) at 37 ºC for 30 h. The enzyme was denatured by heating (95 
ºC, 10 min) and centrifuged. The supernatant was analysed by 19F{1H} NMR. 19F{1H} 
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NMR (470.40 MHz, deuterium oxide) δF -228.8 (5-FDR, 26), -231.1 (5-FDR, 26), -
233.5 (5’-FHPA, 2). 
5.6.5.5 Incubation of 5’-FDA (17) with nucleoside hydrolase (NH) 
5’-FDA (1 mM, 17) was added to an eppendorf tube and dissolved in phosphate buffer 
(20 mM, pH = 7.5). NH (200 µL, 54.3 mg/mL) was added, and the biotransformation 
incubated at 37 ºC for 24 h. The NH was denatured by heating (95 ºC, 10 min) and 
centrifuged; the supernatant was analysed by 19F{1H} NMR. 19F{1H} NMR (470.40 
MHz, deuterium oxide) δF -228.4 (5-FDR, 26), -230.7 (5-FDR, 26). 
5.6.6 Experiments via phytase 
5.6.6.1 Transformation from SAM (16) and fluoride to 5-FHPA (one pH) 
SAM·2HCl  (16, 140 µL, 10 mM) and KF (70 µL, 50 mM) were incubated for 24 h at 
37 °C with a solution of fluorinase (45 µL, 2.2 mg/mL), PNP (40 µL, recombinant, 
expressed in E. coli, Sigma-Aldrich), phytase from wheat (40 µL, 2.5 mg/mL, Sigma-
Aldrich), FdrC (37 µL, 2.7 mg/mL, expressed in E. coli) and NAD+ (70 µL, 10 mM) in 
PBS buffer. The proteins were denatured at 95 °C for 5 min and centrifuged at 13000 
rpm for 10 min. A mixture of the supernatant and D2O was analysed by 19F{1H} NMR 
spectroscopy. 19F{1H} NMR (470.40 MHz, H2O+D2O) δF -228.8 (5-FDR, 26), -231.1 
(5-FDR, 26), -231.1 (5-FDRP, 18), -231.2 (5’-FDI, 153), -231.3 (5’-FDA, 17), -233.5 
(5-FHPA, 2). 
5.6.6.1.1 Control Experiment 1: No fluorinase addition 
SAM·2HCl (16, 140 µL, 10 mM) and KF (70 µL, 50 mM) were incubated for 24 h at 
37 °C with a solution of PNP (40 µL, recombinant, expressed in E. coli, Sigma-
Aldrich), phytase from wheat (40 µL, 2.5 mg/mL, Sigma-Aldrich), FdrC (37 µL, 2.7 
mg/mL, expressed in E. coli) and NAD+ (70 µL, 10 mM) in PBS buffer. The proteins 
were denatured at 95 °C for 5 min and centrifuged at 13000 rpm for 10 min. A mixture 
of the supernatant and D2O was analysed by 19F{1H} NMR spectroscopy. 19F{1H} 
NMR (470.40 MHz, H2O+D2O) δF No fluorine peaks. 
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5.6.6.1.2 Control Experiment 2: No PNP addition 
SAM·2HCl (16, 140 µL, 10 mM) and KF (70 µL, 50 mM) were incubated for 24 h at 
37 °C with a solution of fluorinase (45 µL, 2.2 mg/mL), phytase from wheat (40 µL, 
2.5 mg/mL, Sigma-Aldrich), FdrC (37 µL, 2.7 mg/mL, expressed in E. coli) and NAD+ 
(70 µL, 10 mM) in PBS buffer. The proteins were denatured at 95 °C for 5 min and 
centrifuged at 13000 rpm for 10 min. A mixture of the supernatant and D2O was 
analysed by 19F{1H} NMR spectroscopy. 19F{1H} NMR (470.40 MHz, H2O+D2O) δF    
-231.3 (5’-FDA, 17). 
5.6.6.1.3 Control Experiment 3: No phytase addition 
SAM·2HCl (16, 140 µL, 10 mM) and KF (70 µL, 50 mM) were incubated for 24 h at 
37 °C with a solution of fluorinase (45 µL, 2.2 mg/mL), PNP (40 µL, recombinant, 
expressed in E. coli, Sigma-Aldrich), FdrC (37 µL, 2.7 mg/mL, expressed in E. coli) 
and NAD+ (70 µL, 10 mM) in PBS buffer. The proteins were denatured at 95 °C for 5 
min and centrifuged at 13000 rpm for 10 min. A mixture of the supernatant and D2O 
was analysed by 19F{1H} NMR spectroscopy. 19F{1H} NMR (470.40 MHz, 
H2O+D2O) δF -228.8 (5-FDR, 26), -231.1 (5-FDR, 26), -231.3 (5’-FDA, 17). 
5.6.6.1.4 Control Experiment 4: No FdrC addition 
SAM·2HCl (16, 140 µL, 10 mM) and KF (70 µL, 50 mM) were incubated for 24 h at 
37 °C with a solution of fluorinase (45 µL, 2.2 mg/mL), PNP (40 µL, recombinant, 
expressed in E. coli, Sigma-Aldrich), phytase from wheat (40 µL, 2.5 mg/mL, Sigma-
Aldrich) and NAD+ (70 µL, 10 mM) in PBS buffer. The proteins were denatured at 95 
°C for 5 min and centrifuged at 13000 rpm for 10 min. A mixture of the supernatant 
and D2O was analysed by 19F{1H} NMR spectroscopy. 19F{1H} NMR (470.40 MHz, 
H2O+D2O) δF -228.8 (5-FDR, 26), -231.1 (5-FDR, 26). 
5.6.6.1.5 Control Experiment 5: No NAD+ addition 
SAM·2HCl (16, 140 µL, 10 mM) and KF (70 µL, 50 mM) were incubated for 24 h at 
37 °C with a solution of fluorinase (45 µL, 2.2 mg/mL), PNP (40 µL, recombinant, 
expressed in E. coli, Sigma-Aldrich), phytase from wheat (40 µL, 2.5 mg/mL, Sigma-
Aldrich) and FdrC (37 µL, 2.7 mg/mL, expressed in E. coli) in PBS buffer. The 
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proteins were denatured at 95 °C for 5 min and centrifuged at 13000 rpm for 10 min. A 
mixture of the supernatant and D2O was analysed by 19F{1H} NMR spectroscopy. 
19F{1H} NMR (470.40 MHz, H2O+D2O) δF -228.8 (5-FDR, 26), -231.1 (5-FDRP, 18), 
-231.2 (5’-FDI, 153), -231.3 (5’-FDA, 17). 
5.6.6.2 Transformation from SAM 16 and fluoride to 5-FHPA 2 (three pHs) 
SAM·2HCl (16, 1 mM) and KF (10 mM) were added into an eppendorf tube, followed 
by phosphate-citrate buffer (pH = 7.2). The mixture was incubated for 24 h at 37 °C 
and 30 rpm with a solution of fluorinase (0.5 mg/mL) and PNP (approx. 5 mg, 
immobilised, GSK). The PNP was then filtered, and the fluorinase denatured (95 ºC) 
and centrifuged (13000 rpm, 5 min). The pH of the supernatant was acidified to 5.1 
with citric acid (dropwise addition, 1 M), and the phytase from wheat (110 mg) was 
added. The biotransformation was incubated at 40 ºC and 30 rpm for 48 h. The pH was 
risen to 7.1, causing the phytase to precipitate. The phytase was centrifuged (13000 
rpm, 5 min). FdrC (0.5 mg/mL) and NAD+ (5 mM) were added to the supernatant and 
incubated at 37 ºC for 30 h. FdrC was denatured at 95 °C for 5 min and centrifuged at 
13000 rpm for 10 min. A mixture of the supernatant and D2O was analysed by 19F{1H} 
NMR spectroscopy. 19F{1H} NMR (470.40 MHz, H2O+D2O) δF -230.7 (5-FDRP, 18),        
-233.5 (5-FHPA, 2).  
5.6.7 Experiments via NH 
5.6.7.1 Transformation from SAM (16) and fluoride to 5-FHPA (2) in PBS buffer 
SAM·2HCl (16, 1 mM) and KF (10 mM) were incubated for 48 h at 37 °C with a 
solution of fluorinase (1.7 mg/mL), NH (3.6 mg/mL), FdrC (2.7 mg/mL) and NAD+ (5 
mM) in PBS buffer (pH = 7.4). The proteins were denatured at 95 °C for 5 min and 
centrifuged at 13000 rpm for 10 min. A mixture of the supernatant and D2O was 
analysed by 19F{1H} NMR spectroscopy. 19F{1H} NMR (470.40 MHz, H2O+D2O) δF    
-228.4 (5-FDR, 26), -230.7 (5-FDR, 26), -230.8 (5’-FDI, 153), -231.1 (5’-FDA, 17),    
-233.2 (5-FHPA, 2). 
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5.6.7.2 Transformation from SAM (16) and fluoride to 5-FHPA (2) in phosphate 
buffer 
SAM·2HCl (16, 1 mM) and KF (10 mM) were incubated for 24 h at 37 °C with a 
solution of fluorinase (0.5 mg/mL), NH (1.5 mg/mL), FdrC (37 µL, 2.7 mg/mL, 
expressed in E. coli) and NAD+ (70 µL, 10 mM) in phosphate buffer (pH = 8). The 
biotransformation was supplemented with MgCl2 (2.7 mg/mL). The enzymes were 
denatured at 95 °C for 5 min and centrifuged at 13000 rpm for 10 min. A mixture of 
the supernatant and D2O was analysed by 19F{1H} NMR spectroscopy. 19F{1H} NMR 
(470.40 MHz, H2O+D2O) δF -233.2 (5-FHPA, 2). 
5.6.7.3 Transformation from SAM (16) and fluoride to 5-FHPA (2) in Tris·HCl 
buffer 
SAM·2HCl (16, 1 mM) and KF (10 mM) were incubated for 24 h at 37 °C with a 
solution of fluorinase (0.5 mg/mL), NH (2.7 mg/mL), FdrC (2.7 mg/mL) and NAD+ 
(10 mM) in Tris·HCl buffer (25 mM, pH = 7.8). The biotransformation was 
supplemented with MgCl2 (1 mM). The enzymes were denatured at 95 °C for 5 min 
and centrifuged at 13000 rpm for 10 min. A mixture of the supernatant and D2O was 
analysed by 19F{1H} NMR spectroscopy. 19F{1H} NMR (470.40 MHz, H2O+D2O) δF     
-231.1 (5’-FDA, 17), -233.2 (5-FHPA, 2). 
5.6.8 Biotransformations with LDH as recycling agent for NAD+ 
5.6.8.1 Biotransformation of fluoropyruvate (162) with LDH 
Fluoropyruvate (162, 1 mM) was incubated with LDH from rabbit muscle (5 µL, 
Sigma Aldrich) and NADH (1 mM) in phosphate buffer (20 mM, pH = 7.5) for 18 h at 
37 ºC. The enzyme was denatured by heating (95 ºC, 10 min) and centrifuged. 
Analysis of the supernatant by 19F{1H} NMR indicated full conversion into (2R)-3-
fluorolactate (163). 19F{1H} NMR (470.40 MHz, H2O+D2O) δF -228.7 (163). 
5.6.8.2 Biotransformation of SAM (16) and KF to 5-FHPA (2) via LDH recycling 
SAM·2HCl (16, 1 mM) and KF (10 mM) were incubated for 24 h at 37 °C with a 
solution of fluorinase (0.5 mg/mL), NH (2.7 mg/mL), FdrC (2.7 mg/mL), pyruvate 
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(1.5 mM), LDH (5 µL), and NAD+ (0.5 mM) in Tris·HCl buffer (25 mM, pH = 7.8). 
The biotransformation was supplemented with MgCl2 (1 mM). The enzymes were 
denatured at 95 °C for 5 min and centrifuged at 13000 rpm for 10 min. A mixture of 
the supernatant and D2O was analysed by 19F{1H} NMR spectroscopy. 19F{1H} NMR 
(470.40 MHz, H2O+D2O) δF -231.1 (5’-FDA, 17), -233.2 (5-FHPA, 2). 
5.6.8.3 Biotransformation of 5-FDR (26) via LDH recycling 
5-FDR (26, 1 mM) was incubated for 20 h at 48 °C with a solution of FdrC (2.7 
mg/mL), pyruvate (1.5 mM), LDH (5 µL), and NAD+ (0.5 mM) in Tris·HCl buffer (25 
mM, pH = 7.5). The biotransformation was supplemented with MgCl2 (1 mM). The 
enzymes were denatured at 95 °C for 5 min and centrifuged at 13000 rpm for 10 min. 
A mixture of the supernatant and D2O was analysed by 19F{1H} NMR spectroscopy. 
19F{1H} NMR (470.40 MHz, H2O+D2O) δF -228.5 (5-FDR, 26), -230.7 (5-FDR, 26),   
-233.2 (5-FHPA, 2). 
5.6.8.4 Preparative scale biotransformation of 5’-FDA (17) via LDH recycling 
5’-FDA (17, 1 mM) was incubated for 20 h at 37 °C with a solution of NH (3.0 
mg/mL), FdrC (2.7 mg/mL), pyruvate (1.5 mM), LDH (5 µL), and NAD+ (0.5 mM) in 
Tris·HCl buffer (25 mM, pH = 7.5). The biotransformation was supplemented with 
MgCl2 (1 mM). The enzymes were denatured at 95 °C for 5 min and centrifuged at 
13000 rpm for 10 min. A mixture of the supernatant and D2O was analysed by 19F{1H} 
NMR spectroscopy. 19F{1H} NMR (470.40 MHz, H2O+D2O) δF -233.2 (5-FHPA, 2). 
5.6.9 Biotransformations with FMN as recycling agent for NAD+ 
5.6.9.1 Biotransformation of SAM (16) and KF via FMN recycling (analytical scale) 
SAM·2HCl (16, 1 mM) and KF (10 mM) were incubated for 18 h at 37 °C with a 
solution of fluorinase (0.5 mg/mL), NH (2.7 mg/mL), FdrC (2.7 mg/mL), FMN (12 
mM), and NAD+ (0.1 mM) in Tris·HCl buffer (25 mM, pH = 7.8). The 
biotransformation was supplemented with MgCl2 (1 mM). The enzymes were 
denatured at 95 °C for 5 min and centrifuged at 13000 rpm for 10 min. A mixture of 
the supernatant and D2O was analysed by 19F{1H} NMR spectroscopy. 19F{1H} NMR 
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(470.40 MHz, H2O+D2O) δF -231.1 (5’-FDA, 17), -233.2 (5-FHPA, 2), minimal traces 
of both. 
5.6.9.2 Biotransformation of 5’-FDA (17) via FMN recycling (analytical scale) 
5’-FDA (17, 1 mM) was incubated for 20 h at 37 °C with a solution of NH (3.0 
mg/mL), FdrC (2.7 mg/mL), FMN (12 mM), and NAD+ (0.1 mM) in Tris·HCl buffer 
(25 mM, pH = 7.5). The biotransformation was supplemented with MgCl2 (1 mM). 
The enzymes were denatured at 95 °C for 5 min and centrifuged at 13000 rpm for 10 
min. A mixture of the supernatant and D2O was analysed by 19F{1H} NMR 
spectroscopy. 19F{1H} NMR (470.40 MHz, H2O+D2O) δF -233.2 (5-FHPA, 2). 
5.6.9.3 Biotransformation of SAM (16) and KF via FMN recycling (preparative 
scale) 
SAM·2HCl (16, 5 mg, 1 mM) and KF (10 mM) were incubated for 48 h at 37 °C with 
a solution of fluorinase (2 mg/mL), NH (3.0 mg/mL), FdrC (3.0 mg/mL), FMN (12 
mM), and NAD+ (0.1 mM) in Tris·HCl buffer (25 mM, pH = 7.8). The 
biotransformation was supplemented with MgCl2 (0.5 mM), and was adjusted to a total 
volume of 5 mL. The enzymes were denatured at 95 °C for 5 min and centrifuged at 
13000 rpm for 10 min. A mixture of the supernatant and D2O was analysed by 19F{1H} 
NMR spectroscopy. 19F{1H} NMR (470.40 MHz, H2O+D2O) δF -231.1 (5’-FDA, 17). 
5.6.9.4 Biotransformation of 5’-FDA (17) via FMN recycling (preparative scale) 
5’-FDA (17, 10 mg) was incubated for 20 h at 37 °C with a solution of NH (3.0 
mg/mL), FdrC (2.7 mg/mL), FMN (12 mM), and NAD+ (0.5 mM) in Tris·HCl buffer 
(25 mM, pH = 7.5). The biotransformation was supplemented with MgCl2 (1 mM), and 
adjusted to a total volume of 5 mL. The enzymes were denatured at 95 °C for 5 min 
and centrifuged at 13000 rpm for 10 min. A mixture of the supernatant and D2O was 
analysed by 19F{1H} NMR spectroscopy. 19F{1H} NMR (470.40 MHz, H2O+D2O) δF     
-233.2 (5-FHPA, 2). 
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4.6.9.5 Biotransformation of 5-FDR (26) via FMN recycling (preparative scale) 
5-FDR (26, 10 mg, 1 mM) was incubated for 48 h at 48 °C with a solution of FdrC 
(3.0 mg/mL), FMN (12 mM) and NAD+ (0.1 mM) in Tris·HCl buffer (25 mM, pH = 
7.5). The biotransformation was supplemented with MgCl2 (0.5 mM), and was 
adjusted to a total volume of 5 mL. The enzymes were denatured at 95 °C for 5 min 
and centrifuged at 13000 rpm for 10 min. A mixture of the supernatant and D2O was 
analysed by 19F{1H} NMR spectroscopy. 19F{1H} NMR (470.40 MHz, H2O+D2O) δF    
-228.5 (5-FDR, 26), -230.7 (5-FDR, 26), -233.2 (5-FHPA, 2). 
5.6.10 Scale-up of the biosynthesis of 5-FHPA (2) from 5’-FDA (17) 
5’-FDA (17, 50 mg, 27 mM) was incubated for 1 week at 37 °C with a solution of NH 
(4.0 mg/mL), FdrC (4.0 mg/mL), FMN (40 mM), and NAD+ (0.5 mM) in Tris·HCl 
buffer (25 mM, pH = 7.5). The biotransformation was supplemented with MgCl2 (0.5 
mM), and the total volume adjusted to 7 mL. The enzymes were denatured at 95 °C for 
5 min and centrifuged at 13000 rpm for 10 min. A mixture of the supernatant and D2O 
was analysed by 19F{1H} NMR spectroscopy. 19F{1H} NMR (470.40 MHz, 
H2O+D2O) δF -228.5 (5-FDR, 26), -230.7 (5-FDR, 26), -233.2 (5-FHPA, 2). 
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5.7 Fluorometabolite studies in Streptomyces sp. MA37 (Chapter 4) 
5.7.1 Media preparation 
5.7.1.1 Yeast-Malt Broth (ISP Medium Nº 2) for S. sp. MA37 
Peptic digest of animal tissue (5 g), yeast extract (3 g), malt extract (3 g) and dextrose 
(10 g) were added to a beaker containing a stirring bar, and dissolved in tap water (800 
mL).* The pH was adjusted to 7.0 by dropwise addition of HCl (1 M) while stirring 
vigorously. The solution was transferred to a measuring cylinder, the total volume was 
adjusted to 1 L, and the mixture transferred into a Duran bottle for sterilisation in the 
same day. The sterile medium was stored at 4 ºC. 
* This medium was supplemented with KF (0.5 M) to a final concentration of 2.5 mM 
when necessary, as indicated in each experiment. Supplementation occurred prior to 
the pH adjustment. 
5.7.1.2 Yeast-Malt Agar (YM Agar, ISP Medium Nº 2) for S. sp. MA37 
Peptic digest of animal tissue (5 g), yeast extract (3 g), malt extract (3 g), dextrose (10 
g) and agar (20 g) were added to a beaker containing a stirring bar, and dissolved in tap 
water (800 mL).* The pH was adjusted to 7.0 by dropwise addition of HCl (1 M) 
while stirring vigorously. The solution was transferred to a measuring cylinder, the 
total volume was adjusted to 1 L, and the mixture transferred into a Duran bottle for 
sterilisation in the same day. The sterile medium was stored at 4 ºC. 
* This medium was supplemented with KF (0.5 M) to a final concentration of 2.5 mM 
when necessary, as indicated in each experiment. Supplementation occurred prior to 
the pH adjustment. 
5.7.1.3 Fermentation culture for S. cattleya 
Ion solution (150 mL), filtered carbon solution (75 mL), sterile phosphate buffer (75 
mL, 150 mM, pH = 7) and sterile KF (3 mL, 0.5 M) were mixed with sterile ultra-pure 
water (450 mL). 
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The ion solution (trace elements solution) was prepared with ammonium chloride 
(6.75 g), sodium chloride (2.25 g), magnesium sulfate heptahydrate (2.25 g), calcium 
carbonate (1.13 g), iron sulfate heptahydrate (113 mg), cobalt chloride hexahydrate (45 
mg) and zinc sulfate heptahydrate (45 mg) in ultra-pure water (900 mL). 
The filtered carbon source solution was prepared by dissolving glycerol (45 g), 
monosodium glutamate (22.5 g), myo-inositol (1.8 g) and p-aminobenzoic acid (450 
µL, 1 mg/mL solution) in ultra-pure water (900 mL). The solution was sterilised by 
filtration into a pre-sterilised Schott bottle. 
5.7.1.4 Growth of S. cattleya on solid media 
Soybean flour (2% w/v), mannitol (2% w/v), and agar (1.5% w/v) were dissolved in 
tap water and sterilised before use. 
5.7.1.5 TSBY Rich Medium 
Tryptic soy broth (30 g), sucrose (103 g) and yeast extract (5 g) were dissolved in 
distilled water (800 mL) in a beaker, and the mixture was stirred until complete 
homogenisation. The solution was transferred to a measuring cylinder, and the total 
volume was adjusted to 1 L. The medium was autoclaved in a glass bottle, and stored 
at 4 ºC. 
5.7.2 Preparation of cell-free extracts (CFE) from S. sp. MA37 
A liquid culture of S. sp. MA37 was prepared using ISP2 media, following the usual 
procedure. After 8 days of fermentation, the cells were centrifuged (r.t., 13000 rpm, 20 
minutes). The cell pellets were washed with phosphate buffer (50 mM, pH 7.0) and 
centrifuged. The washing procedure was repeated three times. The resultant pellet was 
stored at -80 °C. A sample of the frozen pellet was thawed and re-suspended in 
phosphate buffer (200 mM, pH 6.8), keeping a concentration of 0.2 g of wet pellet per 
mL of buffer solution.  The cells were disrupted by sonication (60% duty cycle for 30 
– 60 seconds), repeating the procedure three times. Cell debris was removed by 
centrifugation (r.t., 13000 rpm, 30 minutes), and the supernatant was used as a CFE for 
incubation experiments. CFEs were supplemented with or without the different target 
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molecules at 37 °C between 6 and 22 hours. All the CFE experiments were prepared to 
a final concentration of 3 mM of substrate, unless stated otherwise. After the 
incubation, the protein was precipitated by heating at 95 °C for 5-10 min, and then 
removed by centrifugation (13000 rpm, 20 minutes). The results were analysed by 19F-
NMR.  
5.7.2.1 CFE incubation of SAM (16) and KF 
SAM (16, 300 µL, 10 mM) and KF (60 µL, 50 mM) were incubated for 16 h with CFE 
(640 µL, 0.1 g/mL) of S. sp. MA37. The sample was then heated (95 °C, 5 min), and 
the denatured protein removed by centrifugation (13000 rpm, 20 minutes). A mixture 
of the supernatant (650 µL) and D2O (100 µL) was analysed by 19F{1H} NMR 
spectroscopy. 19F{1H} NMR (470.40 MHz, H2O+D2O) δF -119.4 (fluoride ion). 
5.7.2.2 CFE incubation of 5’-FDA (17) 
5’-FDA (17, 300 µL, 10 mM) was incubated for 16 h with a CFE (700 µL, 0.1 g/mL) 
of S. sp. MA37. The sample was then heated (95 °C, 5 min), and the denatured protein 
removed by centrifugation (13000 rpm, 20 minutes). A mixture of the supernatant (650 
µL) and D2O (100 µL) was analysed by 19F{1H} NMR spectroscopy.  19F{1H} NMR 
(470.40 MHz, H2O+D2O) δF -230.7 (5-FDRP, 18), -230.9 (5’-FDI, 153), -231.0 (5’-
FDA, 17) and -231.4 (unknown). 
5.7.2.3 CFE incubation of 5’-FDI (153) 
5’-FDI (153) was incubated for 20 h with a CFE (700 µL, 0.2 g/mL) of S. sp. MA37. 
The sample was then heated (95 °C, 5 min), and the denatured protein removed by 
centrifugation (13000 rpm, 20 minutes). A mixture of the supernatant (650 µL) and 
D2O (100 µL) was analysed by 19F{1H} NMR spectroscopy. 19F{1H} NMR (470.40 
MHz, H2O+D2O) δF -230.9 (5’-FDI, 153). 
5.7.2.4 CFE incubation of 5-FDR (26) 
5-FDR (26, 300 µL, 10 mM) was incubated for 16 h with a CFE (700 µL, 0.1 g/mL) of 
S. sp. MA37. The sample was then heated (95 °C, 5 min), and the denatured protein 
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removed by centrifugation (13000 rpm, 20 minutes). A mixture of the supernatant (650 
µL) and D2O (100 µL) was analysed by 19F{1H} NMR spectroscopy. 19F{1H} NMR 
(470.40 MHz, H2O+D2O) δF -228.2 (unknown), -228.3 (unknown), -228.8 (5-FDR, 
26), -228.8 (unknown), -230.8 (unknown), -231.0 (5-FDR, 26), -231.4 (unknown),       
-233.1 (unknown) and -233.5 (5-FHPA, 2). 
5.7.3 Preparation of a cell-free extract of S. cattleya 
A liquid culture of S. cattleya was prepared inoculating a sample of the organism 
stocked in glycerol stock into a culture of S. cattleya fermentation media. After 8 days 
of fermentation, the cells were centrifuged (r.t., 13000 rpm, 20 min). The cell pellets 
were washed with phosphate buffer (50 mM, pH 7.0). The suspension was centrifuged, 
and the pellet was stored at -80 °C. The pellet was thawed and re-suspended in 
phosphate buffer (200 mM, pH 6.8), keeping a concentration of 0.2 g of wet pellet per 
mL of buffer solution.  The cells were disrupted by sonication (60% duty cycle for 30 
– 60 seconds), repeating the procedure three times. Cell debris was removed by 
centrifugation (r.t., 13000 rpm, 30 min). The supernatant was used as a CFE for 
incubation experiments. CFE were supplemented with or without the different target 
molecules at 37 °C for 16 h. All the CFEs experiments were prepared to a final 
concentration of 3 mM of substrate, unless stated otherwise. After the incubation, 
protein was precipitated by heating at 95 °C for 5-10 min, and removed by 
centrifugation (13000 rpm, 20 minutes). Results were analysed by 19F{1H} NMR 
spectroscopy.  
5.7.3.1 CFE incubation of SAM (16) and KF 
SAM (16, 300 µL, 10 mM) and KF (60 µL, 50 mM) were incubated 16 h with a CFE 
(640 µL, 0.1 g/mL) of S. cattleya. The sample was then heated (95 °C, 5 min), and the 
denatured protein removed by centrifugation (13000 rpm, 20 min). A mixture of the 
supernatant (650 µL) and D2O (100 µL) was analysed by 19F{1H} NMR spectroscopy. 
19F{1H} NMR (470.40 MHz, H2O+D2O) δF -231.2 (4-FT, 4).  
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5.7.3.2 CFE incubation of 5’-FDA (17) 
5’-FDA (17, 300 µL, 10 mM) was incubated for 16 h with a CFE (700 µL, 0.1 g/mL) 
of S. cattleya. The sample was then heated (95 °C, 5 min), and the denatured protein 
removed by centrifugation (13000 rpm, 20 min). A mixture of the supernatant (650 
µL) and D2O (100 µL) was analysed by 19F{1H} NMR spectroscopy. 19F{1H} NMR 
(470.40 MHz, H2O+D2O) δF -217.2 (FAc, 1), -231.0 (unknown), -231.2 (4-FT, 4). 
5.7.4 5’-FDA (17) enzymatic transformations (Section 4.4.1) 
5.7.4.1 5’-FDA (17) reaction with NH 
A mixture of 5’-FDA (17, 500 µL, 10 mM), phosphate buffer (20 µL, 1M, pH 8.0), 
NH (100 µL, 10 mg/mL) and sterile water (480 µL) was incubated for 16 h. The 
protein was denatured at 95 °C for 5 min and centrifuged at 13000 rpm for 10 min. A 
mixture of the supernatant and D2O was analysed by 19F{1H} NMR spectroscopy. 
19F{1H} NMR (470.40 MHz, H2O+D2O) δF -228.8 (5-FDR, 26), -231.1 (5-FDR, 26),   
-231.3 (5’-FDI, 153), -231.5 (5’-FDA, 17). 
5.7.4.2 5’-FDA (17) reaction with ADA 
A mixture of 5’-FDA (17, 500 µL, 10 mM), phosphate buffer (20 µL, 1M, pH 7.5), 
ADA (365 µL) and sterile water (144 µL) was incubated for 16 h. The protein was 
denatured at 95 °C for 5 min and centrifuged at 13000 rpm for 10 min. A mixture of 
the supernatant and D2O was analysed by 19F{1H} NMR spectroscopy. 19F{1H} NMR 
(470.40 MHz, H2O+D2O) δF -228.8 (5-FDR, 26), -231.1 (5-FDR, 26), -231.2 (5’-FDI, 
153), -231.3 (5’-FDA, 17), -231.5 (unknown), -231.7 (unknown). 
5.7.4.3 5’-FDA (17) reaction with PNP 
A mixture of 5’-FDA (17, 500 µL, 10 mM), phosphate buffer (50 µL, 1M, pH 7.8), 
PNP (200 µL) and sterile water (250 µL) was incubated for 16 h. The protein was 
denatured at 95 °C for 5 min and centrifuged at 13000 rpm for 10 min. A mixture of 
the supernatant and D2O was analysed by 19F{1H} NMR spectroscopy. 19F{1H} NMR 
(470.40 MHz, H2O+D2O) δF -231.0 (5-FDRP, 18), -231.1 (5’-FDI, 153), -231.3 (5’-
FDA, 17). 
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5.7.5 Incubations in whole cell cultures of S. sp. MA37 
5.7.5.1 Incubation of 5’-FDA (17). Day 0 
S. sp. MA37 (200 µL of a glycerol stock) was inoculated into a flask containing ISP 
Medium Nº 2 (50 mL). 5’-FDA (17, 5 mg) was added to the flask, and the culture was 
left to incubate at 30 ºC and 180 rpm for 20 days. The culture was then sonicated, and 
the cell debris removed by centrifugation (8000 rpm, 20 min). The supernatant was 
freeze-dried and analysed by 19F{1H} NMR spectroscopy. 19F{1H} NMR (470.40 
MHz, D2O) δF -216.9 (FAc, 1), -228.5 (unknown), -228.5 (5-FDR, 26), -230.9 
(unknown), -231.2 (4-FT, 4), -232.7 (unknown), -233.2 (5-FHPA, 2).  
5.7.5.2 Incubation of 5’-FDA (17). Day 8 
S. sp. MA37 (200 µL of a glycerol stock) was inoculated into a flask containing ISP 
Medium Nº 2 (50 mL), and the culture grown for 8 days at 30 ºC and 180 rpm. 5’-FDA 
17 (5 mg) was added to the flask, and the culture was left to incubate at 30 ºC and 180 
rpm for further 12 days. The culture was then sonicated, and the cell debris removed 
by centrifugation (8000 rpm, 20 min). The supernatant was freeze-dried and analysed 
by 19F{1H} NMR spectroscopy. 19F{1H} NMR (470.40 MHz, D2O) δF -217.0 (FAc, 1), 
-230.8 (5’-FDA, 17), -231.2 (4-FT, 4). 
5.7.5.3 Incubation of [5’,5’-2H2]-5’-FDA (17a). Day 0 
S. sp. MA37 (from a seed culture grown for 2 days) was inoculated into a flask 
containing ISP Medium Nº 2 (50 mL). [5’,5’-2H2]-5’-FDA 17a (8 mg) was added to 
the flask, and the culture was left to incubate at 30 ºC and 180 rpm for 12 days. The 
culture was then sonicated, and the cell debris removed by centrifugation (8000 rpm, 
20 min). The supernatant was freeze-dried and analysed by 19F{1H} NMR 
spectroscopy. 19F{1H} NMR (470.40 MHz, D2O) δF -216.9 (s, FAc, 1), -217.5 (t, J = 
8.1 Hz, [2H1]-FAc, 1b), -218.0 (p, J = 14.0, 8.1 Hz, [2H2]-FAc, 1a), -227.6 (s, 
unknown), -227.8 (s, unknown), -228.9 (m, unknown, possible 5-FDR, 26), -230.7 (s, 
unknown), -231.3 (m, unknown), -231.4 (s, 4-FT, 4), -231.9 (s, unknown), -232.0 (m, 
[2H1]-4-FT, 4b), -232.0 (m, unknown), -232.6 (p, J = 13.0, 5.9 Hz, [2H2]-4-FT, 4a),      
-233.8 (m, [2H1]-5-FHPA), -234.3 (m, [2H2]-5FHPA), -236.1 (m, unknown). 
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5.7.5.4 Incubation of [5’,5’-2H2]-5’-FDA (17a). Day 4, 5 and 6; without KF 
S. sp. MA37 (from a seed culture grown for 2 days) was inoculated into a flask 
containing ISP Medium Nº 2 (50 mL), and the culture grown for 4 days at 30 ºC and 
180 rpm. [5’,5’-2H2]-5’-FDA 17a (2 mg, each, approx.) was added on days 4, 5 and 6, 
and the culture was left to incubate at 30 ºC and 180 rpm for further 6 days. The 
culture was then sonicated, and the cell debris removed by centrifugation (8000 rpm, 
20 min). The supernatant was freeze-dried and analysed by 19F{1H} NMR 
spectroscopy. 19F{1H} NMR (470.40 MHz, D2O) δF -217.0 (s, FAc, 1), -217.5 (t, J = 
8.1 Hz, [2H1]-FAc, 1b), -218.2 (p, J = 14.5, 8.1 Hz, [2H2]-FAc, 1a), -227.7 (s, 
unknown), -227.9 (m, unknown), -229.0 (m, unknown), -230.8 (s, unknown), -231.4 
(m, unknown), -231.5 (s, 4-FT, 4), -231.5 (m, unknown), -232.0 (s, unknown), -232.1 
(m, [2H1]-4-FT, 4b), -232.1 (m, unknown), -232.7 (m, [2H2]-4-FT, 4a). 
5.7.5.5 Incubation of [5’,5’-2H2]-5’-FDA (17a). Days 4, 5 and 6; with KF 
S. sp. MA37 (from a seed culture grown for 2 days) was inoculated into a flask 
containing ISP Medium Nº 2 (50 mL), along with KF (0.2 mM) and the culture grown 
for 4 days at 30 ºC and 180 rpm. [5’,5’-2H2]-5’-FDA 17a (2 mg, each, approx.) was 
added on days 4, 5 and 6, and the culture was left to incubate at 30 ºC and 180 rpm for 
further 6 days. The culture was then sonicated, and the cell debris removed by 
centrifugation (8000 rpm, 20 min). The supernatant was freeze-dried and analysed by 
19F{1H} NMR spectroscopy. 19F{1H} NMR (470.40 MHz, D2O) δF -216.9 (s, FAc, 1), 
-217.4 (t, J = 8.1 Hz, [2H1]-FAc, 1b), -218.2 (p, J = 14.5, 8.1 Hz, [2H2]-FAc, -227.3 (s, 
unknown), -227.6 (s, unknown), -227.7 (s, unknown), -227.9 (m, unknown), -228.2 
(m, unknown), -228.3 (m, unknown), -228.4 (m, unknown), -228.6 (m, unknown),       
-228.7 (s, unknown), -228.8 (m, unknown), -228.9 (m, unknown), -229.6 (s, 
unknown), -229.9 (m, unknown), -230.6 (s, unknown), -230.8 (m, unknown), -231.0 
(s, unknown), -231.2 (m, unknown), -231.2 (s, 4-FT, 4), -231.4 (m, unknown), -231.8 
(s, unknown), -231.9 (m, [2H1]-4-FT, 4b), -231.9 (m, unknown), -232.5 (m, [2H2]-4-
FT, 4a), -232.6 (s, unknown), -233.1 (s, 5-FHPA, 2), -234.8 (m, unknown). 
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Appendix – Crystallographic Data 
3,4-Difluoro-5-phenylcyclohexan-1-ol (80) 
 
Code: agdh1 
Structure Type: Crystal 
Chemical Formula: C12 H14 F2 O  
Display Formula: C12 H14 F2 O  
Spacegroup: P 21 21 21 
  (Allows Chirality) 
Crystal System: Orthorhombic 
  a: 5.2589 Å 
  b: 9.7524 Å 
  c: 20.4698 Å 
Asymmetric Unit: 29 sites 
Unit Cell: 116 sites per unit cell 
Site Density: 0.1105 sites/Å³ 
Visible Atoms: 29 
Cell Volume: 1049.832 Å³ 
Density: 1.3428 g/cm³ 
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4-Fluoro-3-phenylcyclohexan-1-ol (81) 
 
Code: agdh6 
Structure Type: Crystal 
 Chemical Formula: C12 H14.8 F O  
 Display Formula: C12 H14.8 F O  
 Spacegroup: P 21 21 21 
  (Allows Chirality) 
 Crystal System: Orthorhombic 
 a: 5.3302 Å 
 b: 9.6528 Å 
 c: 20.0332 Å 
 Asymmetric Unit: 30 sites 
 Unit Cell: 120 sites per unit cell 
 Site Density: 0.1164 sites/Å³ 
  0.1118 atoms/Å³ 
 Visible Atoms: 30 
 Cell Volume: 1030.743 Å³ 
 Density: 1.2504 g/cm³ 
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2,3-Difluoro-4-phenylcyclohexan-1-ol (82) 
 
Code: agdh2 
Structure Type: Crystal 
 Chemical Formula: C12 H14 F2 O  
 Display Formula: C12 H14 F2 O  
 Spacegroup: P 21/a 
 Crystal System: Monoclinic 
  a: 13.5173 Å 
  b: 5.5730 Å 
  c: 27.4909 Å 
  β: 90.469° 
 Asymmetric Unit: 58 sites 
 Unit Cell: 232 sites per unit cell 
 Site Density: 0.1120 sites/Å³ 
 Visible Atoms: 29 
 Cell Volume: 2070.884 Å³ 
 Density: 1.3614 g/cm³ 
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3,4-Difluoro-5-phenylcyclohexan-1-ol (83) 
 
Code: agdh4 
Structure Type: Crystal 
 Chemical Formula: C12 H14 F2 O  
 Display Formula: C12 H14 F2 O  
 Spacegroup: P 21/c 
 Crystal System: Monoclinic 
  a: 10.5360 Å 
  b: 19.9830 Å 
  c: 10.2720 Å 
  β: 107.972° 
 Asymmetric Unit: 58 sites 
 Unit Cell: 232 sites per unit cell 
 Site Density: 0.1128 sites/Å³ 
 Visible Atoms: 29 
 Cell Volume: 2057.154 Å³ 
 Density: 1.3705 g/cm³ 
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4-(2,3,6-trifluoro-1-hydroxycyclohexyl)benzoic acid (90) 
 
Code: agdh5 
Structure Type: Crystal 
 Chemical Formula: C41.5 H34 F9 O9  
 Display Formula: C14 H11 F3 O3  
 Spacegroup: P 1 
  (Allows Chirality; Polar) 
 Crystal System: Triclinic 
  a: 6.0731 Å 
  b: 13.2193 Å 
  c: 23.0241 Å 
  α: 94.519° 
  β: 93.658° 
  γ: 101.657° 
 Asymmetric Unit: 187 sites 
 Unit Cell: 187 sites per unit cell 
 Site Density: 0.1040 sites/Å³ 
 Visible Atoms: 31 
 Cell Volume: 1798.637 Å³ 
 Density: 1.5652 g/cm³ 
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4-((1,1-Difluoroethyl)sulfinyl)phenol (113) 
 
Code: agdh14 
Structure Type: Crystal 
 Chemical Formula: C8 H8 F2 O2 S  
 Display Formula: C8 H8 F2 O2 S  
 Spacegroup: P 21 21 21 
  (Allows Chirality) 
 Crystal System: Orthorhombic 
  a: 8.5526 Å 
  b: 9.2693 Å 
  c: 10.9710 Å 
 Asymmetric Unit: 21 sites 
 Unit Cell: 84 sites per unit cell 
 Site Density: 0.0966 sites/Å³ 
 Visible Atoms: 21 
 Cell Volume: 869.744 Å³ 
 Density: 1.5748 g/cm³ 
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Metabolism and hydrophilicity of the polarised
‘Janus face’ all-cis tetraﬂuorocyclohexyl ring,
a candidate motif for drug discovery†
Andrea Rodil,a Stefano Bosisio,b Mohammed Salah Ayoup,ad Laura Quinn,c
David B. Cordes, a Alexandra M. Z. Slawin, a Cormac D. Murphy,c Julien Michel*b
and David O'Hagan *a
The metabolism and polarity of the all-cis tetra-ﬂuorocyclohexane motif is explored in the context
of its potential as a motif for inclusion in drug discovery programmes. Biotransformations of
phenyl all-cis tetra-, tri- and di- ﬂuoro cyclohexanes with the human metabolism model
organism Cunninghamella elegans illustrates various hydroxylated products, but limited to
benzylic hydroxylation for the phenyl all-cis tetraﬂuorocyclohexyl ring system. Evaluation of the
lipophilicities (log P) indicates a signiﬁcant and progressive increase in polarity with increasing
ﬂuorination on the cyclohexane ring system. Molecular dynamics simulations indicate that water
associates much more closely with the hydrogen face of these Janus face cyclohexyl rings than the
ﬂuorine face owing to enhanced hydrogen bonding interactions with the polarised hydrogens
and water.
Introduction
Approximately one third of drugs on the market or in devel-
opment contain at least one uorine atom1 and around a third
of herbicides historically,2 and half the commercial pesticides
introduced in the last period (2010–2016)3 contain uorine
atoms. The element is also important in organic materials
with applications in next generation displays4 and high value
materials.5 The investigation of new products bearing uori-
nated moieties is an ever expanding eld, given the particular
properties that uorine bestows on organic compounds.6 We
have recently synthesised all-cis 1,2,4,5-tetrauorocyclohexane
ring systems such as 1 and 2 as a novel motif in organic
chemistry.7 This tetrauorocyclohexane isomer displays
a particular polar property across the cyclohexane, largely
because all of the uorines are on one face of the ring and
there are two 1,3-diaxial C–F bonds, with dipoles orientated
parallel to each other.
As an extreme example, we extended this concept to the
preparation and analysis of all-cis hexauorocyclohexane 3
which is even more polar due to a cyclohexane ring accommo-
dating three axial C–F bonds.8a This cyclohexane has been
referred to as a ‘Janus’-like molecule,8b because of its very well
diﬀerentiated faces, and recent experimental and theoretical
studies have indicated that these rings will coordinate cations to
the uorine face and anions to the hydrogen face, consistent
with the electrostatic polarity of the ring system.9 The confor-
mational and polar properties of these multi-vicinal uorinated
aliphatics is beginning to attract the attention of the synthesis
community and new methods are emerging for their prepara-
tion, for example, from the Gilmour,9 Jacobsen10 and Carreira11
laboratories. For the cyclohexanes, a recent report fromGlorius's
laboratory12 has demonstrated the direct catalytic hydrogenation
of uorinated aromatics to generate all-cis uorinated cyclo-
hexanes in a single step, and this methodology promises to
make compounds such as cyclohexanes 1 and 3 much more
accessible to the organic chemistry community. With these
developments in synthesis methods, we believe the cyclohexane
motif merits exploration as a candidate substituent for agro-
chemicals or pharmaceutical drug discovery programmes.
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Immediate questions which arise are how will these selec-
tively uorinated cyclohexane rings be metabolised and how
lipophilic are these ring systems. It is commonly understood
that increasing the level of uorination of an organic motif will
generally result in increasing its resistance to metabolism at
certain sites.13 Also, the prevailing dogma is that increased
levels of uorination render a motif more lipophilic and, thus,
its introduction would have a tendency to raise log P values in
a manner detrimental to judicious selection in medicinal
chemistry. However, it is more complex than that, and Mu¨ller
and Carreira have exemplied this extensively in recent contri-
butions e.g. mapping log Ps of RCH3 compounds through
progressive uorination to RCF3, where intermediate uorina-
tions (RCH2F & RCF2H) decrease lipophilicity.14 It is a feature of
these ring systems,15 where the uorines have a relative
stereochemistry such that they are all on one face of the cyclo-
hexane, that the rings become polar, and thus increasing uo-
rination could reasonably increase hydrophilicity. Thus we set
out to explore the nature of these ring systems in the context of
their properties and potential as a novel motif for inclusion in
bioactive research programmes. To that end we focus on phe-
nylcyclohexane 2, because it is readily prepared7c and has been
shown to be amenable to a range of synthetic transformations
and diversication.16,7b The study compared the metabolism of
2 to close analogues 4–7 by incubation with the human
metabolism model organism Cunninghamella elegans.17 Lip-
ophilicity trends (log P) were also explored comparing cyclo-
hexanes with four, three, two and no uorine atoms. Lastly,
a molecular dynamics simulation study was carried out to
elucidate the structural basis of the observed lipophilicity
trends.
Results and discussion
Biotransformations with Cunninghamella elegans
The fungus Cunninghamella elegans represents a well-
established model for drug metabolism in mammals due to
its ability to biotransform and degrade a wide range of xeno-
biotics.18 The organism contains a range of cytochrome P450
enzymes and this gives an oxidative metabolic prole which
mimics phase-I oxidative metabolism. In order to investigate
how the tetrauorocyclohexyl motif may be metabolised, we
have explored the incubation of phenyl tetrauorocyclohexanes
and also compounds with three and two uorine atoms. Five
compounds were investigated in total, three of which were the
phenyl derivatives 2, 4 and 5, and two were the benzoic acid
derivatives 6 and 7.7d Incubations with C. elegans were carried
out in triplicate in submerged liquid cultures. In each case, the
incubations were worked up aer three days and products were
extracted and analysed.
Phenylcyclohexane 2 gave rise to only one obviousmetabolite
in a conversion of around 30%. This product arose by direct
hydroxylation at the benzylic position of 2 to give benzyl alcohol
8. Only one product as a single isomer could be detected, with
the hydroxyl group congured anti to the adjacent uorine
atoms of the cyclohexane ring. The identity of 8 and its stereo-
chemistry was conrmed by X-ray structure analysis.
Phenyl triuorocyclohexane 4 was similarly incubated with
the fungus and it too gave rise to the analogous benzyl
hydroxylated product 9. The extent of microbial conversion was
approximately 50% aer the three day incubation. The residual
4 was assayed for enantiomeric purity by chiral HPLC, and it
was shown to be almost racemic, thus there is no indication that
the microbial hydroxylation was signicantly enantioselective.
Finally in this series, diuorocyclohexane 5 was subject to
a similar incubation with C. elegans. This compound was
completely and extensively metabolised, and it generated
a much greater product prole of which compounds 10–13 were
isolated. Compounds 11–13 were characterised by X-ray crys-
tallography as illustrated in Fig. 1. Monohydroxylated products
Fig. 1 Biotransformations of selectively ﬂuorinated phenyl ﬂuo-
rocyclohexanes 2 and 4–7 by C. elegans. Some of the products were
crystalline and amenable to X-ray structure analysis.
3024 | Chem. Sci., 2018, 9, 3023–3028 This journal is © The Royal Society of Chemistry 2018
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10–12, can be rationalised by direct methylene P450 type
hydroxylations, however the monouorinated cyclohexanol 13
is less easily rationalised and presumably arises from a series of
biotransformations involving uoride elimination. More
generally, it is clear that removal of two of the ring uorines
from positions 2 and 3 of the phenyl all-cis tetracyclohexyl ring
system has rendered the aliphatic ring much more susceptible
to metabolism.
The benzoic acids 6 and 7 were also incubated with
C. elegans. The tetrauorocyclohexyl benzoic acid 6 was poorly
biotransformed and only a very low conversion to alcohol 14was
obvious aer the three day incubation. Triuorocyclohexyl
benzoic acid 7 was more readily transformed, but only to ben-
zylalcohol 15 (!50% conversion). This product was isolated and
crystallised and X-ray analysis conrmed its structure. Again, in
order to explore any enantioselectivity for this biotransforma-
tion, the methyl ester of the residual carboxylic acid 7 was
analysed by chiral HPLC and this indicated a very low enan-
tioselectivity, thus in a similar outcome to substrate 4, there was
no obvious selectivity for 7 by the hydroxylation enzyme
involved.
Lipophilicity study of selectively uorinated phenyl
cyclohexanes
An important measure of the druggability of a substituent is its
lipophilicity,19 and given the polarity of the phenyl all-cis tetra-
uorocyclohexyl moiety it was of interest to explore the relative
log Ps of various analogous compounds. log P's were measured
by reverse phase HPLC (AcCN 60%: water 40%, with TFA
0.05%), as previously described.20 The measured log P's of
a series of phenyl uorocyclohexane derivatives are summarised
in Fig. 2 and against a series of compounds, of known log P
values, which were re-measured for comparison, including
biphenyl 16 and phenylcyclohexane 17.
It is clear that there is a signicant reduction in log P with
increasing uorination. Phenyldiuorocyclohexane 5
(log P 3.30) is signicantly more polar than the phenyl-
cyclohexane (log P 4.99), and then both the tri-and tetra- uoro
cyclohexanes progressively increase in polarity (log Ps of 2.64
and 2.58 respectively) with additional uorine atoms. An
interesting comparison on log Ps can be made with the two
triuorinated stereoisomers 4 and 18. Compound 4 is more
polar, and this presumably arises as it has a preferred diaxial
arrangement of the C2 and C6 C–F bonds.7c This parallel
alignment can be expected to increase the molecular dipole
relative to isomer 18which has one of these uorines lying in an
equatorial orientation.
The study extended to substituted aryls of the benzoic acids 6
and 7 and the anilines 21 and 22(ref. 7b) as illustrated in Fig. 3.
In each case both the triuoro- and tetrauoro- cyclohexanes
are around two log P units more lipophilic than the non-
uorinated cyclohexanes 20 and 24, whereas the phenyl deriv-
atives 19 and 23 lie in between. There is a clear trend that
selective uorinations around the ring increases the polarity of
the cyclohexane.
Computational analysis of lipophilicity trends
Molecular dynamics (MD) simulations were carried out for
phenylcyclohexanes 2, 4, 5, 16 and 17 to clarify the mechanisms
by which progressive uorination decreases lipophilicity. log Ps
were predicted by computing absolute solvation free energies in
aqueous and organic phases using explicit solvent molecular
dynamics simulations.21 Fig. 4 shows a comparison of calcu-
lated (log Ppred) and measured (log Pexp) log P values, as well as
calculated solvation free energies in aqueous (DGaq) and cyclo-
hexane (DGorg) phases. Overall, the log P calculations are in
good agreement with the experimental data (Kendall tau 0.5 "
0.1 and mean unsigned error 0.77 " 0.07 log P units). Inspec-
tion of the solvation free energies shows that the trend for
decreased log P upon increased uorination is due to a more
rapid decrease in solvation free energies in the aqueous phase
(from ca. #2.5 to #5.2 kcal mol#1 for 16 and 2 respectively) vs.
the cyclohexane phase (ca. #7.5 kcal mol#1 for all compounds).
Further insights were investigated to help rationalise the
calculated diﬀerences in hydration free energies by grid-cell
theory (GCT) analyses of the MD simulation trajectories.22
Fig. 2 Measured20 log P values for compounds selectively ﬂuorinated
phenylcyclohexanes and reference compounds 16 and 17. Increasing
ﬂuorination lowers log P consistent with increasing hydrophilicity.
Fig. 3 Measured20 log P values for benzoic acid and aniline derivatives
of selectively ﬂuorinated cyclohexanes.
This journal is © The Royal Society of Chemistry 2018 Chem. Sci., 2018, 9, 3023–3028 | 3025
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GCT is a MD trajectory post-processing method that spatially
resolves the water contribution to enthalpies, entropies and free
energies of the hydration for small molecules, host/guests and
protein-ligands complexes.23
Fig. 5 depicts spatially resolved hydration thermodynamics
around the non-uorinated cyclohexane 17 and the tetra-
uorinated cyclohexane 2. Comparison of water density
contours show water structuring above and below thep-cloud of
the phenyl ring due to the expected weak hydrogen bonding
interactions in this region. In addition the four uorine atoms
in 2 induce further structuring of water around the cyclohexyl
moiety, with a more pronounced eﬀect around the hydrogen
face of the cyclohexane (panels A and B). Owing to the diﬀerent
polarities of the cyclohexyl ring in 2, water near the uorine-face
preferentially orients hydrogen atoms towards the ring, whereas
water near the hydrogen-face preferentially orients oxygen
atoms towards the ring. Water near the hydrogen-face is more
enthalpically stabilised and entropically destabilised with
respect to bulk, whereas the energetics are not signicantly
diﬀerent from the bulk in the vicinity of the uorine face
(panels C and D and E and F). Overall favourable enthalpic
contributions oﬀset unfavourable entropic contributions for
water near the hydrogen face and water in this region makes
additional favourable contributions to the hydration free energy
(panels G and H). Therefore the decreased lipophilicity of 2 with
respect to 17 is attributed to enhanced hydrogen bonding
interactions between water and the hydrogen face of the all-cis
tetrauorocyclohexane ring.
Conclusions
The all-cis tetrauorocyclohexane motif has been recognised to
have particularly polar properties and the ease of synthesis of
the phenyl derivative 2 has prompted us to investigate it prop-
erties further as it emerges as a building block for the intro-
duction of this new motif into medicinal chemistry and other
bioactives discovery programmes. The metabolism of the
phenyl cyclohexane derivatives 2, 4–7 with varying levels of
uorination was explored in incubations with Cunninghamella
elegans. This fungus has been used as a microbial model for
mammalian metabolism. In the present study we observed
that increasing the degree of uorination of cyclohexyl ring
leads to a more stable xenobiotic. The phenyl all-cis tetra-
uorocyclohexane 2 was signicantly less metabolised than the
triuoro-4 and then diuoro-5, the latter of which was exten-
sively metabolised. In the case of 2, 4, 6 and 7 metabolism is
conned to benzylic hydroxylation.
A systematic log P evaluation of these ring systems shows an
increase in hydrophilicity with increasing uorination, and for
the phenyl all-cis tetrauorocyclohexanes (including anilines
and benzoic acids) there is a maximal eﬀect. These ring systems
are at least two full log P units (100 fold) more hydrophilic than
their non-uorinated cyclohexane counterparts.
Molecular dynamics simulations reproduce the experi-
mental trends and suggest that the decreased lipophilicity of 2
is due to enhanced hydrogen bonding interactions of water
molecules with the hydrogen face of the cyclohexane ring with
respect to bulk water. The orientation of the water near this face
of the ring was consistent with the hydrogen bonding donor
ability of the polarised hydrogens of the ring.
This contrasts with the energetics of water near the uorine
face of the ring which are comparable to bulk water. Altogether
these studies indicate that metabolism of the all-cis tetra-
uorocyclohexyl motif is slow, and that the ring system is
signicantly hydrophilic for an aliphatic motif. These factors
Fig. 4 The positive y-axis depicts a comparison between calculated
(cyan) and measured (blue) log P values for compounds 2, 4, 5, 16 and
17. The negative y-axis depicts calculated solvation free energy in
cyclohexane, DGorg (red), and aqueous, DGaq (yellow), phases.
Fig. 5 Spatial resolution of hydration thermodynamics around 17 and
2. Panels A and B show isocontours for density (red: rwat > 2.33 bulk
density, blue: rwat < 0.5 bulk density). Panels C and D show isocontours
for regions where water is enthalpically stabilised with respect to bulk
water (red: DHw < #0.0055 kcal mol#1 A#3). Panels E and F show
isocontours for regions where water is entropically destabilised with
respect to bulk water (blue: #TDSw > 0.0033 kcal mol#1 A#3). Panels G
and H show isocontours for regions where water is more stable than
bulk water (red: DGw < #0.0055 kcal mol#1 A#3).
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add to the unique facially polarised aspect of this motif and
make it an attractive option for inclusion in medicinal chem-
istry or crop protection studies.
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